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In previous prospective studies conducted in our department, PCR was used to detect 
the three p-herpesviruses, human cytomegalovirus (HCMV), and human herpesviruses 
6  and  7  (HHV-6  and  HHV-7)  in  the  blood  of solid  organ  transplant  patients.  The 
viruses  were  commonly  detected  post-transplantation,  and  HCMV  and  HHV-6  were 
independently  associated  with  graft  rejection  in  liver  recipients.  HHV-7  was  also 
associated with increased episodes of rejection in renal transplant patients.  To better 
understand the role of these viruses in graft rejection, in situ techniques including in situ 
hybridisation (ISH)  and  immunohistochemistry (IHC) were developed to detect these 
viruses  in  renal  and  liver allograft biopsies  from patients  in  the  original  prospective 
studies.  HCMV  DNA  was  detected  in  a  significant  proportion  of liver  and  renal 
biopsies (approximately  50%) by ISH,  with detection being widespread especially in 
renal allografts.  The presence of HCMV DNA in the biopsies is likely to represent low 
level HCMV replication not detectable by IHC.  HCMV was not statistically associated 
with either renal or liver allograft rejection by ISH.  It remains possible that HCMV 
infection  in  the  graft  leads  to  dysfunction  and  is  clinically  interpreted  as  allograft 
rejection.  HHV-6 and HHV-7 were not detected in any allografts by ISH or IHC.
In  addition,  an uncommon form of HHV-6 persistence  is characterized by high viral 
loads  in  blood  and  integration  of  viral  sequences  into  host  cell  chromosomes. 
Fluorescence in situ hybridisation (FISH) was developed to examine integration events 
in  a  healthy  individual  with  a  consistently  high  HHV-6  load  and  also  in  a  case  of 
genetic transmission of integrated virus through stem cell transplantation.  In the former 
individual, integrated HHV-6 was identified on chromosome  lip 15.5 and in the latter 
shown  in  the  donor  and  the  recipient  (post-transplantation  only)  on  chromosome 
17pl3.3.  The  confounding  effect  of HHV-6  integration  must  be  considered  when 
investigating novel disease associations of HHV-6.
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1.1 Transplantation
Transplantation  is  used  to  describe  the  surgical  procedure  by  which healthy  organs, 
tissues or cells (graft) are transferred from one individual (the donor) to another in need 
of the transplant (the recipient).  Over the years, advances in surgical techniques, tissue 
typing,  immunosuppressive  therapy,  and  the  management  of  infection  post­
transplantation has  led to substantial  improvement in the quality of life  and  survival 
rates following solid organ transplantation (SOT) (reviewed in Patel and Paya,  1997). 
SOT has now become a therapeutic option for many end-stage diseases e.g. alcoholic 
cirrhosis,  insulin-dependent  diabetes  mellitus,  and  chronic  glomerulonephritis. 
However, infection and treatment are closely interrelated, and with the advent of newer 
and more potent immunosuppressive regimens aimed at reducing allograft rejection, an 
increase  risk  and  morbidity  of infectious  complications  in  transplant  patients  have 
resulted (Villacian and Paya,  1999).  This thesis examines the potential pathogenic role 
of  the  human  p-herpesviruses  in  the  post-transplantation  setting  and  in  particular 
focuses on the role of these viruses in organ allograft rejection.
1.1.1 Immunological basis of allograft rejection
Allografts are grafts donated from one person to a genetically different individual of the 
same species.  In humans the majority of organ grafts from one individual to another are 
allografts,  unless  an  identical  twin  is  available  as  a  donor.  Allografts  express 
alloantigens which are recognized as foreign by the recipient and therefore result in a 
rejection response.  Allograft rejection is a major problem in SOT as it can lead to either 
acute or chronic  loss of the graft.  The primary immunological event responsible for 
initiating a complex network of cellular and humoral interactions that ultimately leads to 
graft  rejection  is  the  recognition  of  non-self  antigens  (Ags)  by  the  recipient’s  T 
lymphocytes (allorecognition).  The second part involves activation, proliferation and 
differentiation of allospecific  T  lymphocytes  into  effector cells or to provide help to 
other cells to inflict damage to the graft.
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1.1.1.1 Allorecognition
It  is  generally  agreed  that  there  are  two  nonmutually  exclusive  pathways  of 
allorecognition, the direct and the indirect pathways (reviewed in Game and  Lechler, 
2000).  Allorecognition was  traditionally considered to  occur by the  direct pathway, 
where  the  recipient’s  T  lymphocytes  directly  recognize  intact  allogeneic  human 
leukocyte antigens (HLA) (usually class I) expressed on the surface of donor antigen 
presenting cells (APCs).  However, in the early 1980s Lechler and Batchelor proposed 
an  alternative  mechanism,  namely  the  indirect  pathway  of allorecognition,  whereby 
donor HLA alloantigens are shed by donor cells, taken up and processed by recipient 
APCs and presented to the recipients T lymphocytes in the groove of self-HLA (usually 
class II).
1.1.1.2 T lymphocyte activation and response
The  immune response to alloantigen can be described as a sequence of three  signals 
(reviewed by Marion, 2003).  The first signal involves the specific interaction of T cell 
receptors (TCR) with allopeptides bound to the groove of self or allo-HLA molecule. 
This interaction between TCR and allopeptides has high specificity but low affinity and 
requires a second signal (also known as “costimulation”) before T-cell activation can 
occur.  This  second  signal  is  provided  by  ligands  on  the  APC.  Although  many 
costimulatory  molecules  have  been  identified,  the  CD28  molecule  is  the  best 
characterized (June et al., 1994).  CD28 has two known ligands, B7-1 (CD80) and B7-2 
(CD86) expressed primarily on APCs (Lenschow et al.,  1996).  The interaction of IL-2 
with  its  TCR  constitutes  the  third  signal  in  T  cell  activation,  and  leads  to  T  cell 
differentiation (Sayegh and Turka, 1998).
1.1.1.3 Central role of CD4+ T cells
CD4+  T  cells  play  a  key  role  in  orchestrating  the  various  effector  arms  of  the 
alloimmune  response  (reviewed  in  Hemandez-Fuentes  et  al,  1999).  Once  fully 
activated,  CD4+ T cells differentiate into either Thl  or Th2  effector cells (Mosmann 
and  Sad,  1996).  Thl  cells  typically  support  delayed-type  hypersensitivity  (DTH) 
responses,  the  development  of  cytotoxic  CD8+  cells  and  the  production  of  some 
immunoglobulin  (Ig)-G  antibody  (Ab)  subclasses.  Thl  cells  are  also  involved  in 
secretion  of the  cytokines;  interferon  (IFN)-y, tumour  necrosis  factor. (TNF)-p,  and 
interleukin (IL)-2.  Th2 cells, in contrast, support the production of other classes of Ab
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and secrete the cytokines IL-4, IL-5 and IL-10.  Cytokines play a central role in driving 
Thl or Th2 expansion upon activation (Abbas et al., 1996).
1.1.1.4  Effector mechanisms of rejection
A multitude of cell types recruited by CD4+ T cells are involved in allograft rejection. 
They include cytotoxic T lymphocytes (CTL), macrophages, natural killer (NK) cells 
and alloreactive Abs (produced by B lymphocytes) (reviewed in Arakelov and Lakkis, 
2000).
1.1.1.4.1 Cytotoxic T lymphocytes
CTLs play an  important role  in  allograft rejection by killing target cells  which bear 
foreign major histocompatibility complex (MHC) (Liu et al.,  1996).  In general, CTLs 
express CD8  molecules and recognize peptides presented by HLA class  I molecules. 
CTLs kill donor target cells by at least two pathways.  One pathway is mediated by the 
release of granules containing membrane poreforming proteins called perforins and a 
family of proteases called granzymes.  Perforin forms large pores in the cell membrane 
and cause lysis, while granzymes enter the cytosol through perforin channels and induce 
cell death by apoptosis.  Alternatively, CTLs can bind Fas on the target cell using their 
Fas ligand (FasL).  Fas is a member of the TNF family of ‘death receptors’ which signal 
cell apoptosis (Nagata and Golstein, 1995).
1.1.1.4.2 Macrophages
Both CD4 T cells and activated macrophages can contribute to graft rejection by a DTH 
response (reviewed in Arakelov and Lakkis 2000).  Activated CD4+ T cells stimulate 
macrophages via the CD40L-CD40 pathway and by secreting IFN-y and lymphotoxin. 
Macrophages then release a host of mediators which include cytokines (TNF, IL-1, IL- 
6,  IL-10,  IL-12,  and  IL-15),  chemokines,  reactive  oxygen  species,  nitric  oxide, 
proteolytic enzymes, and extracellular matrix proteins that lead to fibrosis.
1.1.1.43  Natural killer cells
NK cells are a lymphocyte subset which do not express T- or B-lymphocyte markers. 
They are activated by IL-2, IL-15, and IFN-y.  NK cells appear to kill target cells by a 
process similar to CTL-mediated lysis, by releasing perforins and granzymes.  Unlike 
CTLs, NK cells lack Ag-specific receptors.  They express a low affinity receptor for the
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constant (Fc) portion of IgG thereby binding to and killing Ab-coated target cells (Ab- 
dependent  cell-mediated  cytotoxcity  or  ADCC  (Arakelov  and  Lakkis,  2000).  The 
function  of NK cells  is  regulated by a  series  of inhibitory receptors  (Moretta et al., 
1996).  These include members of the killer inhibitory receptor (KIR) family and the 
leukocyte  Immunoglobulin-like receptors  (LIR-l/ILT-2  and LIR-2/ILT-4)  which bind 
HLA class I molecules.  The inhibitory receptors, specific for HLA class I molecules, 
allow  NK  cells  to  discriminate  between  normal  cells  and  cells  that  have  lost  the 
expression  of HLA  class  I  (e.g.  tumor  cells).  As  predicted  by  the  “missing  self 
hypothesis” (Ljunggren and Karre,  1990), NK cells recognize HLA class I molecules 
via surface receptors delivering signals that inhibit the NK cell function.  Thus, NK cells 
lyse those target cells that have lost (or express insufficient amounts) of HLA class I 
molecules,  a  frequent  event  following  tumour  transformation  and  viral  infection 
(reviewed in Moretta et al., 2002).  Most human NK cells also express a surface C-type 
lectin receptor CD94/NKG2A/B  shown to  interact with the nonclassical HLA class I 
molecule, HLA-E, to deliver an inhibitory signal to NK cells (Borrego et al.,  1998; Lee 
etal.y 1998) (see section 1.3.4).
1.1.1.4.4  Alloantibodies
Allogeneic HLA molecules are strong inducers of humoral responses.  In  vivo, serum 
Abs against HLA are induced by multiple blood transfusions, pregnancies, and also by 
previous transplants.  These preformed alloantibodies mediate allograft damage in what 
is known as hyperacute rejection (discussed in section  1.1.2.1).  Alloantibodies cause 
tissue damage by activating the complement cascade or by mediating ADCC (Rocha et 
a l, 2003).
Although the association between the presence of preformed circulating alloantibodies 
and  hyperacute  rejection  has  been  well  established  (Terasaki,  2003),  the  clinical 
importance  of donor  specific  antibodies  (DSA)  is  surfacing.  This  has  been  made 
possible with development of objective diagnostic criteria, (Racusen, 2003) (see section 
1.1.3.2) and the demonstration of the complement protein C4d in allograft biopsy as an 
important diagnostic tool (Feucht, 2003) (see section 1.1.3.2).
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1.1.2  Clinical manifestations of graft rejection
Graft rejection has various time courses depending on the type of tissue or organ grafted 
and immune response involved.  There are three patterns of graft rejection; hyperacute, 
acute and chronic rejection.
1.1.2.1 Hyperacute rejection
Hyperacute rejection usually appears within the first 48 hrs.  This form of rejection is 
initiated by preformed donor-specific alloantibodies which bind to Ags on the graft’s 
vascular  endothelium.  This  subsequently  leads  to  activation  of  complement, 
coagulation factors and other mediators of inflammation resulting in endothelial damage 
and  vascular  thrombosis  and  immediate  graft  loss  (Arakelov  and  Lakkis,  2000). 
Preformed Abs which cause hyperacute rejection include two main groups, low affinity 
IgM Abs which are specific for the ABO blood group Ags, and high affinity IgG Abs 
targeted against class I HLA Ags (Williams et al., 1968).  Hyperacute rejection has been 
largely  eliminated  by  ABO  matching  and  by  routine  pre-transplant  cross-matching 
whereby donor lymphocytes are mixed with the recipient’s serum to detect the presence 
of cytotoxic Abs (Hemandez-Fuentes et al., 1999).
1.1.2.2 Acute rejection
Rejection of solid organ grafts can still take place in the absence of any preformed Abs. 
In the clinical  situation, with immunosuppression, this form of rejection  occurs  most 
frequently between 5 days and 3 months after transplantation (Hemandez-Fuentes et al.,
1999).  T  cells  play  a  central  role  in  the  acute  rejection  process,  although  much 
controversy  remains  over  the  relative  importance  of the  CD4+  and  CD8+  T  cell 
subpopulations  in mediating transplant rejection.  In  some  studies,  CD8+  cells  alone 
seem  to  be  able  to  initiate  allograft rejection  (Hall,  1991),  while  in  others,  evidence 
suggests that CD4+ T cells are an absolute requirement (Kreiger et al., 1996).  In human 
biopsy studies there is also evidence to suggest that other molecules, including adhesion 
molecules  and  chemokines  may  also  play  an  important  role  in  acute  rejection  by 
facilitating the inflammatory process and mediating the recruitment of lymphocytes into 
the allograft (Fairchild et al., 1997; Solez et al., 1997).
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Despite the well-documented role  of cellular mechanisms  in  acute rejection,  there  is 
accumulating evidence to suggest that Ab-mediated immune mechanisms are significant 
in acute allograft rejection (reviewed by Mauiyyedi and Colvin, 2002).  Trpkov et al. 
(1996)  reported  several  specific  morphological  features  in  rejecting  allografts  that 
correlated  with  the  presence  of anti-class  I  Ab  in  the  recipient.  Ab-mediated  graft 
rejection has however been difficult to diagnose due to the rapid removal of Ig from the 
surface of endothelial cells.  Recently, the identification of C4d as a specific marker of 
Ab-mediated  acute  rejection  has  emerged  (Feucht  et al.,  1993;  2003;  Regele  et al., 
2001;  Bohmig  et  al.,  2002).  C4d  is  the  stable  remnant  of  classical  complement 
activation,  which  binds  covalently  to  the  capillary  wall,  thereby  providing  in  situ 
pathologic evidence of Ab-mediated injury.  Pioneering studies by Feucht et al. (1993) 
reported capillary deposition of C4d,  in 51  of 93  biopsies  from renal  allografts with 
early graft dysfunction.  Among patients with C4d,  1-year survival was 57% compared 
with 90% survival in those without C4d.  In 2001, the same group provided evidence of 
Abs producing early graft failures (Lederer et al., 2001).  They showed that the presence 
of C4d in  117 renal grafts led to significantly lower graft survival than in  101  grafts 
without C4d (p=0.0001).  Later studies have confirmed a clear correlation of PTC C4d 
staining with concurrent circulating anti-donor-specific Ab and with certain pathologic 
features  (Collins  et  al.,  1999;  Mauiyyedi  et  al.,  2002).  Capillary  C4d  is  now 
incorporated in the ‘Banff classification’ for renal allografts (see section 1.1.3.2).
1.1.2.3  Chronic rejection
A significant complication in SOT is the progressive decline of allograft function that 
develops months or years after successful transplantation, commonly known as chronic 
rejection.  The  pathogenesis  of chronic  rejection  remains  elusive.  For  many  years, 
chronic rejection has been considered to be immune mediated, driven by alloantigen- 
dependent  mechanisms.  However,  alloantigen-independent  risk  factors  have  been 
identified  as  contributing  to  the  development  of  chronic  rejection.  This  will  be 
discussed  in  section  1.1.3.2  as  most  of the  research  into  chronic  rejection  has  been 
carried out in renal transplantation.
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1.1.3  Organ transplantation
1.1.3.1  Liver transplantation
In comparison with other organs such as the kidney, the liver is relatively resistant to 
hyperacute  Ab-mediated  rejection,  as  shown  by  the  ability  to  carry  out  successful 
transplantation  in  the  face  of  positive  anti-donor  cross-matching,  including  ABO- 
incompatibility (Gordon et al.,  1986).  The basis for resistance to humoral rejection has 
been reviewed by Knechtle (1998).  The most common cause of graft dysfunction  is 
acute cellular rejection with an incidence of 50-80% (Wiesner et al.,  1998).  It most 
commonly  occurs  between  4  and  14  days  after  transplantation  (Neuberger,  1995). 
Histological examination of a liver biopsy specimen is considered the  ‘gold standard’ 
for diagnosing acute rejection.  An international consensus grading system called the 
Banff  Schema  for  liver  allograft  rejection  has  been  established  for  grading  acute 
rejection (International Panel Comprised of Demetris, Batts, Dhillon et al.,  1997) (see 
table  1.1).  Chronic liver allograft rejection, also termed vanishing bile duct syndrome 
(VBDS), develops slowly over a period of months or years and is a major cause of graft 
failure and retransplantation, although incidence is <5% (Knechtle,  1998).  Diagnostic 
criteria for chronic rejection are (1) the presence of bile duct atrophy/pyknosis, affecting 
the  majority  of bile  ducts,  with  or  without bile  duct  loss;  (2)  convincing  foam  cell 
obliterative  vasculopathy;  or  (3)  bile  duct  loss  affecting  >50%  of the  portal  tracts 
(Demetris et al., 2000).
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Grading of Acute Liver Allograft Rejection
Global assessment of rejection grade made on a review of the biopsy and after the 
diagnosis of rejection has been established.
Global
Assessment*
Criteria
Indeterminate Portal inflammatory infiltrate that fails to meet the criteria for the 
diagnosis of acute rejection (see reference below)
Mild
Rejection infiltrate in a minority of the triads, that is generally 
mild, and confined within the portal spaces
Moderate Rejection infiltrate, expanding most or all of the triads
Severe
As above for moderate, with spillover into periportal areas and 
moderate to severe perivenular inflammation that extends into the 
hepatic parenchyma and is associated with perivenular hepatocyte 
necrosis
* Verbal description of mild, moderate or severe acute rejection could also be labeled 
as Grade I, II and III, respectively.
Table  1.1  Banff Schema for Grading Liver allograft Rejection:  An International 
Consensus Document (International Panel Comprised of Demetris, Batts, Dhillon 
et al., 1997).
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1.1.3.2  Kidney transplantation
In renal transplantation, acute allograft dysfunction secondary to acute rejection occurs 
in 30-40% of patients (Chandraker,  1999).  The ‘gold standard’ for diagnosis of acute 
rejection  is  histologic  evaluation  of a  percutaneous  needle  biopsy  of the  transplant 
kidney.  This  has  been  aided by the  development  of an  internationally  standardized 
histological grading system known as the Banff 97 working classification (Racusen et 
al.,  1999).  The Banff 97 working classification combined data from the previous Banff 
classification  (Solez  et  al.,  1993)  and  the  Collaborative  Clinical  Trials  in 
Transplantation (Colvin et al.,  1997).  In recent years,  the Banff 97  classification  of 
renal  allograft  rejection  has  been  updated  to  include  criteria  for  acute  Ab-mediated 
rejection  in  renal  allografts  (see  table  1.2)  (Racusen et al.,  2003).  Although  in  the 
majority  of patients  immunosuppressive  agents  may  prevent  or  reverse  most  acute 
rejection episodes, the graft may still succumb to chronic rejection.  More recently, the 
term chronic allograft nephropathy (CAN) was proposed because it was suggested that 
both  immune  and  nonimmune  factors  may  participate  in  the  development  of  this 
progressive  renal  dysfunction  (Tiley  and  Paul,  1996).  The  strongest  evidence  that 
chronic rejection is immune mediated stems from its association with acute rejection, 
and  the  degree  of histocompatibility  mismatching.  In  renal  transplantation,  acute 
rejection  episodes  that  are  either  functionally  or  histologically  more  severe,  and 
rejection episodes that are recurrent tend to be stronger predictors of chronic rejection 
(Tesi et al.,  1993).  Chronic rejection is also less common in grafts that are better HLA 
matched, irrespective of whether they are from live-related or cadaveric donors (Cecka,
1998).  In addition, HLA Abs has also been associated with chronic rejection and graft 
loss  (McKenna  et  al.,  2000;  reviewed  in  Terakasi,  2003).  Recently,  alloantigen- 
independent risk factors for chronic rejection have also been identified.  These include 
donor source (living-related versus cadaveric), delayed graft function, size mismatching, 
donor  age,  donor  and  recipient  gender,  hyperlipidemia  and  hypertension  (Ponticelli, 
2000).
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1.  Normal
2.  Antibody-mediated rejection
Rejection due, at least in part, to documented anti-donor antibody (‘suspicious 
for’ if antibody not demonstrated); may coincide with categories 3,4 and 5 
Type (Grade)
I.  ATN-like -  C4d+, minimal inflammation
II.  Capillary-margination and/or thromboses, C4d+
III.  Arterial -  v3, C4d+
3.  Borderline changes: ‘Suspicious’ for acute cellular rejection
This category is used when no intimal arteritis is present, but these are foci of 
mild tubulitis (1-4 mononuclear cells/tubular cross-section) and at least il may 
coincide with categories 2 and 5
4.  Acute/active cellular rejection
T-cell-mediated rejection; may coincide with categories 2 and 5 
Type (Grade) Histopathological findings
LA.  Cases with significant interstitial infiltration (>25%  of parenchyma
affected) and foci of moderate tubulitis(>4 mononuclear cells/tubular 
cross-section or group of 10 tubular cells)
IB.  Cases with significant interstitial infiltration (>25%  of parenchyma
affected) and foci of severe tubulitis (>10 mononuclear cells/tubular 
cross-section or group of 10 tubular cells)
IIA.  Cases with mild to moderate intimal arteritis (v 1)
IIB.  Cases with severe intimal arteritis comprising >25% of the luminal 
area (v2)
III.  Cases with ‘transmural’ arteritis and/or arterial fibrinoid change and
necrosis of medial smooth muscle cells with accompanying 
lymphocytic inflammation (v3)
5.  Chronic/sclerosing allograft nephropathy
Fibrosing changes in the allograft, with or without features of true alloimmune 
injury to the graft; may coincide with categories 2, 3 and 4.
Grade Histopathological findings
Grade I Mild interstitial fibrosis and tubular atrophy without (a) or
(mild) with (b) specific changed suggesting chronic rejection
Grade II Moderate interstitial fibrosis and tubular atrophy (a) or (b)
(moderate)
Grade III Severe interstitial fibrosis and tubular atrophy and tubular loss
(severe) (a)or(b)
6.  Other Changes not considered to be due to rejection; may coincide with 
categories 2, 3,4 and 5
Table 1.2 Banff 97 diagnostic categories for renal allograft biopsies -  update 
(Racusen et al.9  2003).
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1.1.4  Immunosuppressive therapy
The main aim of transplantation is the ultimate survival of the graft in the transplant 
recipient, and where possible to ensure early engraftment of the organ with no rejection. 
Graft rejection can be minimized by cross-matching donor and graft for ABO and HLA 
tissue types, however, this is not always possible due to the shortage of available donor 
organs  for  transplantation.  To  prevent  rejection  of the  transplanted  organ  or  bone 
marrow,  immunosuppression is therefore required.  This can be achieved through the 
use of immunosuppressive drugs.
1.1.4.1  Pharmacological drugs
The  current  immunosuppressive  drugs  include  cyclosporin  A,  tacrolimus  (FK506), 
prednisolone, azathioprine and a preparation of anti-T-cell Abs.  They act to inhibit the 
various steps of the T-cell activation pathway (table 1.3 shows the mechanism of action 
of these drugs and side effects).  Immunosuppressive drugs are effective  in reducing 
acute rejection.  However, their potential adverse effects and contribution to increased 
risk  of  infectious  complications  in  transplant  recipients,  means  their  use  must  be 
reduced to a manageable level.  Currently, a combination of immunosuppressive drugs 
has proved to be an effective strategy to inhibit diverse pathways involved in allograft 
rejection,  and  allowing  the  reduction  of both  dosage  and  adverse  effects  of  each 
individual  drug.  Many  centers  have  administered  a  combination  of  cyclosporin, 
prednisolone and azathioprine, often referred to as ‘triple therapy’.
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Agent Mode of Action Side-Effects
ATG/ALG
Binds multiple antigens on lymphoid 
cells, resulting in modification of cell 
surface receptors or complement 
mediated lysis
Serum sickness
Thrombocytopenia
Leucopenia
OKT3 Ab Binds T cell CD3
Cytokine release 
syndrome
Increase risk of PTLD
IL-2 receptor 
antibody
Block cytokine gene transcription via 
inhibition of NFAT
Glucose intolerance 
Hypertension 
Hyperlipidemia 
Growth Delay 
Osteopenia
Cyclosporin Inhibit action of calcineurin, thereby 
inhibiting production of IL-2
Hypertension 
Nephrotoxicity 
Hirsuitism, gum 
hypertrophy
Tacrolimus
(FK506)
Inhibit action of calcineurin, thereby 
inhibiting production of IL-2
Glucose intolerance
Hypertension
Nephrotoxicity
Azathioprine Inhibits purine (adenosine) synthesis
Bone marrow
suppression
Transaminitis
Mycophenolate
mofetil Inhibits purine (guanosine) synthesis
Bone marrow 
suppression 
Gastrointestinal upset
Rapamycin
(Sirolimus)
Blocks IL-2 induced cell cycle 
progression
Hyperlipidemia
Leukopenia,
thrombocytopenia
Table  13  Current  Immunosuppressants:  Mode  of  Action  and  Associated  Side 
Effects  (Marion,  2003).  Abbreviations:  ATG  anti-thymocyte  globulin;  ALG  anti­
lymphocyte  globulin;  NFAT  nuclear  factor  of  activated  T-cells;  PTLD  post­
transplantation lymphoproliferative disease.
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1.1.5  Infections following solid organ transplantation (SOT)
The  occurrence  of infection  in  SOT  is  a  major  determinant  of transplant  outcome 
(reviewed by Patel and Paya, 1997; and Fishman and Rubin, 1998).  Infection is closely 
related to the degree of immunosuppression, and thus to the frequency and intensity of 
rejection and its therapy.  There are three time frames, influenced by surgical factors, 
the level of immunosuppression, and environmental exposures, during which infections 
of specific  types  most  frequently occur post-transplantation.  These  include  the  first 
month;  one to six months, and more than six months after transplantation (see figure 
1.1).
Most infections that occur in the first month post-transplantation are related to surgical 
complications.  These  include  bacterial  and  candidal  wound  infections.  From  the 
second  to  sixth  month  post-transplantation  period,  infections  are  usually  a  result  of 
opportunistic pathogens (HCMV, Epstein Barr virus (EBV), other human herpesviruses, 
hepatitis B and C viruses (HBV and HCV) and human immunodeficiency virus (HIV). 
From six months post-transplantation onwards most transplant recipients do relatively 
well,  suffering  from  the  same  infections  seen  in  the  general  community,  namely 
influenza virus  infection,  urinary tract  infection  and pneumoccocal  pneumonia.  The 
only  opportunistic  viral  infection  commonly  seen  during  this  period  is  reactivated 
varicella  zoster  virus  (VZV).  However,  two  conditions  can  predispose  patients  to 
infection  during  this  late  post-transplantation  period.  Firstly,  patients  who  have 
frequent episodes of acute rejection requiring augmented immunosuppression, or those 
with  chronic  rejection  who  are  maintained  at  a  higher  baseline  level  of 
immunosuppression, are at increased risk of opportunistic infections typically seen in 
the  second  to  six  month  post-transplantation  period.  Secondly,  patients  who  have 
chronic or progressive infection with HBV, HCV, HCMV, and uncommonly HIV, may 
suffer from morbidity associated with these agents which may lead to an  increase in 
other infections.  Although evidence is far from being conclusive, several studies have 
suggested  that  herpesvirus  infections  could  perhaps  trigger  allograft  rejection  in 
different transplant settings.  The evidence linking these viruses, particularly HCMV, 
HHV-6 and -7 to allograft rejection will be examined in later sections.
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Conventional
Nosocomial  Community-Acquired or
Infections  Unconventional or Opportunistic Infections  Persistent Infections
Viral  i  I
H hsv
Onset of CMV  .........
I  H"EBV,VZV(shingles),influenza,RSV,adenovirus “ I
CMV retinitis or colitis —  —  —
I- Papillomavirus, PTLD  —  —  —
h  Onset of hepatitis B or hepatitis C
Bacterial!
I
■ Wound infections, catheter-related infections, pneumonia
I-
Nocardia
Listeria, tuberculosis
Fungal
Pneumocystis 
|“  Aspergillus  —
i   i
h" Candida 
I
Parasitic I
I
I
H" Cryptococcus  j  “  “
I— Geographically restricted, endemic fungi
\— Strongyloides  —  
I   . I  t— Toxoplasma  ----------
i-  Leishmania-----------------------
I
j  h  Trypanosoma cruzi
3  4  5  6
Months after Transplantation
Figure 1.1 Usual sequence of infections after Organ Transplantation (Fishman and 
Rubin,  1998).  Exceptions  to  the  usual  sequence  of infections  after  transplantation 
suggest  the  presence  of  unusual  epidemiologic  exposure  or  excessive 
immunosuppression.  Abbreviations:  HSV  denotes  herpes  simplex  virus;  CMV 
cytomegalovirus; EBV Epstein-Barr virus; VZV varicella zoster virus; RSV respiratory 
syncytial  virus;  and  PTLD  post-transplantation  lymphoproliferative  disease.  Zero 
indicates the time of transplantation.  Solid lines indicate the most common period for 
the  onset  of infection;  dotted  lines  and  arrows  indicate  periods  of continued  risk  at 
reduced levels.
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1.2  The herpesviruses
The  family Herpesviridae are made up  of a group  of more  than  100 viruses,  which 
infect  and  cause  a  variety  of  diseases  in  most  animal  species.  Eight  human 
herpesviruses have been discovered to date.
1.2.1  Herpesvirus structure
Under  the  electron  microscope,  all  herpesviruses  appear  identical.  Typically  the 
herpesviruses consists of a core, which contains the linear double-stranded DNA and a 
100-110 nm icosadeltahedral capsid containing  162 capsomeres,  12 pentameric at the 
vertices and 150 hexameric.  The capsid is in turn surrounded by an amorphous layer of 
proteins called the tegument, which may vary in thickness, depending on the location of 
the virion within the cell.  Surrounding the tegument is the  lipid envelope.  It has  a 
trilaminar appearance,  suggestive of it being derived from patches of altered cellular 
membranes.  The  outer  surface  of the  envelope  contains  numerous  protrusions  of 
glycoprotein,  which  appears  to  be  acquired  from  the  host  by  budding  through  the 
nuclear membrane (figure 1.2).
In addition to  the  morphological  properties  described  so  far,  the herpesviruses  share 
many  significant  biologic  properties.  All  herpesviruses  encode  a  large  range  of 
enzymes  involved  in  nucleic  acid  metabolism,  DNA  synthesis  and  processing  of 
proteins (i.e. kinase activity).  The synthesis of viral DNAs and the assembly of capsids 
occur  in  the  nucleus,  and  the  release  of  progeny  virus  invariably  results  in  the 
destruction of the host cell.  The herpesviruses also have the ability to remain latent 
within the natural host.  In the cells harbouring latent virus only a subset of viral genes, 
if any are expressed.
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glycoprotein
spikes
envelope
viral
genome
tegument
capsid
Figure  1.2  Schematic showing the major structural components of a  herpesvirus 
particle.
1.2.2  Herpesvirus classification
In the past, the classification of the Herpesviruses was predominantly based upon their 
biological properties such as host range and cell tropism, cell pathology in laboratory 
culture,  and  cellular  sites  of  latent  infection.  The  international  Committee  on  the 
Taxonomy of Viruses (ICTV) has classified the herpesviruses into three subfamilies, the 
a-herpesvirinae, 0-herpesvirinae, and  y-herpesvirinae,  on the basis of these biological 
properties.  Table  1.4 shows the classification of the human herpesviruses.  Although 
the classification of Herpesviruses on biological characteristics is useful, it is subjective 
and does produce anomalies e.g. EBV, a y-herpesvirus, is lytic in some cell types like 
the  a-herpesviruses,  but  lymphotropic  like  the  p-herpes  viruses.  In  addition,  recent 
advances in molecular biology have led to the discovery of new herpesviruses, HHV-8, 
before it could be propagated in cell culture.  Therefore, classification of the viruses is 
now based on genome analysis of the human herpesviruses,  with parameters  such as 
similarities  of genomic  organization,  homology  between  nucleotide  and  amino  acid 
sequences taken into account.
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Human Herpesvirus Classification Genome size
(kbp)
Herpes simplex virus 1  (HSV-1) a 152
Herpes simplex virus 2 (HSV-2) a 152
Varicella zoster virus (VZV) a 125
Epstein-Barr virus (EBV) 7 175
Human Cytomegalovirus (HCMV) p 230
Human herpesvirus 6 (HHV-6) p 160-162
Human herpesvirus 7 (HHV-7) p 145
Human Herpesvirus 8 (HHV-8)
165-170 y
(Kaposi’s sarcoma-associated herpes virus)
Table 1.4 Classification of the Human Herpesviruses.
1.2.3  Herpesvirus life cycle
The kinetics of herpesvirus replication has been most intensely investigated for HSV, 
and general mechanisms are similar throughout the other subfamilies.  However, there 
are significant differences among the various subfamilies and amongst members within 
the same subfamily.
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1.23.1 Attachment and penetration
Prior to replication, the virus must gain entry into the host cell.  The virus attaches itself 
to the cell surface via the interaction between its surface glycoprotein’s and specific cell 
receptors.  This is mediated by a number of receptor/ligand interactions.  For HSV-1 
and HCMV, glycoprotein’s such as gB, gD (not HCMV), gH and gL are required.  In 
HSV-1 replication the initial interaction involves the viral envelope gC, and to a lesser 
extent gB, with the glycosaminoglycan moieties of cell surface heparan sulphate (Shieh 
et al.,  1992).  The  second step is followed by association of gD with one of several 
cellular molecules that belong to three different classes of cell-surface receptor families 
(Spear  et  al.,  2000).  Entry  into  the  cytoplasm  is  mediated  by  fusion  of the  viral 
envelope with the plasma membrane of the host cell.  This requires the intervention of 
four  glycoproteins,  gD,  gB,  and the  heterodimer gH-gL  (Turner  et al.,  1998).  The 
capsid is then transported along the cytoskeleton to the nucleus, where viral DNA is 
released,  enters  the  nucleus  through  a  nuclear pore,  and  circularizes  (Garber  et  al., 
1993).
1.23.2 Genome replication
Productive infection of the herpesviruses follows a highly co-ordinated cascade of gene 
expression (see figure 1.3).  Three classes of messenger RNA (mRNA) are transcribed 
in a highly co-ordinated fashion by the cellular RNA polymerase II; the immediate early 
(EE), early (E) and late (L) genes (or a, p and y genes).  The HSV IE genes expressed 
consist of six proteins designated as ICPO, ICP4, ICP22, ICP27, ICP47, and Us 1.5, most 
of which are transactivators.  Although transcription of the a genes requires no prior 
viral protein synthesis a tegument protein, VP 16 in HSV-1  (also called a-TIF (a-gene 
transcription-inducing factor) augments the transcription of the a  genes.  The tegument 
protein  associates  with  other cellular proteins  to  form  a  complex  which  upregulates 
cellular RNA polymerase activity by binding to  the  IE promoter enhancer region  of 
viral DNA.  After transcription, the a-mRNAs are transported to the cytoplasm where 
they  are  translated  into  regulatory  proteins.  These  regulatory  proteins  control  the 
expression of all later genes, in particular the P-genes, the products of which include 
enzymes involved in viral DNA replication and nucleic acid metabolism, and depending 
on the virus include ribonucleotide reductase, thymidine kinase, helicase primase and 
viral  DNA  polymerase.  Viral  DNA  replication  follows,  by  the  rolling  circle 
mechanism,  where  complete  head-to-tail  concatamers  of viral  genomes  are  formed.
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Following DNA replication, p proteins induce the switch from transcription of p genes 
to y genes and the resulting ‘late’ mRNAs are translated into y-proteins, most of which 
have structural roles in the assembly of the virion.
Protein a-protein B-protein
Y mRNA a mRNA
Figure  1.3  Cascade genome expression  of herpesviruses  (Griffiths, 2000).  Genes 
labeled a  (immediate-early),  p (early) or y (late) are transcribed into messenger RNA 
and then translated into proteins.
1.233 Assembly and budding
Capsid proteins associate to form empty capsids in the nucleus, and genome unit-length 
viral DNA cleaved from the concatamers is packaged to produce nucleocapsids, which 
then associate with patches of nuclear membrane to which tegument and glycosylated 
envelope proteins  have  bound.  Envelopment  of the  capsids  is  achieved  by budding 
through the inner nuclear membrane.  The route for egress of the virion particle from the 
space between the inner and outer nuclear membranes to the exterior of the infected cell 
is controversial.  It may occur by either of two general pathways (reviewed in Roizman 
and  Knipe,  2001).  In  pathway  A,  often  called  the  re-envelopment  pathway,  the 
envelope fuses with the outer nuclear membrane, de-enveloping the capsid and releasing
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it into the cytoplasm.  The capsid then buds into the Golgi apparatus (GA), forming an 
enveloped virion, which is transported to the surface by vesicular transport.  In pathway 
B,  called  the  luminal  pathway,  the  virion  particle  buds  through  the  outer  nuclear 
membrane and is transported by vesicular movement through the GA to the exterior of 
the cell.
1.2.4  Viral persistence
Following primary infection, all herpesviruses can persist in the host.  This may take the 
form  of  latency  or  chronic  active  replication.  During  latent  infection,  infectious 
progeny are not produced, and viral gene expression is limited to a small subset of viral 
genes required for maintenance of latency, the number of which varies among viruses. 
Reactivation from latency with concomitant virus production is an efficient means by 
which the virus can spread within the host population.  Each human herpesvirus has 
evolved its own unique ecological niche within the host that allows the maintenance of 
latency over the life of the individual (see table 1.5).  Primary HSV-1  infection is often 
an inapparent asymptomatic infection of the mouth and lips or can cause herpes labialis, 
after which the virus becomes latent in dorsal root ganglia.  Reactivation of latent HSV- 
1  can be asymptomatic or result in localized epithelial eruptions (cold sores) that usually 
resolve  in  a  few  days.  During  the  latent  phase  of  HSV-1  infection,  viral  gene 
expression  is  highly  restricted.  Only  the  latency  associated  transcripts  (LAT)  are 
produced in abundance during latency.  The unprocessed 8.3 kb LAT message maps to 
the opposite strand encoding the IE HSV-1 gene, ICPO (Zwaagstra et al., 1990).  While 
mutations that eliminate a large portion of the HSV-1 LAT still establish and reactivate 
from  latency  (Javier  et  al.,  1988),  reduced  levels  of  LAT  transcripts  have  been 
associated with a reduced efficiency of reactivation (Pemg et al.,  1994).  HCMV and 
HHV-6  establish  latent  infection  in  monocyte/macrophage  lineage,  and  during  latent 
infection both viruses also express LAT that show similar features: (i) both transcripts 
contain open reading frames (ORFs) encoding IE proteins IE-1  and IE-2 (Kondo et al.y  
2002a;  1996)  and  both  transcripts  are  expressed  in  a  small  proportion  of  latently 
infected  cells  (Kondo  et al.,  1991;  Slobedman  and Mocarski,  1999).  However,  it  is 
unclear if these LAT are required for latency or reactivation (Lunetta and Wiedeman,
2000).  In a recent study, HHV-6 LATs were found to be abundantly expressed at an 
immediate stage between latency and reactivation.  HHV-6 LATs functioned as sources
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of IE-1  protein at this  stage, which up-regulated the viral reactivation (Kondo et al., 
2003).
Sub-family name Cellular site of latency
Herpes simplex virus type 1 neurons
Herpes simplex virus type 2 neurons
Varicella Zoster Virus neurons
Epstein Barr Virus B lymphocytes
Human Cytomegalovirus monocytes
Human Herpesvirus 6 T cells/monocytes
Human Herpesvirus 7 
Human Herpesvirus 8 
(Kaposi’s sarcoma associated herpes virus)
T cells/monocytes 
B cells, endothelial cells?
Table 1.5 Human herpesviruses and the sites in which they establish latency.
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1.3  Human Cytomegalovirus (HCMV)
HCMV  is  the  prototype  member  of the  p-herpesvirus  subfamily.  HCMV  infects 
approximately 60% of adults in developed countries and more than 90% of adults in the 
developing  world.  In  the  immunocompetent  individual,  infection  is  usually 
asymptomatic.  Occasionally, however, primary infections  can produce  a  self-limited 
mononucleosis syndrome.  After primary infection the virus is not eliminated from the 
body, but persists lifelong including a latent state.  However, when the host’s immune 
system  is  compromised  as a result of infection  (e.g.  HIV),  immaturity (neonates)  or 
iatrogenic immunosuppression in SOT or bone marrow transplantation (BMT), the virus 
replicates exerting its full pathogenic potential.
In SOT recipients the incidence of active HCMV infection ranges from 23% to 85% and 
symptomatic  disease  develops  in  approximately  half of these  patients  (Kanj  et  al., 
1996).  HCMV  infection  in  SOT  recipients  exhibits  a  wide  range  of  disease 
manifestations  from  asymptomatic  infection  to  severe,  lethal  HCMV  disease.  In 
addition to the direct pathogenicity on  end-organs,  HCMV has been  associated with 
increased  incidence  of  opportunistic  bacterial  and  fungal  infections,  accelerated 
atherosclerosis,  and  allograft  rejection,  collectively  they  are  known  as  the  ‘indirect 
effects’ of HCMV (Rubin, 1989) (described in sections 1.3.9).
13.1  Discovery
HCMV was first discovered in the 1950s when investigating the pathological features of 
cytomegalic  inclusion  disease  (CED),  a  syndrome  affecting neonates  and  infants.  In 
1956,  three  groups  (Smith,  Rowe  and  Weller)  subsequently  isolated  HCMV 
independently.  The AD 169 laboratory strain was the first to be completely sequenced. 
Analysis of its 230 kbp genome has revealed that it encodes 225 ORFs of approximately 
100 or more amino acids (Chee et al.,  1990).  However, laboratory-adapted strains of 
HCMV  have  extensive  gene  deletions  compared  to  wild-type  strains  and  so  do  not 
accurately represent the authentic virus which infects humans (Cha et al.,  1996; Dolan 
et  al.,  2004).  Recently,  a  low  passage  strain  (Merlin)  has  been  sequenced  and  its 
genetic content has been found to be close to the authentic HCMV genome (Dolan et 
al., 2004).
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13.2  Propagation and Cell tropism
HCMV  exhibits  a  highly  restricted  host  range  in  cell  culture.  In  vitro,  primary 
differentiated human fibroblasts from skin or lung are the only cells fully permissive for 
replication  of laboratory  strains,  whereas  clinical  isolates  replicate  preferentially  in 
endothelial  cell  cultures.  In fibroblasts,  the  replication cycle  is  slow,  with  a typical 
cytopathic effect (CPE) characterized by cell enlargement and rounding with both intra- 
and perinuclear inclusions.  In contrast, during natural infection, HCMV has been found 
to  be  capable  of replicating  in  a  wide  variety  of cell  types  including  fibroblastic, 
epithelial,  macrophage,  smooth  muscle,  and  endothelial  cells  (Sinzger  et  al.,  1995; 
1996).  Latent viral DNA, thus, can be detected in macrophage-granulocyte progenitors 
in  the  bone  marrow  and  in  peripheral  monocytes  (Kondo  et  al.,  1994;  Soderberg- 
Naucler et al.,  1997).  The replication rate of HCMV in vivo has been shown by the 
frequent  measurement  of HCMV  load  in  the  blood  following  antiviral  intervention 
(Emery et al., 1999a).  This study demonstrated that, during an active HCMV infection, 
the doubling time of HCMV is approximately one day; thus HCMV replication occurs 
dynamically in the host, contrasting to the results obtained from in vitro propagation 
(Emery et al., 1999a).
133 HCMV and immunomodulation
A characteristic feature of HCMV infection in the normal host is persistence of the virus 
in a latent state at specific anatomical sites for months or years.  Recurrent infections 
may  occur  when  the  host  becomes  immunocompromised.  This  ability  to  avoid 
elimination by the  immune  system  is  the  result  of (1)  induction  of a  latent  state  of 
infection where the virus does not adversely affect the host but restricts the number of 
viral genes expressed so as to minimize exposure to the immune system, (2) exploitation 
of immunologically privileged sites for replication (i.e. epithelial cells of the  salivary 
glands).  These cells do not express  sufficient HLA class I molecules to trigger viral 
clearance by CD8+ cell, (3) expression of genes that interfere with the immune response 
(reviewed in Mocarski, 2002; Landolfo et al., 2003).
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This section will focus on the means by which HCMV can evade the host’s immune 
system.  Escape  from  cell-mediated  immunity  is  mediated  by  several  mechanisms. 
HCMV phosphoprotein (pp)65  (UL83) a tegument protein,  inhibits Ag processing by 
phosphorylating the 72-kDa IE protein (one of the first viral proteins produced in the 
infected  cell)  leading  to  a  lack  of processing  within  the  proteosome  (Gilbert  et al., 
1996).  HCMV  encodes  four  proteins-  glycoprotein  (gp)  US2,  gpUS3,  gpUS6  and 
gpUSl 1  which independently decreases cell-surface expression of HLA class I proteins 
(Ahn et al., 1997; Jones et al.t 1996; Wiertz et al., 1996).
Downregulation of HLA class I expression on infected cells is thought to render the cell 
susceptible to NK cell killing, because cells require presentation of the signal peptides 
derived from HLA class I A, B, or C to be protected against NK cell lysis (Borrego et 
al.,  1998).  However, the HCMV genome contains an HLA class I homologue (UL18) 
(Fahnestock et al., 1995), which exhibits high affinity for LIR-l/ILT-2 (Chapman et al.,
1999).  The function of gpUL18 during virus infection is not yet resolved.  One study 
reported protection  against NK cell  lysis  (Reybum et al.,  1997),  whereas  in  another 
study,  expression  of gp  UL18  was  shown to  enhance NK  cell  killing  (Leong  et al., 
1998).  As mentioned in section 1.1.1.4.3, NK cells also express a surface C-type lectin 
receptor CD94/NKG2A/B which interacts with the nonclassical HLA class I molecule, 
HLA-E to deliver inhibitory signal to NK cells.  HLA-E exhibits limited polymorphism 
and binds a restricted set of peptides derived from the leader sequence of classical HLA 
class  I molecules and HLA-G  (Lee et al.,  1998;  Llano  et al.,  1998).  Class  I  leader 
peptides are released in the cytoplasm and then transported by a transporter associated 
with Ag processing (TAP) into the lumen of the endoplasmic reticulum (ER), where it 
binds to HLA-E in a fashion similar to that of the classical HLA molecules (Lee et al., 
1998).  It has been shown that the HLA-E binding peptide is contained within the leader 
sequence  of  HCMV  gpUL40.  Independently  of  TAP,  gpUL40  can  up-regulate 
expression of the HLA-E, which protects targets from NK cell lysis (Tomasec et al.,
2000).
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HCMV  contains  four  ORF  with  homology  to  G-protein-coupled  receptors  (GPCR) 
(UL33, UL78, US27 and US28) which may act as receptors for chemokines (Chee et 
al.,  1990).  The US28-encoded GPCR pUS28  is  capable of binding  CC  chemokines 
MIP-la (macrophage  inflammatory  protein  la),  MCP-1  (monocyte  chemotactic 
protein-1), and RANTES (regulated upon activation, normal T expressed and secreted) 
(Bodaghi  et al.,  1998),  as well  as soluble forms of the  CX3C  chemokine  ffactalkine 
(Kledal et al.,  1998).  In accordance with its chemokine binding activity, pUS28 was 
suggested to be responsible for CC chemokine sequestration in HCMV-infected cells, 
thereby eliminating these chemoattractants from the environment of these cells in vivo 
(Bodaghi et al., 1998).  Furthermore, upon interaction with the CC chemokines, pUS28 
induces  intracellular calcium  mobilization  (Vieira et al.,  1998).  Thus,  this  receptor 
functions  as  a  ‘chemokine  sink’,  possibly  enabling  HCMV-infected  cells  to  evade 
immune surveillance (Randolph-Habecker et al., 2002).  In addition, the expression of 
US28  in  smooth  muscle  cells  (SMCs)  in  the  presence  of  MCP-1  and  RANTES 
promoted  SMC  migration  (Streblow  et  al.,  1999).  This  provides  evidence  linking 
HCMV  to  the  acceleration  of vascular  diseases,  such  as  restenosis,  SOT  vascular 
sclerosis and atherosclerosis (Streblow et al., 1999).
Two genes (UL146 and UL147) within the HCMV genome exhibit weak amino acid 
homology to the CXC chemokines.  UL146 encodes an IL-8 like chemokine, denoted 
vCXC-1  (Penfold  et  al.,  1999).  The  UL146  stimulates  neutrophil  migration,  thus 
possibly  aiding  the  dissemination  of the  virus.  HCMV  also  encodes  a  viral  IL-10 
homologue (Kotenko  et al.,  2000).  Analogous to host  IL-10,  HCMV  IL-10 reduces 
cell-surface  expression  of  HLA  class  I  and  class  II  proteins  on  peripheral  blood 
mononuclear cells (PBMCs) (Spencer et al., 2002).
1.3.4  Epidemiology and Transmission
Primary infection with HCMV occurs mostly during childhood.  In developed countries 
HCMV seropositivity varies from 30% to 70% (approaching >70% in older populations 
and  in  the  lower  socioeconomic  groups)  and  is  near  100%  in  developing  countries 
(Griffiths,  2000).  HCMV  can  be  acquired  by  intrauterine  infection,  perinatal 
transmission from mother to child either during delivery following ingestion of infected 
maternal genital secretions or by ingestion of breast milk containing HCMV (Stagno et 
al.,  1980)  (5-20%),  or  by  close  contact  between  individuals  through  exposure  to
46Chapter  1   General  Introduction
infected bodily fluids  such as  saliva,  tears,  urine  and  semen.  In addition to  natural 
routes of transmission, HCMV can be transmitted by iatrogenic means, such as blood 
transfusion (Adler et al.,  1983) or following organ transplantation in the donor organ 
(Passe/a/., 1983).
13.5 Congenital HCMV infection
Around  5%  to  10%  of  congenitally  infected  babies  are  bom  with  symptoms 
characteristic of what was initially termed CID.  The clinical findings usually include 
one  or  more  of the  following;  low  birth  weight,  petechial  haemorrhages,  jaundice, 
hepatosplenomegaly,  microcephaly,  encephalitis,  and occasionally chorioretinitis,  and 
inguinal hernia.  Congenital HCMV  infection is  important medically as  it can  cause 
permanent  neurological  damage  and  accounts  for the  long-term  morbidity  and  poor 
prognosis of HCMV inclusion disease (Boppana et al., 1992a).
13.6 HCMV infection in children and adults
Primary  infection  in  adolescence  and  adults  is  usually  subclinical  or  mild,  but 
nonetheless, is thought to account for 8% of all cases of mononucleosis. (Nesmith and 
Pass,  1995).  Clinical manifestations of mononucleosis due to HCMV are very similar 
to that caused by EBV although lymphadenopathy is uncommon.
13.7 HCMV infection in transplant recipients
In  the  immunocompromised  host,  HCMV  exhibits  a  wide  range  of  disease 
manifestations.  Most cases  of HCMV disease present with a non-specific  syndrome 
which manifests as fever, malaise, neutropenia, thrombocytopaenia, and elevated liver 
enzymes in serum, such as transaminases.  These symptoms may be mild and temporary 
or may progress  to  more  severe  end  organ  disease.  Organ  involvement  by  HCMV 
varies amongst different immunocompromised patient groups e.g. hepatitis is frequently 
diagnosed  in  liver transplant recipients,  whereas pneumonitis  is the  major disease  in 
bone marrow recipients (table 1.6).
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HCMV infection can be transmitted to transplant recipients from one of three routes 1) 
primary infection occurs  when a  CMV-seronegative  recipient becomes  infected with 
latent virus from an organ or from virus carried in blood products from the seropositive 
donor; 2)  secondary or reactivation infection occurs when endogenous latent virus is 
reactivated  in  a  seropositive  recipient;  3)  reinfection  occurs  when  a  seropositive 
recipient receives latent virus from the seropositive donor and the virus that reactivates 
post-transplantation is of donor origin.  Symptomatic disease occurs most frequently in 
patients experiencing primary infection.
Symptoms Solid organ 
transplant
Bone marrow 
transplant
AIDS
Fever/hepatitis ++ + +
Gastrointestinal + + +
Retinitis + + ++
Pneumonitis + ++
Myelosuppression ++
Encephalopathy +
Polyradiculopathy +
Addisonian state 4-
Immunosuppression +
Rejection/GVHD + ?
Table 1.6 HCMV diseases in the immunocompromised (Griffiths et al., 2000).
Abbreviation: GVHD graft verses host disease 
+, Diseases that occur in the designated patient population 
++, Diseases that were the most common 
?, Suggested, but not proven association
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1J.8 Diagnosis of HCMV disease
HCMV infection and disease are important causes of morbidity and mortality among 
transplant  recipients.  As  mentioned  above  HCMV  causes  a  range  of  diseases  in 
immunocompromised patient groups, and so for the purpose of developing consistent 
reporting of HCMV in clinical trials, definitions of HCMV infection and disease has 
been internationally agreed (Ljungman and Plotkins,  1995; Ljungman et al., 2002).  A 
case  definition  for  HCMV  disease  requires  the  patient  to  have  compatible  clinical 
syndrome consisting of both symptoms and signs, together with the detection of HCMV 
in  biopsies  of  the  affected  organ  (with  the  exception  of  the  retina,  where  the 
characteristic clinical appearance is sufficient) (see table 1.7).
Disease OefiiitioB
Pneumonia Signs and/or symptoms of pulmonary disease 
Detection of CMV in BAL fluid or lung tissue sample
Gastrointestinal disease Clinical symptoms developed in the upper or lower 
gastrointestinal tract
Macroscopic mucosal lesions on endoscopy 
Demonstration of CMV infection (by culture, 
histopathological testing, IHC or ISH) in a 
gastrointestinal tract biopsy specimen
Hepatitis Elevated bilirubin and/or enzyme levels during liver 
function testing
Absence of any other documented cause of hepatitis 
Detection of CMV infection in a liver biopsy specimen
CNS disease Identification of CNS symptoms
Detection of CMV in CSF samples, by culture or PCR,
or in brain biopsy specimens
Retinitis Typical ophthalmological lesions without virological 
proof
Table  1.7  Definitions  of  Cytomegalovirus  end  organ  disease  (updated  from 
Ljungman et al.9  2002).  Abbreviations:  BAL, bronchoalveolar lavage;  CNS, central 
nervous  system;  CSF,  cerebrospinal  fluid;  ISH,  is  situ  hybridisation;  IHC, 
immunohistochemistry.
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13.8.1  Risk factors for HCMV disease
Primary infection is one of the risk factors for the development of HCMV disease for 
recipients  of SOT  but  not  for  BMT  recipients.  Studies  have  shown  that  primary 
infection acquired from a seropositive donor is associated with a high risk of HCMV 
disease, whereas reactivation of the recipient’s latent virus has a lower risk of disease 
(Betts et al., 1977; Grundy et al., 1988, Ranjan et al., 1991).  Re-infection (donor virus 
infecting  an  immune  recipient)  is  associated  with  an  intermediate  risk  of  disease 
(Grundy et al.,  1988).  Viraemia has also been shown to be a risk factor for HCMV 
disease (Pillay et al., 1993; Kidd et al., 1993).
The importance between the quantity of HCMV and the development of HCMV disease 
was first reported in  1975  by  Stagno  and coworkers,  who  showed that high HCMV 
titres  in the urine were  significantly associated with disease  in  congenitally infected 
infants.  More recently using molecular methods the importance of HCMV virus load in 
liver transplant (Cope et al.,  1997a),  renal transplant (Cope et al.,  1997b), and BMT 
(Gor et al.,  1998) patients has been shown.  Furthermore, multivariate analyses showed 
that  once  virus  load  had  been  controlled  for,  other  recognized  risk  factors  of 
donor/recipient  (D/R)  serostatus  and  the  detection  of HCMV  in  the  blood  by  PCR 
(DNAemia) were no longer statistically associated with HCMV disease  (Cope et al., 
1997a; 1997b; Gor et al., 1998; Hassan-Walker et al.,  1999).  These results demonstrate 
that high HCMV load is the major determinant of HCMV disease, and that previously 
recognized  risk  factors  of DNAemia  and  donor/recipient  serostatus  are  markers  of 
HCMV disease simply because of their correlation with a high virus load.  In addition, 
Cope et al. (1997a) showed in a multivariate analysis that receipt of methylprednisolone 
to control rejection episodes  in liver transplant recipients  is a risk factor for HCMV 
disease, independent of high viral load.  Thus, the administration of methylprednisolone 
seemed to make a patient more susceptible to disease at a lower peak HCMV load.  This 
effect appears to be particular to methylprednisolone because association between the 
increased  risk  of HCMV  disease  and  the  administration  of anti-thymocyte  globulin 
(ATG) can be explained wholly by raised HCMV load (Hassan-Walker et al,  1999).
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1.3.9  Indirect effects of HCMV
In addition to the direct end organ diseases discussed above, HCMV has been associated 
with  indirect  effects  including  the  virus’  contribution  to  the  net  state  of 
immunosuppression thus increasing the risk of bacterial and fungal infections, and acute 
and chronic allograft rejection in different transplant settings (reviewed in Cainelli and 
Vento, 2002; Lautenschlager, 2003).
13.9.1  Secondary infections
One  of  the  most  important  effects  of  HCMV  infection  after  transplantation  is 
predisposition  to  life-threatening  superinfection  with  a  variety  of microbial  agents 
including  Listeria  monocytogenes,  Pseudomonas  aeruginosa,  Candida  albicans  and 
Aspergillus species (Rubin et al.,  1977;  Chatteijee et al.,  1978;  George et al.,  1997). 
However, in a recent multicenter study, HCMV was not found among the risk factors 
predicting invasive candidiasis in liver transplant patients (Husain et al., 2003)
Recently, associations between HCMV and other viral infections have been reported.  In 
HCV-infected liver transplant recipients who reactivate HCMV, higher rates of allograft 
failure  and  mortality  were  found  compared  to  those  who  do  not  reactivate  HCMV 
(Razonable et al., 2002a).  The causal relationship between HCMV and opportunistic 
infections  can  be  demonstrated  in  randomized  trials  with  antiviral  agents  which 
suppress  HCMV  replication.  In  a  recent  study  by  Lowance  et  al.  (1999),  antiviral 
prophylaxis with valaciclovir (VACV) was found to significantly reduce the incidence 
of HCMV infection and disease, and nonherpesvirus infections such as Candida (10% 
VACV versus 22% placebo) and staphylococcal infections (12% versus 21%) in renal 
transplant  recipients.  Wagner et al.  (1995)  reported  ganciclovir  (GCV)  prophylaxis 
reduced the risk for fungal infections compared with placebo (7% versus 27%) in heart 
transplant recipients.
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1.3.9.2  HCMV and atherosclerosis
In 1970, Richard Simmons and coworkers first suggested a relationship between acute 
and  chronic  allograft  injury  and  HCMV  infection.  Since  then,  there  has  been 
considerable controversy over this putative relationship.  The most convincing evidence 
for an association between HCMV infection and allograft-related pathology stems from 
cardiac  transplantation.  Several  groups  reported  that  HCMV  infection  is  related  to 
enhanced  cardiac  allograft  vasculopathy  (chronic  rejection)  (Grattan  et  al.,  1989; 
McDonald et al., 1989; Loebe et al., 1990), and classical atherosclerosis (Melnick et al., 
1990;  Hendrix  et  al.,  1989).  These  findings  have  been  confirmed  in  studies  of 
endomyocardial biopsies where an association between CMV antigenemia and a mild 
inflammatory cell response in the vessel wall, with alterations in small intramyocardial 
arterioles leading to a narrowing of the vascular lumen of the graft was demonstrated 
(Koskinen et al.,  1993a:  1993b).  In an autopsy study of three heart allograft recipients 
with  severe  graft  arteriosclerosis,  HCMV  nucleic  acids  were  recovered  from  the 
coronary arteries (Hruban et al., 1990).
Clinical evidence indicating that CMV infection enhances the development of cardiac 
allograft vasculopathy is  further supported by studies  in animal models  (reviewed  in 
Koskinen et al., 1999).  In experimental animal models of rat transplanted with aortic or 
cardiac  allografts,  rat  CMV  (RCMV)  infection  resulted  in  an  early  inflammatory 
response  that  leads  to  enhanced  intimal  thickening  in  the  allograft  vascular  wall 
(Lemstrom et al.,  1993; Koskinen et al.,  1994).  In a study by Lemstrom et al. (1995), 
RCMV  infection  accelerated  cardiac  allograft  atherosclerosis,  particularly  in  small 
intramyocardial arterioles.  IHC revealed upregulated presence of helper T cells, CTL, 
NK cells and macrophages in the perivascular space of arterioles; this imflammatory 
infiltrate also showed increased MHC class II molecule expression.  RCMV early and 
late  Ags  were  demonstrated  in  both  vascular  wall  smooth  muscle  cells  and 
macrophages, and replicating virus was present in allograft structures (Lemstrom et al., 
1995).  This enhanced intimal response in aortic and cardiac allografts can be entirely 
abolished  by  the  administration  of prophylactic  GCV,  a  potent  inhibitor  of  CMV 
replication (Soghikian et al.,  1996; Lemstrom et al.,  1997), thus implicating CMV as a 
causative agent in chronic rejection.
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13.9.3  Solid organ allograft rejection
In  renal  transplant  recipients  HCMV  infection  has  been  linked  with  acute  allograft 
rejection, which in turn may lead to graft loss (von Willebrand et al.,  1986;  Pouteil- 
Noble et al.,  1993; Sagedal et al., 2002).  In a study by Sagedal et al. (2002), HCMV 
disease  was  found  to  constitute  an  independent  risk  factor  for  biopsy-proven  acute 
tubulointerstitial but not vascular rejection in renal transplant recipients.  In a study of 
192  consecutive  renal  transplant  recipients,  HCMV  disease  but  not  symptomless 
viraemia was seen as a risk factor for acute rejection (Toupance et al., 2000).  Support 
for the role of HCMV in triggering acute allograft rejection can be found in a study 
where  administration of GCV,  without conventional  antirejection  therapy resulted  in 
stable improved graft function in renal transplant patients with HCMV infection and 
biopsy proven late acute rejection (Reinke et al.,  1994).  Similarly,  in a randomized, 
double-bind, placebo-controlled trial by Lowance et al.  (1999),  in which VACV was 
reported to prevent HCMV disease after renal transplantation (the incidence of HCMV 
disease ninety days after transplantation was 45% among placebo-treated patients and 
only 3% among VACV-treated patients; at 6 months, the incidence was 45% and 16% 
respectively),  a  reduction  of  biopsy  confirmed  acute  rejection  was  observed  in 
seronegative VACV recipients compared with placebo recipients (52% versus 26%) at 
six  months  after  transplantation.  These  findings  suggested  that  HCMV  infection 
contributes significantly to acute graft rejection in the kidney.
The role of HCMV in the pathogenesis of CAN remains controversial.  HCMV disease 
has been found to be associated with both early graft dysfunction and chronic allograft 
nephropathy (Tong  et al.,  2002).  One  recent  study found  that HCMV  disease  only 
increased the risk for chronic rejection in renal patients who have experienced serious 
episodes  of acute  rejection  (Humar  et al.,  1999).  Other  studies  have  not  found  an 
association between HCMV and chronic rejection in the kidney (Nadasdy et al.,  1994). 
In a recent study, the HCMV inclusions in renal allograft biopsies were not associated 
with  inflammatory  response,  and  graft  outcome  was  determined  by  coexisting  acute 
rejection and CAN rather than CMV infection (Kashyap et al., 1999).
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Several  rat models  of chronic  renal  allograft rejection have  also  shown  that  RCMV 
infection increases the inflammatory response and accelerates chronic rejection (Yilmaz 
et al.,  1996;  Lautenschlager  et al.,  1997b).  In  the  study by  Kloover  et  al.  (2000), 
RCMV  caused a significant prolonged increase  in vascular cell adhesion molecule-1  
(VCAM-1) and intercellular adhesion molecule-1   (ICAM-1) expression in the vascular 
endothelium, and the number of cells expressing activation markers, leukocyte function 
antigen-1  (LFA-1) and very late antigen-4 (VLA-4) was significantly enhanced in these 
animals.  Significantly enhanced histological  changes  of chronic  rejection  were  also 
seen in the RCMV-infected rats.  Recently, a rat kidney transplant model also showed 
RCMV  increased  collagen  synthesis  and  the  generation  of  fibrosis  during  the 
development of CAN (Inkinen et al., 2002).
In liver transplantation, HCMV infection causes severe hepatitis and systemic infection 
in liver graft recipients (Stratta et al.,  1989).  HCMV hepatitis has been found to be a 
rare event with an incidence of 2.1% in a series of 1146 liver transplantations (Seehofer 
et al., 2002).  A study focusing on HCMV hepatitis showed an increase incidence of 
chronic rejection in those patients (Manez et al.,  1993).  However, these findings have 
not been confirmed in a recent study where long-term complications of HCMV hepatitis 
were not observed, and no correlation with chronic rejection was found (Seehofer et al., 
2002).
Several  studies  have  also  suggest  that  HCMV  infection  maybe  a  risk  factor  in  the 
evolution of VBDS, a chronic cholestatic disorder,  characteristic of chronic rejection 
(O’Grady et al.,  1988; Arnold et al.,  1992; Lautenschlager et al.,  1997a; Evans et al.,
2000).  The persistence  of HCMV DNA has been demonstrated in  liver hepatocytes 
(Arnold  et  al.,  1992;  Evans  et  al.,  1999)  and  in  bile  ducts  and  vascular  structures 
(Lautenschlager et al.,  1997a)  of liver grafts with chronic rejection.  These findings, 
however,  have  not  been  confirmed  in  a  prospective  study  of  81  consecutive  liver 
transplant recipients where the occurrence of HCMV infection did not correlate with 
VBDS in the allograft recipients (Paya et al.,  1992).  A recent study also showed that 
neither HCMV viraemia nor HCMV disease after liver transplantation had an adverse 
affect on the incidence and grade of acute rejection episodes during the first year after 
grafting in patients with HCV-related cirrhosis (Teixeira et al.,  2000).  On the other 
hand,  a  recent  study  investigating  bile  duct  complications  during  1   year  after  liver
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transplantation  found  a  clear  association  between  HCMV  infection  and  biliary 
complication rate (Halme et al., 2003).  HCMV Ags and DNA were also demonstrated 
in the bile ducts.
More recently, support of CMV in hepatic allograft rejection has been reported in rat 
liver  allograft  models.  In  liver  allografts  undergoing  acute  rejection,  RCMV 
significantly increased portal inflammation and caused more severe bile duct damage 
linked to the induction of VCAM-1  in the endothelial cells (Martelius et al.,  1998). A 
further  study  showed  vascular  adhesion  protein-1   (VAP-1),  an  adhesion  molecule 
involved in lymphocyte adhesion, was upregulated in acute liver rejection of sinusoids, 
hepatocytes in bile duct,  and this upregulation was prolonged by RCMV.  Thus,  the 
severity of acute rejection was intensified (Martelius et al., 2000).
1.3.10  Bidirectional effects of HCMV with allograft rejection
The  exact nature  of the  interaction between  allograft  dysfunction  and rejection,  and 
HCMV  infection  is  controversial,  in  the  absence  of  specific  pathological  patterns 
directly attributable to HCMV.  The relation between rejection and HCMV appears to 
be bi-directional, with acute HCMV infection accelerating rejection, and inflammation 
caused  by  rejection  may  increase  viral  replication.  Thus,  allograft  rejection  is 
associated with HCMV, although it may not be exclusively caused by HCMV.
1.3.10.1  Effects of allograft rejection on HCMV infection
There are two key steps in the pathogenesis of HCMV infection in allograft recipients; 
reactivation of the virus from latency and viral replication and dissemination (reviewed 
by Tolkoff-Rubin et al., 2001; Rubin, 2001).  The effects of the rejection process on the 
pathogenesis of HCMV include those that stem from the rejection process  itself,  and 
those due to immunosuppressive drugs required to prevent and treat rejection.
A  potential  mediator  involved  in  reactivating  HCMV  from  latency  is  the 
proinflammatory cytokine,  TNF-a.  This  has been demonstrated  in  an  animal  model 
where allogeneic transplantation was found to induce CMV IE-1  gene expression and 
the  expression  of cytokines  such  as  TNF  (Hummel  and  Abecassis,  2002).  TNF- 
a associates with the TNF-receptor on latently infected cells, resulting in activation of 
protein kinase C  and NFkB,  a promoter of the  IE  gene of HCMV that initiates viral
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replication (Stein et al.,  1993; Prosch et al.,  1995).  Allograft rejection results in both 
local  and  systemic  TNF  release,  and  therefore  the  amount  of  TNF  released  will 
determine the amount of viral reactivation.  Two other pathways have been shown to 
lead to HCMV reactivation (reviewed in Reinke et al.,  1999).  They include the stress 
mediators, epinephrine and norepinephrine, which activate HCMV by increasing cyclic 
AMP (cAMP) resulting in IE enhancer/promoter stimulation as well as viral replication 
in vitro.  Proinflammatory prostaglandins can also contribute to HCMV reactivation via 
the same cAMP pathway.  Hence, common events that occur during allograft rejection 
such as TNF release, stress, and inflammation can mediate the critical first step in the 
pathogenesis of HCMV infection (see figure 1.4).
The type and intensity of immunosuppressive therapy for the management of rejection 
also  contributes  significantly to  viral  replication and  disease.  The  administration  of 
ATG, OKT3 or other antilymphocyte Abs to control rejection results in release of large 
amounts  of  TNF  and  other  proinflammatory  factors  that  are  associated  with  the 
activation of the virus (Hibberd et al., 1992; 1995; Turgeon et al., 1998).  Drugs such as 
calcineurin  inhibitors,  cyclosporine  and  tacrolimus  do  not  reactivate  HCMV  from 
latency,  but  once  there  is  replicating virus,  the  effects  of HCMV  will  be  amplified 
through  inhibition  of virus  specific,  cytotoxic  T-cell  response.  A  similar  effect  is 
demonstrated by high-dose corticosteroids.
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Figure  1.4  HCMV  is  (re)activated  by  very  ‘ordinary  events’  and  the  immune 
response determines the outcome of an active infection (Reinke,  1999).  Different 
events  activate  HCMV  via  distinct  intracellular  pathways.  The  immune  response 
determines the  clinical  outcome:  normally the  virus  is rapidly eliminated by cellular 
immunity while in severely immunocompromised patients the virus can replicate and 
spread  without  control  resulting  in  ‘classic’  HCMV  disease.  A  partially  deficient 
immune response may prevent uncontrolled spreading and replication but insufficient 
clearance resulting in persistent virus mediated inflammatory processes.
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13.10.2  Effects of HCMV infection on allograft rejection
A number of potential mechanisms have been proposed to account for the effects of 
HCMV  infection  on the allograft.  A direct form of injury has  also  been  suggested. 
Sequence  homology  and  immunologic  crossreactivity  between  an  IE-2  protein  of 
HCMV and the HLA-DR p-chain have been demonstrated (Fujinami et al.,  1988).  In 
addition, the HCMV UL18 gene encodes a protein with homology to the class I heavy 
chain  (Beck  and  Barrell,  1988),  which  can  complex  with  the  light  chain  ((3-2- 
microglobulin) (Browne et al., 1990) and is able to bind peptides similar to HLA class I 
(Fahnestock et al., 1995).  Thus, immune injury triggered by the virus could be directed 
at cells that bear either the appropriate HLA-DR Ag or the particular class  I Ag in a 
form of molecular mimicry (Fujinami et al., 1988; Beck and Barrell, 1988).  In a recent 
study by  Saverino  et al.  (2004)  HCMV  UL18  was  detected  in  organ  biopsies  from 
immunocompromised patients with productive infection.  HCMV UL18 was found to 
bind  to  T  cells  via  CD85j,  in  the  absence  of CD3/TCR  involvement,  resulting  in 
activation of T cells and the subsequent lysis of HCMV infected cells.  Pietra et al 
(2003)  also  showed  that  HCMV  UL40  peptides  presented  by  HLA-E  can  stimulate 
some CD8+ T cells in addition to inhibiting NK cell killing (Wang et al., 2002).
As  mentioned  previously,  allograft  rejection  has  been  associated  with  the  increased 
expression of intercellular adhesion molecules.  It has been shown that HCMV infection 
in fibroblasts causes an increased expression of ICAM-1  (CD54) and LFA-3  (CD58) 
(Craigen and Grundy, 1996; Grundy and Downes, 1993).  In vivo, HCMV was shown to 
infect endothelial cells, causing an increase in the expression of the adhesion molecules 
ICAM-1  and VCAM-1, which was  accompanied by an increase  in the  infiltration of 
inflammatory cells into the allograft, particularly CD1 la (LFA-1) and CD49d (VLA-4)- 
positive cells (Steinhoff et al.,  1996).  Allograft rejection is also associated with the 
upregulation of MHC Ags on allograft cells, which may in part be due to the expression 
of IFN.  In human renal transplant recipients, an increased HLA class II Ag expression 
was seen in the graft during active HCMV infection, and such increase was associated 
with acute rejection (von Willebrand et al., 1986).  CMV infection may directly increase 
MHC  Ags  on  the  surface  of  graft  cells  through  the  induction  of proinflammatory 
cytokines as such as TNF-a and EFN-y (reviewed in Cainelli and Vento, 2002) and may 
activate  cytotoxic  T  cells,  which  can  trigger  acute  rejection  in  association  with 
concurrent alloantigen  stimulation.  In the murine CMV model the  cytotoxic T-cell
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response to alloantigens has been shown to be increased during CMV infection in vivo 
(Grundy  and  Shearer,  1984).  Kas-Deelen  et  al.  (2000)  have  postulated  that  the 
occurrence  of acute rejection  episodes  at  the  allograft  site  sensitizes  the  endothelial 
surface of the host to HCMV-induced damage.  These endothelial cells then become a 
target for alloreactive T cells.
HCMV  infection  of allograft recipients  has  also  been  shown  to  induce  a polyclonal 
activation  of  humoral  immune  responses,  including  an  80%  incidence  of  anti- 
endothelial cell Abs (AECAs) that could contribute to allograft injury (Toyoda et al.,
1999).
13.11 Prevention and treatment of HCMV infection and disease
HCMV  disease  is  a  major  problem  after  organ  transplantation  and  in  individuals 
infected  with HIV.  Consequently,  antiviral  agents  have  been  introduced  in  clinical 
practice to inhibit HCMV replication.  The currently approved drugs  for use against 
HCMV  include  GCV,  foscamet  (PFA)  and  cidofovir  (CDV).  In  addition  to  the 
treatment of overt clinical disease two major strategies are employed: prophylaxis with 
antiviral agents and pre-emptive therapy for the management of HCMV infection.
13.11.1 Antiviral Chemotherapy
To date, GCV, CDV and PFA have been licensed for serious or life-threatening HCMV 
infections  in  immunocompromised  individuals.  These  drugs  have  produced  clinical 
improvement in many patients, but suffer from poor oral bioavailability, low potency, 
development  of drug  resistance,  and  dose-limiting  toxicities,  and  hospitalization  is 
sometimes required.
1.3.11.1.1 Ganciclovir (GCV)
Ganciclovir  [9-(l,3-dihydroxy-2-propoxymethyl)-guanine]  is  a  guanosine  nucleoside 
analogue  that  requires phosphorylation  at  the  5’  position  for antiviral  activity.  The 
initial  phosphorylation  in  HCMV  infected  cells  is  mediated  by the  HCMV  encoded 
UL97 gene product (Littler et al., 1992).  The modified drug is then converted into GCV 
triphosphate  through  the  action  of  cellular  enzymes.  The  fully  activated  GCV 
triphosphate inhibits viral replication by competing with deoxyguanosine triphosphate 
(dGTP) as a substrate for the viral DNA polymerase (HCMV UL54) (Noble and Faulds,
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1998).  The incorporation of GCV triphosphate into the growing chain of viral DNA 
does  not  lead  to  obligatory  chain  termination  but  rather  slows  the  rate  of  DNA 
polymerization.  GCV is administered by intravenous infusion, although more recently 
an  oral  formulation  has  been  used.  While  this  has  proved  effective  in  preventing 
HCMV disease in SOT recipients (Gane et al., 1997; Flechner et al., 1998), it has a low 
bioavailability  (about  6-10%).  This  low  bioavailability  limits  the  degree  of viral 
suppression  and  thus  may  predispose  to  the  emergence  of  GCV  resistant  strains 
(discussed in section 1.3.11.2).
13.11.1.2  Foscarnet (PFA)
Foscamet  (phosphono  formic  acid;  PFA)  is  a  pyrophosphate  analogue  which  binds 
directly  to  the  pyrophosphate-binding  site  of the  viral  DNA  polymerase  in  a  non­
competitive manner resulting in the inhibition of DNA polymerization.  PFA is not used 
routinely in transplant patients because of its nephrotoxicity.  In general, it is reserved 
for patients who are intolerant of GCV, or who have failed GCV therapy, usually due to 
resistance.  However, in a recent study by Mattes et al. (2004) comparing GCV to GCV 
plus PFA (each at half dose) for pre-emptive therapy of HCMV infection in transplant 
recipients, a synergistic effect of GCV plus PFA in vivo was not supported.
13.11.13 Cidofovir (CDV)
Cidofovir  (HPMPC,  (S)-l-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine)  is  an 
acyclic nucleotide phosphonate, an analogue of cytosine monophosphate and therefore 
does not require virally mediated initial phosphorylation (Kendle and Fanhavard, 1998). 
CDV is then converted by cellular enzymes to a triphosphate form which inhibits viral 
DNA synthesis.  The main side effect of cidofovir is its nephrotoxicity, which can be 
accompanied  with  neutropenia.  CDV  is  mainly  used  to  treat  HCMV  infections  in 
patients who have acquired resistance to either GCV or PFA.
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1.3.11.2  Prophylaxis
Prophylaxis is where an antiviral is administered to all patients after transplantation in 
order  to  prevent  HCMV  infection/disease  from  occurring.  At  present,  prophylaxis 
against HCMV has used drugs such as aciclovir (ACV) or its prodrug VACV or oral 
GCV.  Clinical  trials  of these  agents  in  SOT  have  been  extremely  successful  at 
controlling HCMV replication for the defined period of prophylaxis (Gane et al.,  1997; 
Lowance et al.,  1999).  In the study by Lowance et al. (1999) prophylactic use of oral 
VACV for ninety days post-transplant reduced the incidence of HCMV disease in the 
D+/R-  group  from  45%  (placebo)  to  3%  (VACV),  and  reduced  the  rate  of biopsy- 
confirmed  acute  graft  rejection  at  6  months  from  52%  (placebo)  to  26%  (VACV). 
However, at six months post-transplant, the incidence of disease was the same in the 
placebo group, but had increased to 16% in the VACV group.
It has become increasingly evident that approximately 25-30 days following the end of 
antiviral prophylaxis,  late-onset HCMV  infection and disease has become  a problem 
(Emery, 2001).  This is intensified by the delay in antiviral drug intervention when viral 
loads are low due to infrequent outpatient visits, thus resulting in an increased risk of 
HCMV disease and viral replication that is more difficult to control.  Furthermore, since 
the duration of therapy required to reduce viral load to undetectable levels is directly 
related  to  the  initial  viral  load,  these  patients  will  require  an  extended  period  of 
intravenous  (iv)  GCV  therapy.  Another  potential  problem  concerning  prophylactic 
therapy is the development of resistance of HCMV to the antiviral drugs.  Mutations in 
the  UL97  protein  kinase,  the  UL54  CMV  DNA  polymerase  or  both  are  the  major 
mechanisms  by  which  HCMV  becomes  resistance  to  GCV  (Chou  et  al.,  1999). 
Resistance  to  GCV  following  prophylaxis  has  been  reported  in  organ  transplant 
recipients (Limaye et al., 2000).  Cross-resistance to other antiviral agents has also been 
demonstrated (Baldanti et al.,  1996).  Recently, valganciclovir (VGCV), a valine ester 
prodrug of GCV,  was developed to  overcome the  limitations  of GCV.  This  drug  is 
currently  undergoing  clinical  trials,  and  there  is  limited  data  available  on  VGCV 
prophylaxis in organ transplant recipients.  In one recent study, oral VGCV (900 mg 
once-daily) was as clinically effective and well-tolerated as oral GCV (1000 mg three 
times a day) for HCMV prevention in D+R- SOT recipients.  The safety profile was 
also similar for both drugs (Paya et al., 2004).
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13.113 Pre-emptive therapy
Pre-emptive therapy is given to high-risk patients on the basis of detection of HCMV in 
the blood (Emery, 2001).  Since the drug is only targeted to patients who are at risk of 
future HCMV disease, it reduces the number of patients exposed to the potentially toxic 
antiviral  drug,  lowers  the  risk  of drug  resistance,  and  maximizes  cost-benefit.  The 
success  of pre-emptive  therapy  is  dependent  on  early diagnosis  of HCMV  infection 
using  sensitive  detection  methods  such  as  PCR,  nucleic  acid  sequence-based 
amplification (NASBA) and antigenemia.  In our centre, pre-emptive therapy is initiated 
when two consecutive blood samples are HCMV DNA positive by PCR (Mattes et al., 
2004).  Studies  in  BMT  and  SOT  recipients  have  shown  that  using  either  PCR  or 
antigenemia to initiate pre-emptive therapy is superior to therapy initiated on the basis 
of cell culture results (Hebart et al.,  1997; Boeckh et al.,  1996).  A number of studies 
involving the pre-emptive treatment of high risk transplant patients have demonstrated a 
reduction  in  the  rate  of HCMV  disease  comparable  to  that of universal  prophylaxis 
(Boeckh et al., 1996; Kusne et al., 1999).
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1.4  Human herpesvirus 6 (HHV-6)
1.4.1 Discovery
HHV-6  was  first  isolated  in  1986  from  the  PBMCs  of  six  patients  with 
lymphoproliferative disorders, some of whom were infected with HIV-1  (Salahuddin et 
al.,  1986).  The  herpesvirus  was  originally  designated  human  B-lymphotropic  virus 
(HBLV) based on its apparent in vitro tropism for freshly isolated B-cells.  However, 
subsequent laboratories established that this newly described virus was most likely to be 
found and to grow in CD4+ T lymphocytes (Downing et al.,  1987; Lopez et al.,  1988; 
Lusso et al., 1988; Takahashi et al., 1989).  The virus was subsequently renamed HHV- 
6,  in accordance with the guidelines established by the  ICTV  (Ablashi  et al.,  1987). 
The HHV-6 genome is  160-162 kbp, and contains over 100 ORFs.  More than 65% of 
the HHV-6 predicted genes have a recognized counterpart in HCMV (Gompels et al., 
1995).
1.4.2 HHV-6 variants A and B
HHV-6  consists  of two  closely related  yet distinct viruses,  designated HHV-6A  and 
HHV-6B.  Recently,  the  complete  nucleotide  sequence  of HHV-6A prototype  strain 
U1102 and HHV-6B strains Z29 and HST has been determined (Gompels et al.,  1995; 
Isegawa  et al.,  1999).  HHV-6A  and  HHV-6B  have  an  overall  nucleotide  sequence 
identity  of  90%.  However,  the  two  variants  differ  with  respect  to  a  number  of 
properties  including  restriction  enzyme  profiles,  nucleotide  sequences,  growth 
properties in vitro and reactivity with panels of monoclonal Abs (mAbs) (Ablashi et al., 
1991; Aubin et al., 1993).
1.4.3 Propagation and Cell Tropism
The  primary  target  cells  for  HHV-6  are  CD4+  T-lymphocytes  (Lusso  et  al.,  1988; 
Takahashi et al.,  1989).  All HHV-6 isolates replicate in activated peripheral or cord 
blood mononuclear cells, but can be  adapted to grow in continuous  T-cell  lines  that 
include HSB-2 and JJHAN cells for HHV-6  A, and Molt-3 and MT-4 T cells for HHV- 
6B (Ablashi et al.,  1991).  Although HHV-6 most efficiently replicates in activated T 
cells,  it  has  the  ability  to  infect  a  broad  range  of  cell  types  in  vitro  including 
lymphocytes,  monocytes,  epithelial  cells,  endothelial  cells,  fibroblasts,  glioblastoma 
cells,  fetal astrocytes and adult oligodendrocytes (Ablashi et al.,  1987;  Kondo et al., 
1991; He et al., 1996; Albright et al.,  1998; Wu and Shanley,  1998).  In vivo, CD4+ T
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cells and monocytes appear to be the preferential target for fully permissive replication 
(Takahashi et al.,  1989; Kondo et al., 2002b).  In addition, CD8+, gamma/delta (y5) T- 
lymphocytes,  and  NK  cells  support  HHV-6  replication  in  association  with  surface 
expression  of CD4  (Lusso  et a l,  1993;  1995).  An  HHV-6A  and  HHV-6B  cellular 
receptor (CD46) was recently identified  (Santoro  et al.,  1999).  CD46,  a ubiquitous 
type-1  glycoprotein (also a cellular receptor for vaccine strains of measles virus and 
group B adenovirus), is expressed on the surface of all nucleated cells and is a regulator 
of complement activation (Santoro et al., 1999).
1.4.4  Epidemiology and virus transmission
Seroepidemiologic  studies  have  shown  that  HHV-6  is  ubiquitous  in  the  population, 
seroprevalence is over 90% in healthy adults, and infection is widespread throughout 
the  world.  The  majority  of individuals  undergo  primary  HHV-6  infection  during 
childhood, usually within the first two years of life (Okuno et al., 1989).  Viral loads in 
blood  are  also  high  during  primary  infection  and  appear  to  peak  at  around  105  
genomes/pg PBMC DNA (Clark et al., 1997).  The most likely route of transmission of 
HHV-6 is the saliva.  HHV-6 DNA has been detected in saliva of children and healthy 
adults  by  PCR,  and  there  is  evidence  of horizontal  infection  through  saliva  within 
families  (van  Loon  et al.,  1995).  HHV-6B  DNA has  been  detected by  PCR  in  the 
cervices of nearly 20% of 72  women in the late stages of their pregnancies, compared 
with 6% of non-pregnant controls (Okuno et al.,  1995), and in the female genital tract 
by  PCR  (Leach  et  al.,  1994)  suggesting  perinatal  virus  transmission  through 
transvaginal delivery.  Intrauterine transmission of HHV-6 has also been reported.  Viral 
DNA is detectable in fetus or blood of newborn babies (Aubin et al.,  1992; Hall et al., 
1994).
Most HHV-6 infections in children are believed to be due to HHV-6B.  HHV-6B was 
detected by PCR in oropharyngeal secretions and PBMCs of >90% of children, whereas 
HHV-6A was found in <3% (Hall et al., 1998).  However, the true prevalence of HHV- 
6A appears to be underestimated by testing blood and saliva (Clark, 2003).  HHV-6A is 
more frequently detected in skin biopsies (Di Luca et al., 1996) and cerebral spinal fluid 
(CSF) (Hall et al, 1998).
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1.4.5 Primary infection
Primary  infection  with  HHV-6B  has  been  shown  to  be  associated  with  exanthem 
subitum  (ES)  (roseola  infantum),  a  common,  mild  acute  febrile  disease  of  infants 
(Yamanashi et al.,  1988).  Although febrile illness is usually self-limiting, it accounted 
for nearly  10% of visits of children with acute febrile illness to a hospital emergency 
room (Hall et al.,  1994).  Complications of primary HHV-6 infections have also been 
reported, but are uncommon.  The most common is febrile convulsion and more rarely 
meningitis  (Huang  et al.,  1991),  hepatitis  (Asano  et al.,  1990),  meningoencephalitis 
(Ishiguro et al.,  1990) and fatal encephalitis (Asano et al.,  1992).  Reports of HHV-6 
DNA detection in CSF of children complicated by seizures (Kondo et al., 1993; Suga et 
al., 1993) indicate that neurological complications in children infected with HHV-6 are 
a likely result of HHV-6 directly infecting the central nervous system (CNS).  Primary 
infection in adults is relatively rare and more severe than in children.  An EBV-negative 
infectious  mononucleosis  (Steeper  et  al.,  1990),  prolonged  lymphadenopathy 
(Niederman  et  al.,  1988),  and  fulminant  hepatitis  (Sobue  et  al.,  1991)  have  been 
described.
1.4.6 HHV-6 persistence in the host
Like the other human herpesviruses, HHV-6 persistently infects humans after primary 
infection.  This persistence is likely to include both a latent state with infectious virus 
only produced during episodes of reactivation, and chronic replication with production 
of infectious virus.  Salivary glands are a candidate site of chronic infection as HHV-6 
is frequently detected in the saliva by PCR (Jarrett et al., 1990).  In a study by Sada et 
al.  (1996)  HHV-6  DNA  was  demonstrated  in  three  different  salivary  glands 
(submandibular,  parotid  and  lip),  although  the  submandibular  gland  (88%)  had  the 
highest frequency of HHV-6 DNA compared to 63% in the parotid gland and 53% in 
the lip salivary gland.
HHV-6  can be  detected  in the  PBMCs using nested PCR,  reflecting  low viral  loads 
(Clark et al.,  1996) and most likely latent virus.  The detection of HHV-6 U94 mRNA 
in  the peripheral  blood  of healthy  individuals  has  been reported  suggesting  latency- 
associated  gene  expression  (Rotola  et  al.,  1998).  The  actual  site  of HHV-6  latent 
infection is not completely clear, although possible sites include monocytes and early 
bone marrow progenitor cells (Kondo et al.,  1991; Luppi et al.,  1999).  HHV-6  A and
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HHV-6B are also neurotropic.  In a study investigating the presence of HHV-6 in post 
mortem brain tissue, up to 85% of individuals harboured HHV-6 DNA in the brain as 
detected  by  PCR.  HHV-6B  was  predominantly  detected,  although  HHV-6A  was 
detected in 27.5% of brains and co-infections were also observed (Chan et al., 2001). 
These results suggest that human brain may be another site for HHV-6 latency.  HHV- 
6B has been shown to be reactivated from latency by infection with HHV-7 but not by 
T-cell stimulation in vitro (Katsafanas et al., 1996).  The stimuli for HHV-6 reactivation 
in vivo are uncharacterized, but are likely to include immunosuppression.
Some studies have also demonstrated widespread distribution of HHV-6 DNA in organs 
derived  from  both  immunocompetent  and  immunocompromised  hosts  (Clark  et  al., 
1996;  Emery et al.,  1999b) with  overall  low viral  loads  detected  in  the  majority  of 
tissues.  In  the  study  by  Clark  et  al.  (1996),  HHV-6  viral  loads  were  however, 
significantly  increased  in  autopsy  tissues  from  AIDS  patients  compared  to  controls 
suggesting upregulation of HHV-6 replication in the former.
1.4.7  HHV-6 integration
An  alternative  form  of HHV-6 persistence  characterized by very high  viral  loads  in 
PBMC and  integration of apparently whole-genome length HHV-6 sequences into host­
cell chromosomes is present in a small but significant subset of the population (Luppi et 
al.,  1993; Torelli et al.,  1995).  Integration of HHV-6 into host cell chromosomes was 
first reported in three individuals (B cell lymphoma, Hodgkin’s disease, and a patient 
with  multiple  sclerosis)  who  had  unusually  high  copy  numbers  of HHV-6  in  their 
PBMC (Luppi et al., 1993).  Abnormally high viral loads found in PBMC may represent 
integration in a bone marrow progenitor cell which gives rise to a range of differentiated 
cells,  each  harbouring  viral  sequences  (Luppi  et  al.,  1999).  Further  analysis  by 
fluorescence  in situ hybridisation  (FISH)  with HHV-6  specific  probes  showed  in  all 
three  cases the presence  of a specific hybridisation  site,  located  on the  short arm  of 
chromosome  17 (Torelli et al.,  1995).  Morris et al. (1999) suggested that the sites of 
integration were close to or in the telomeres of chromosome  17 (Morris et al.,  1999). 
At present the exact molecular mechanisms of HHV-6 integration to chromosomal sites 
are unknown.  There  are human telomeric-like repeat sequences  at both ends  of the 
HHV-6 genome (Gompels and Macaulay,  1995), which may be relevant to the mode by 
which  the  virus  integrates  into  human  chromosomal  DNA  (Clark,  2000;  2003).
66Chapter  1   General  Introduction
Recently,  the  possibility  of  chromosomal  transmission  of  HHV-6  DNA  has  been 
reported  (Daibata  et  al.,  1999).  A  woman  with  Burkitts  lymphoma,  and  her 
asymptomatic husband had HHV-6 DNA  integrated at chromosome 22ql3  and  lq44 
respectively.  Their  daughter  was  found  to  have  integrated  virus  at  both  these 
chromosomal  sites  suggesting  entry  of  viral  sequences  into  the  germline  and 
chromosomal inheritance (Daibata et al., 1999).
The clinical  significance of integrated forms of HHV-6  sequences remains uncertain, 
although viral reactivation  from  an  integrated  latent  state  has been  demonstrated for 
Marek’s disease virus, which is a T-cell tropic herpesvirus that infects birds (Delecluse 
et al.,  1993).  Integrated virus  is also a potential confounder in  studies  investigating 
HHV-6 disease associations and also in the medical management of infection (Emery 
and Clark, in press).  Unproven associations between HHV-6 and disease may reflect 
the unrecognized detection of integrated virus and interpreted as a high viral load.  From 
the management perspective, it is important to differentiate patients with active HHV-6 
infection  from  those  patients  with  integrated  virus  to  prevent  the  latter  receiving 
unnecessary exposure to potentially toxic antiviral drugs.
1.4.8  HHV-6 and immunomodulation
Based on in vitro studies, HHV-6 has potential immunomodulating properties including 
the ability to alter the expression of immune activation molecules (reviewed by Clark, 
2003).
Productive  infection  of  HHV-6  has  a  variety  of  effects  on  T  cells.  The  virus 
downregulates CD3  in  infected T cells  (Lusso et al.,  1991).  Because the CD3/TCR 
complex  is important in the T cell activation processes, downregulation of CD3  may 
have  an  immunosuppressive  effect.  HHV-6  has  also  been  shown  to  upregulate  the 
chemokine  receptor,  CCR7,  in  infected  T  cells  (Yoshida et al.,  1997)  and to  down- 
regulate  CXCR4  expression  by  decreasing  the  association  of  the  CXCR4  gene 
repressor,  YYl,  thereby  altering  the  chemotactic  response  of directly  infected  cells 
(Hasegawa et al.,  2001).  Downregulation  of CD46  also  occurred  following  HHV-6 
infection  (Santoro  et  al.,  1999).  In  addition,  HHV-6A  has  been  reported  to 
downregulate HLA class  1   molecules in infected dendritic cells, suggesting a potential 
immune  evasion  strategy  (Hirata  et  al.,  2001).  HHV-6  may  also  modulate  the
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expression of a number of cytokines.  HHV-6 is potent inducer of IFN-y, TNF-a, and 
IL-1(3  (Flamand  et  al.,  1991)  as  well  as  IL-10  and  IL-12  expression  in 
monocytes/macrophages (Li et al.,  1997).  HHV-6 infection of PBMC was reported to 
upregulate NK cell cytotoxicity, which may be mediated in part by increased expression 
of EL-15 (Flamand et al.,  1996).  Furthermore, infection of PBMC by HHV-6 has been 
found to suppress T cell function including reduced IL-2 synthesis and cell proliferation 
(Flamand et al., 1995).
HHV-6 also possess genes with homology to the GPCRs (U12 and U51).  HHV-6 U12 
functionally encoded a calcium-mobilizing receptor for p-chemokines RANTES, MIP-1 
a  and  -lp,  and  MCP-1,  but  not  the  a-chemokine  IL-8  (Isegawa  et  al.,  1998).  The 
product of U12  may therefore play an important role in the pathogenesis  of HHV-6 
through  transmembrane  signaling.  HHV-6  U51  showed  specific  binding  of the  CC 
chemokine  RANTES,  and  in  epithelial  cells  already  secreting  RANTES,  U51 
expression led to specific transcriptional downregulation (Milne et al., 2000).
HHV-6 also encodes a potential viral chemokine.  The HHV-6B U83 protein was found 
to be capable of inducing transient calcium mobilization and to chemotactically activate 
human monocytic THP-1  cells (Zou et al.,  1999).  Recently, the chemokine receptor 
CCR2 which binds U83B has been reported (Luttichau et al., 2003).  These findings 
suggest  that  the  protein  may  play  a  critical  role  in  HHV-6  replication  in  vivo  by 
activating and recruiting mononuclear cells.  However, the U83 gene in HHV-6  A strains 
appears to lack a signal peptide and may therefore not be secreted from an infected cell 
(Zou et al., 1999).
1.4.9  HHV-6 infection following transplantation
Like  other  members  of  the  herpesviruses,  HHV-6  has  the  potential  for  enhanced 
pathogenicity in the immunocompromised host such as those iatrogenically-suppressed 
as a result of transplantation.  Studies using both cell culture and more sensitive PCR- 
based  assays  have  shown  that  infection  with  HHV-6  in the  post-transplant period  is 
common.  The peak  incidence  of HHV-6  infection  is  2-4 weeks post-transplantation 
(Griffiths  et  al.,  2000)  and  although  the  source  of the  virus  has  not  been  precisely 
defined, the high HHV-6 rate of seropositivity in the general population suggests most 
infections in transplant patients are likely to result from reactivation of the recipient’s
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latent virus.  This has been demonstrated to occur in a case where a transplant recipient 
had two  HHV-6  strains  isolated before  and after BMT.  Restriction fragment length 
polymorphism analysis of both strains indicated that the virus which later reactivated 
was  the  same  as  that  harboured  latently  in  the  recipient  (Yoshikawa  et  al.,  1991). 
However,  HHV-6  DNA  has  been  detected  in  28%  of bone  marrow  samples  from 
healthy individuals by PCR indicating a possible source of virus transmission from the 
donor to the recipient (Gautheret-Dejean et al., 2000), and cases of primary infection 
have been reported  in BMT  recipients  (Lau  et al.,  1998),  and  in  living-related  liver 
transplantation  (Yoshikawa  et  al.,  2001).  Both  HHV-6A  and  HHV-6B  have  been 
detected in the post-transplant period, although the latter is more common.
1.4.9.1  HHV-6 infection in bone marrow transplant recipients
Most studies delineating the potential pathogenic role of HHV-6 in transplant patients 
have  arisen  from  BMT  recipients.  The  reported  incidence  of  HHV-6  infection 
following BMT ranges from 28% to 75% (median 48%) depending on the diagnostic 
method (Dockrell and Paya, 2001).
Case reports and retrospective studies have reported the association of HHV-6 with a
range of disease manifestations including pneumonitis (Carrigan et al.,  1991; Cone et
al.,  1993), bone marrow suppression (Drobyski et al.,  1993; Carrigan and Knox,  1994),
early  and  late  graft  failure  (Rosenfeld  et  al.,  1995;  Johnston  et  al.,  1999),  and
encephalitis (Drobyski et al.,  1994).  A study of 16 BMT patients from which HHV-6
was  directly  isolated  from  the  blood  of  6  patients,  showed  idiopathic  marrow
suppression occurred more frequently in 67% (4 of 6) of patients with concurrent HHV-
6 viraemia, than in  10% (1 of 10) of patients without viraemia (P<0.05).  In addition,
HHV-6 was cultured from the bone marrow of all four patients with viraemia at the time
of marrow suppression (Drobyski et al.,  1993).  This is supported by in vitro evidence
of  HHV-6  suppression  on  the  maturation  and  growth  of  normal  bone  marrow
precursors, including granulocyte/macrophage, erythroid, and megakaryocytic lineages
(Burd et al.,  1993;  Drobyski  et al.,  1993;  Isomura et al.,  1997;  2000).  To critically
assess the clinical impact of HHV-6 following BMT, a number of prospective studies
have  been  carried  out  (see  table  1.8).  In  some  of these  studies  where  the  whole
population  was  analysed,  definitive  HHV-6  associated  diseases  have  not  been
established.  However, subgroup analysis has reported the association of HHV-6 with
clinical  illness  including  rash,  delayed  engraftment,  and  graft  versus  host  disease
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(GVHD) (Cone et al.,  1999; Yoshikawa et al.,  1991; Wilbom et al.,  1994; Appleton et 
al.,  1995).  Other studies have not linked HHV-6 with clinical disease (Kadakia et al., 
1996; Chan et al., 1997).
70Study Method of 
Detection No. of Pts No. of 
bloods Observed disease
Wilbom et al (1994) PCR 57 514 GVHD*
Appleton et al (1995) PCR 57 NG
GVHD* (PCR skin/rectal 
biopsies)
Kadakia et al(1996) VI 26 NG None
Wanget al (1996) PCR 37 270
Delayed granulocyte and 
platelet engraftment*
Chan et al (1997) PCR 61 563 None
Cone et al (1999) PCR 20 264 Rash*
Maeda et al (1999) PCR 38 209 Delayed platelet 
engraftment
Ljungman et al (2000) QCPCR 74 494
Viral load correlated with 
delayed platelet engraftment
Imbert-Marcille et al 
(2000) PCR 92 961 Myelosuppression and fever
Yoshikawa et al (2002) VI 82 NG Rash*
Table 1.8 Prospective studies of HHV-6 post bone marrow/ stem cell transplantation (Clark, 2003).
Abbreviations: * analysis on subgroup of patient population; NG, not given; PCR, polymerase chain 
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1.4.9.2  HHV-6 infection in solid organ transplant recipients
As  with  BMT,  HHV-6  infection  occurs  frequently  after  SOT  with  detection  rates 
varying from 0% to 82% (median 32%) again depending on the assay used (Dockrell 
and Paya, 2001).  The clinical impact of HHV-6 infection after liver transplantation has 
been  mostly  supported  by  case  reports  where  HHV-6  associated  bone  marrow 
suppression,  interstitial  pneumonitis,  encephalitis  and  hepatitis  (Singh  et  al.,  1997; 
Singh and Paterson, 2000; Ward et al.,  1989) have been reported.  However,  several 
prospective  studies  examining  the  pathogenic  role  of HHV-6  in  patients  who  have 
undergone  liver  or  renal  transplantation  have  failed  to  show  any  particular  disease 
association (Schmidt et al.,  1996; Herbein et al., 1996; Osman et al.,  1996; Kidd et al., 
2000) (see table 1.9).
Although prospective studies report a low incidence of HHV-6 end-organ disease, the 
indirect effects  of this virus  are  likely to be  significant in the post-transplant period 
(Humar et al., 2002; Mendez et al., 2001; Griffiths et al., 1999a).  As mentioned above, 
HHV-6 is common after transplantation, therefore infection with more than one human 
p-herpesvirus may occur and interaction among these viruses could exacerbate existing 
pathological processes.  A study by Desjardin et al. (1998) in renal transplant recipients 
showed HHV-6 reactivation, documented by a 4-fold rise in Ab titre, was associated 
with an increased risk of HCMV disease after primary HCMV infection.  Similarly, in a 
cohort  of  247  liver  transplant  recipients,  HHV-6  seroconversion  was  significantly 
associated  with  symptomatic  HCMV  infection  in  HCMV-positive  recipients  of 
transplants from HCMV-positive donors (Dockrell et al.,  1997).  Studies in both liver 
and renal transplant patients have shown that concomitant infection with both HHV-6 
and  HCMV  is  associated  with  more  severe  clinical  disease  (Herbein  et  al.,  1996; 
Ratnamohan et al.,  1998).  HHV-6 infection has also been suggested to predispose to 
bacterial  and  fungal  superinfections,  possibly  due  to  its  immunosuppressive  effects. 
HHV-6  seronegativity  before  transplantation  has  been  shown  to  be  an  independent 
predictor  of invasive  fungal  infection  during  the  first  90  days  after  transplantation 
(Dockrell et al.,  1999).  In a study of 200 liver transplant patients Humar et al. (2002) 
showed  that  HHV-6  infection  was  significantly  associated  with  the  development  of 
opportunistic  infections  (predefined  viral,  fungal  and  bacterial  disease)  and  HCMV 
disease.
72Study Transplant type Method of 
detection No. of pts No. of bloods Observed disease
Schmidt (1996) liver PCR 46 287 None
Herbein (1996) liver, renal VI 32 NG None
Osman (1996) renal PCR 56 NG None
Ratnamohan (1998) renal, pancreas PCR 30 NG Fever
Griffiths (1999a) liver PCR 60 536 Graft rejection
Kidd (2000) renal PCR 52 596 None
Lautenschlager (2000) liver Ag 51 622 Graft dysfunction*
Rogers (2000) liver VI 80 NG
CNS disease Fungal 
infections
Mendez (2001) liver PCR 33 NG CMV disease
Humar (2002) liver PCR 200 NG
Opportunistic 
infections 
CMV disease 
Graft rejection*
Table 1.9. Prospective studies of HHV-6 post solid organ transplantation (Clark, 2003).
Abbreviations: * analysis on subgroup of patient population; NG, not given; PCR, polymerase chain reaction; VI, virus 
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An association between HHV-6 and graft rejection has also been suggested.  A study 
conducted in our centre (and which forms the basis of the work presented in chapter 5) 
of 60 consecutive liver transplant recipients showed that infections with HHV-6 and/or 
HHV-7  are  common  after  transplantation,  and  that  they  occur  earlier  than  HCMV 
infection (the median time to first PCR positive sample was 20 days for HHV-6, 26 
days  for HHV-7  and 36 days for HCMV) (Griffiths et al.,  1999a).  The quantitative 
competitive PCR (QC-PCR) results also showed that the peak viral load of non-primary 
HCMV  infection  was  significantly  greater  than  that  for  HHV-6  and  HHV-7. 
Clinicopathological  analyses  have  shown  that  all  three  viruses  were  significantly 
associated  with  altered  graft  function,  and  that  both  HHV-6  and  HCMV  were 
independently associated with biopsy proven rejection suggesting that HHV-6 may be a 
previously  unrecognized  pathogen  in  this  patient  group  (Griffiths  et  al.,  1999a). 
Consistent with these  findings  is  a  study by Lautenschlager et al.  (2000)  who  used 
HHV-6 antigenemia assay for the diagnosis of HHV-6 infection.  Of 51  consecutive 
liver  transplant  recipients,  approximately  22%  of  patients  had  HHV-6  infection 
diagnosed  during  the  first  year  after  transplantation.  Significant  graft  dysfunction 
consistent with organ rejection was associated with the detection of HHV-6 antigenemia 
in  8  of the  11  patients,  and  in  3  of these  patients  HHV-6  viral  Ags  could  also  be 
detected in the liver biopsy.  HHV-6 could directly participate in the rejection process 
by  triggering  or  exacerbating  the  inflammatory response.  This  is  supported  by  the 
finding  that  HHV-6  infection  in  the  liver  increased  the  expression  of  adhesion 
molecules and the number of HLA class II positive cells (Lautenschlager et al.,  1999). 
Some studies have also linked HHV-6 infection with graft rejection in renal transplant 
patients  (Okuno  et  al.,  1990;  Jacobs  et  al.,  1994),  although  this  has  not  been 
demonstrated by others (Merlino et al., 1992).
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1.5  Human herpesvirus 7 (HHV-7)
HHV-7  is  the  most  recently  discovered  member  of the  p-herpesvirus  subfamily  of 
herpesviruses.  HHV-7 is  145 kbp in genome size and potentially encodes at least 84 
different proteins.  HHV-7 is genetically most closely related to both HHV-6 variants, 
with nucleic  acid sequence identities ranging from 20.7% to  75.7% in various  genes 
(Dominguez  et  al.,  1996;  Singer  and  Frenkel,  1997).  The  virus  also  shares  some 
similarities in cell tropisms, disease associations, and some common antigenic epitopes 
(reviewed in Black and Pellett, 1999).
1.5.1 Discovery
HHV-7 was first isolated in 1990 from CD4+ T lymphocytes purified from PBMCs of a 
healthy HIV-negative  donor.  The  cells were  activated with  anti-CD3  mAb  together 
with either EL-2 or anti-CD28 mAb (Frenkel et al.,  1990).  The cells exhibited a CPE 
after approximately 2 weeks in culture,  and electron microscopic analysis revealed a 
characteristic herpesvirus structure.  The virus could not be isolated from unstimulated 
cells.  Using similar methods, additional strains of HHV-7 were isolated from peripheral 
blood lymphocytes (PBL) (Frenkel and Wyatt,  1992), and from the cell-free fraction of 
more than 75% of saliva specimens (Wyatt and Frenkel, 1992; Hidaka et al., 1993) from 
healthy adults.
1.5.2 Propagation and Cell Tropism
HHV-7  has  a  narrow  cell  tropism  of CD4+  T  cells,  such  as  phytohaemagglutinin 
(PHA)-stimulated human  cord blood mononuclear cells  (CBMCs)  and  PBMCs,  after 
which infection can be transferred to the continuous CD4+ immature T-cell line SupTl 
to support HHV-7 growth (Bememan et al.,  1992).  HHV-7 uses CD4 as its cellular 
receptor for primary attachment onto  susceptible cells  (Lusso  et al.,  1994),  although 
CD4  alone  is  not  sufficient  to  support  a  productive  infection  as  suggested  by  the 
inability of HHV-7 to infect several CD4+ lymphoid cell lines (Yasukawa et al.,  1997). 
HHV-7 infection down-modulates cell surface CD4 expression (Furukawa et al.,  1994), 
as  well  as  the  CXCR4  in  CD4  T  cells  (Secchiero  et  al.,  1998).  Because  of the 
competition for the CD4 receptor,  in vitro HHV-7 is able to interfere negatively with 
HIV and to protect infected cells from HIV superinfection (Lusso et al., 1994).  In vivo, 
HHV-7  tropism  is  less  restricted  than  in  cell  cultures.  CD68-positive 
monocytes/macrophages  appear  to  be  infected  with  HHV-7  (Kempf  et  al.,  1997).
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Zhang et al. (2001) have also demonstrated productive infection of macrophages with 
HHV-7.  In addition, HHV-7 has also been detected in normal human tissues by IHC, at 
higher levels in lung, skin and mammary glands and at lower levels in liver, kidney and 
tonsils  (Kempf et al.,  1998).  These  findings  show that the  virus  remains  in human 
tissues in a persistent form.
1.53 Epidemiology and transmission
HHV-7 is ubiquitous and seroprevalence ranges from 60% to over 90% in the healthy 
adult populations (Black and Pellet, 1999).  Like HHV-6, infection with HHV-7 occurs 
early in life.  The peak of seroconversion for HHV-7  occurs after 24 months of age 
(Tanaka-Taya et al.,  1996) and is slightly later than seroconversion for HHV-6 which 
peak at 13 months (Okuno et al., 1989).  Viral loads are also high during this period of 
acute infection and can reach 107 genomes/pg PBMC DNA (Clark et al., 1997).  HHV-7 
DNA can frequently be detected by PCR in the saliva of both adults and children (Kidd 
et  al.,  1996;  Tanaka-Taya  et  al.,  1996).  Molecular  epidemiological  evidence  for 
horizontal transmission of HHV-7 also exists (Takahashi et al.,  1997a; Thawaranantha 
et al., 2002).  In the study by Takahashi et al. (1997a) similar restriction endonuclease 
patterns of viral DNA purified from saliva isolates of family members living in the same 
household were  found.  HHV-7  DNA has  also been detected at high  frequencies  in 
salivary gland tissue (Di Luca et al.,  1995;  Sada et al.,  1996), and viral protein was 
detected in the acini and the epithelial cells (Yadav et al., 1997).  Thus, salivary glands 
appear to be the reservoir of persistent HHV-7 replication and saliva is the most likely 
route of viral transmission.  In addition, HHV-7 has been detected by PCR in 3% of the 
cervixes of women in the later stages of pregnancy (Okuno et al.,  1995) suggesting the 
potential for perinatal transmission.  HHV-7, but not HHV-6 has also been detected in 3 
of 29 breast milk samples, breast feeding may therefore be  another route  of HHV-7 
transmission (Fujisaki et al., 1998).
76Chapter  1   General  Introduction
1.5.4 Primary infection
Similar to HHV-6, primary infection usually occurs during childhood, with majority of 
children infected by 3 years of age (Clark et al.,  1993).  Early reports have suggested 
that the primary aetiological agent of ES is HHV-6B (Yamanashi et al.,  1988).  Recent 
studies have  also  indicated that HHV-7  may be  an additional  causative  agent of ES 
(Tanaka et al,  1994; Asano et al,  1995).  However, several serological studies have 
indicated that most children acquire HHV-6 prior to HHV-7 (Tanaka-Taya et al., 1996; 
Caserta et al., 1998) suggesting that reactivated HHV-6 may be a potential cause of the 
clinical  symptoms.  An association between HHV-7  and Pityriasis rosea,  a relapsing 
rash illness, has also been described (Drago et a l, 1997) although results have not been 
confirmed (Kempf et al, 1999).  A recent case of delayed primary HHV-7 infection in a 
19  year  old  immunocompetent  individual  with  encephalitis  has  also  been  reported 
(Ward etal, 2002).
1.5.5 HHV-7 latency and persistence
Like  the  other  p-herpesviruses,  after  primary  HHV-7  infection,  the  virus  is  able  to 
establish lifelong persistence.  Similar to HHV-6, HHV-7 DNA can be detected in the 
PBMC  of healthy  immunocompetent  individuals  using  nested  PCR  suggesting  low 
levels of latent virus in peripheral blood (Kidd et al,  1996).  In contrast, HHV-7 viral 
loads are maintained at high levels in saliva of seropositive individuals (Fujiwara et al., 
2000).  As mentioned above, salivary glands are a major site of replication following 
primary infection, and saliva the mode of virus transmission.
1.5.6 HHV-7 infection following transplantation
Yalcin et al (1994) used virus isolation, PCR and serological assays to investigate the 
prevalence of HHV-7 infection in renal transplant patients compared to that in a control 
group.  The  prevalence  of HHV-7  DNA  was  found  to  be  the  same  in  patients  and 
controls (19%).  However, the mean Ab titre of HHV-7  in patients was  significantly 
higher than that of the matched healthy controls (1:171  versus  1:49),  suggesting that 
HHV-7  primary  infection  or  reactivation  occurring  at  some  time  during  the  post­
transplantation period.  A direct causal association between HHV-7 and clinical illness 
in the transplant setting has not yet been established.  HHV-7 has been associated with 
encephalitis in BMT and hepatitis in liver transplant patients (Griffiths et al.,  1999a;
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Chan et al., 1997), although others have failed to detect an association between HHV-7 
and engraftment or the incidence of GVHD (Wang et al., 1996; Chan et al., 1997).
Subsequent prospective studies have reported associations between the development of 
HCMV disease in transplant recipients and concurrent HHV-7 activity (see table 1.10). 
Osman et al.  (1996)  monitored PBL from  56 renal  transplant recipients  by PCR  for 
approximately  3  months  after  transplantation.  Twenty  eight  patients  had  HCMV 
DNAemia, and 8  developed HCMV disease.  The risk of developing HCMV disease 
was increased if patients had HCMV and HHV-7 DNA in PBMCs.  Development of 
HCMV disease was also associated with rising Ab titres to HHV-7, and this suggests 
that HHV-7 may be a cofactor in disease progression.  A recent study by Tong et al. 
(2000) investigated 37 renal transplant recipients for the presence of HHV-6 and HHV- 
7 DNA and serologic responses to these viruses for 12 weeks after renal transplantation. 
They found that plasma HCMV load and the occurrence of HCMV disease was related 
to the serologic response to HHV-6 and HHV-7, although only the presence of HHV-7 
DNA in PBL and HCMV donor/recipient serostatus were significantly associated with 
HCMV disease in logistic regression analysis.  Consistent with data showing that high 
HCMV load increases the possibility of HCMV disease, patients with detectable HHV-7 
DNA had significantly higher peak plasma HCMV loads.  The possibility of HHV-7 
affecting the replication of other p-herpesviruses is supported by reports showing that in 
vitro HHV-7  infection can reactivate latent HHV-6 (Katsafanas et al.,  1996;  Tanaka- 
Taya et al., 2000).
The association of HHV-7 and graft rejection has also been reported.  A prospective 
study by Kidd et al. (2000) carried out in our centre (and which forms the basis of the 
patient population studied in chapter 4) on 52 renal transplant recipients showed that the 
median  maximum viral  load  of HCMV  to be  greater than  that  for either HHV-6  or 
HHV-7.  There was a trend for HHV-7 maximum viral loads tend to be greater than 
those  of HHV-6  (P=0.08).  Clinicopathological  analysis  showed  that  patients  with 
HCMV and HHV-7  coinfection were more likely to have HCMV disease than those 
with HCMV infection only.  HHV-7, but not HHV-6 was significantly associated with 
increased episodes of graft rejection.  HHV-7 is a possible cofactor in the development 
of HCMV disease  in renal transplant recipients  and may potentially exacerbate graft 
rejection.  A recent report by Lowance et al. (1999) showed that prophylactic treatment
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with a high dose VACV for 90 days after renal transplantation reduced the risk of acute 
graft rejection (50% reduction), and this may partly be mediated by the inhibitory effect 
of this  drug  on  HHV-6  and  HHV-7  replication  as  well  as  to  its  effects  on  HCMV 
replication.
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Study Transplant type Method of 
detection No. of pts No. of 
bloods
Observed
disease
Osman et al (1996) renal PCR 56 NG CMV disease
Kidd et al (2000) renal PCR 52 296
CMV disease 
Graft rejection*
Tongetal  (2000) renal PCR 37 NG CMV disease
Mendez et al (2001) liver PCR 33 NG CMV disease
Wang et al(1996) bone marrow PCR 37 270 None
Chan et al (1997) bone marrow PCR 61 563
Delayed
engraftment*
Maeda et al (1999) bone marrow PCR 38 209 None
* analysis on subgroup of patient population
Table 1.10 Prospective studies of HHV-7 post-transplantation (adapted from Clark, 2002)Chapter  1   General  Introduction
1.5.7  Antiviral susceptibility of HHV-6 and HHV-7
There  have  been no  controlled  trials  of antiviral  therapy  against  HHV-6  or  HHV-7 
infection.  However, case reports have shown the potential of existing antiviral drugs 
(GCV and/or PFA) used for HCMV to suppress HHV-6 replication in vivo (Johnston et 
al.,  1999; Zerr et al., 2002).  Clinical response of HHV-6 encephalitis or other CNS 
disease  after  BMT  to  therapy with  either GCV  or PFA  or both  have  been  reported 
(Mookeijee and Vogelsang, 1997; Bethge et al., 1999).
It  has  been  shown  that  the  U69  protein  of  HHV-6  is  the  homologue  of  UL97 
phosphotransferase,  the  CMV  gene  responsible  for  the  activation  of  GCV  to  its 
monophosphate form (Ansari and Emery,  1999;  deBolle et al., 2002).  Resistance to 
GCV has been mapped to HHV-6 U69 gene (Manichanh et al., 2001).  HHV-7 encodes 
a gene homologous to HHV-6 U69, although no functional studies on this gene product 
have been reported.  Less is known of HHV-7 susceptibility to antivirals.  Some studies 
have reported that HHV-7 shows a similar degree of susceptibility to GCV as HHV-6 
(Takahashi et al., 1997b), whereas other studies have not shown such an effect (Yoshida 
etal., 1998).
In  vitro,  HHV-6, which lacks a thymidine kinase,  shows little or no  susceptibility to 
thymidine kinase-dependent drugs such as ACV (Takahashi et al., 1997b).  However, in 
a study by Wang et al. (1996) fewer HHV-6 PCR positive blood samples were reported 
in  BMT  patients  receiving  high-dose  ACV  compared  with  those  without  the  drug. 
These results  suggest that  in  vivo,  high doses  of ACV may provide  some  inhibitory 
effects against HHV-6 replication.  In a prospective study of liver transplant recipients, 
high HHV-6  or HHV-7  viral  loads,  concomitant with HCMV  infection  and  disease, 
were reduced by GCV therapy (Mendez et al., 2001).  Therefore the observed clinical 
benefits  of these  antiviral  drugs  could  result  from  inhibition  of HCMV,  HHV-6  or 
HHV-7.
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1.6  Laboratory diagnosis of HCMV infection
All  human  (3-herpesviruses  can  cause  morbidity  in  organ  transplant  recipients,  but 
HCMV causes the major burden of disease.  Important risk factors have been identified 
for  the  potential  development  of HCMV  (end  organ)  disease.  These  include  D/R 
serostatus, viraemia (Pillay et al.,  1993) and peak viral load following transplantation 
(Cope et al.,  1997a;  1997b; Gor et al.,  1998).  HCMV viral load is a central factor in 
HCMV  pathogenesis,  such  that  increased  HCMV  replication  is  the  single  most 
significant risk factor for disease.  Therefore the concept of a threshold value of HCMV 
load can be introduced, with the absence of disease being characterized by a lower or 
absence  of viral  load  and  disease  being  associated with higher viral  load.  In  some 
patients,  this  viraemia  could  result  in  the  seeding  of multiple  organs  with  HCMV 
infection.  Whilst the measurement of HCMV in the blood is a reliable indication of the 
degree  of viraemic  dissemination,  it does not allow diagnosis  of direct HCMV  end- 
organ  involvement  (for  example  pneumonitis,  hepatitis,  and  gastrointestinal  disease) 
which requires detection of virus at the tissue level.
This  section  describes  some  of  the  laboratory  methods  for  diagnosis  of  HCMV 
infection.  The  more  conventional  cell  culture  methods  for  detecting  viraemia  are 
currently replaced by more rapid cell culture methods including shell vial or detection 
of early antigen fluorescent foci (DEAFF).  Serological assays are of limited value for 
the diagnosis of active infection after transplantation and during increased intensity of 
immunosuppression,  as  significant Ab  rises  come  (too)  late  and tests  for  IgM  often 
remain negative.  However, HCMV serology is useful for pre-transplant assessment of 
the recipient’s risk of HCMV infection because of the increased risk associated with 
donor and recipient  seropositivity.  Molecular techniques  such  as  QC-PCR,  and  the 
semiquantitative HCMV pp65 antigenemia assay (Kim et al., 2003) have been used to 
diagnose HCMV infection and assess the viral  load in transplant patients.  Recently, 
new  applications  based  on  real-time  quantitative  PCR  technology  such  as  the 
Lightcycler, or the TaqMan technology have been developed (Mengelle et al., 2003; Li 
et al.,  2003).  Blood either whole blood, plasma,  or PBMC  are used to  monitor for 
infection.  However, to study more closely the pathogenesis of HCMV  infection and 
disease,  at  the  organ  level,  in  situ  techniques  must  be  utilized.  Traditionally,  the 
diagnosis of HCMV direct end organ disease has relied on classical histopathological 
techniques to visualize “owl’s eye inclusions” (Smith,  1959; Macasaet et al.,  1975) in
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the biopsies of the affected organ.  However, this method is insensitive (Mattes et al.,
2000).  Currently, more sensitive and specific methods  including IHC  and ISH have 
been developed.
1.6.1 Virus isolation
Isolation of HCMV from tissue or body secretions remains the ‘gold standard’ against 
which other tests are compared.  For conventional cell culture, clinical specimens are 
inoculated onto semi-continuous human fibroblast cells obtained from the foreskin or 
embryonic  lung  and  tube  cultures  of  these  cells  are  observed  regularly  for  the 
development of HCMV CPE characterized by foci of flat, swollen cells.  Development 
of CPE can take up to 28 days, depending on the titre of the virus in the sample.  The 
long time required for diagnostic confirmation of this method therefore limits its clinical 
usefulness.
1.6.2 DEAFF and shell-vial assays
More  rapid  cell  culture  methods  relying  on  culture  confirmation  with  monoclonal 
antibodies termed shell vial (Gleaves et al.,  1984) or DEAFF (Griffiths et al.,  1984) 
allows detection of virus within 24-48 hrs but is no more sensitive than traditional virus 
isolation (Boppana et al., 1992b).
1.6.3 Antigenemia assay
The antigenemia assay measures a late structural protein.  HCMV pp65  is a 65  kDa 
lower  matrix  protein  and  can  be  detected  in  PBL  (Revello  et  al.,  1992).  The 
quantitative nature of this assay provides a useful tool for predicting the likelihood of 
HCMV disease- the presence of a small number of Ag-positive cells  following  SOT 
generally  indicates  asymptomatic  infection,  whereas  a  large  number  implies  an 
increased likelihood of HCMV disease (Niubo et al., 1996; The et al., 1993).
1.6.4 The polymerase chain reaction (PCR)
Qualitative  PCR  is  used  for  routine  monitoring  of  HCMV  in  clinical  samples. 
However, qualitative PCR often cannot distinguish between latent and active infection 
unless a limited input quantity of DNA is tested.  In our centre 30 ng of DNA extracted 
from whole blood is used for our PCR assay,  an amount below the threshold where 
virus  is detected in blood of persons with normal  immunity.  Alternatively,  reverse-
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transcription (RT)-PCR can be used.  Quantitative PCR has been employed to perform 
longitudinal studies in different patient groups at risk of HCMV disease (Bowen et al., 
1998; Cope et al., 1997a; 1997b; Fox et al., 1995; Hassan-Walker et al., 1999).
1.6.5  In situ techniques
1.6.5.1 Histopathology
The  diagnosis  of HCMV  organ  disease has  traditionally been based upon histologic 
recognition of cytomegalic inclusion bodies with the characteristic intranuclear ‘owl’s 
eye’ appearance in hematoxylin and eosin (H and E)-stained tissue specimens.  In most 
cases, the detection of viral inclusion bodies in liver tissue correlates with symptomatic 
HCMV  disease.  However,  histopathology  is  known  to  be  insensitive  although  it 
provides a specific diagnosis.  In a study correlating HCMV load in tissues obtained at 
postmortem  examination of AIDS  patients  with the  histological  evidence  of HCMV 
inclusions, a viral load of >5 000 000 genomes/pg DIIA was required before HCMV 
inclusions were observed (Mattes et al., 2000).
1.6.5.2 Immunohistochemistry (IHC)
The detection of HCMV Ags with MAbs has increased the sensitivity for the histologic 
diagnosis of CMV disease in transplant patients compared to standard H and E staining 
(Barkholt et al., 1994; Paya et al., 1990).
1.6.5.2.1  Technique of IHC
The  principle  steps  of IHC  include  (1)  preparation  of the  biological  material,  (2) 
Antigen unmasking, (3) Ab staining, and (4) Ab detection (see figure 1.5).  Preparation 
of cells and tissue sections for IHC (and ISH) involves routine fixation to ensure the 
preservation of tissue architecture and cell morphology.  The predominant method of 
tissue preservation for microscopic analysis is by fixation with a formaldehyde-based 
fixative, followed by tissue processing for paraffin embedding.  The development of Ag 
unmasking  (Shi  et al.,  1991)  has  helped  improve  the  sensitivity of immunostaining. 
This technique uses a combination of high temperature and buffers of different pH (the 
most commonly used is 0.1M Citrate buffer, pH 6.0), and recently the introduction of 
non-heating methods, including enzymatic digestion (Shi, 2001) have also been applied. 
There  are  two  methods  of Ab  staining.  The  direct  method  involves  a  labeled  Ab 
reacting with the Ag in the tissue followed by the  subsequent  addition  of substrate-
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chromagen.  This procedure is short and quick but relatively insensitive.  This led to 
more sensitive indirect methods involving an unlabeled primary Ab which reacts with 
tissue Ag and a labelled secondary.  Ab  staining methods  frequently utilize  enzyme 
coloured reactions to convert chromagens into coloured end products.  Peroxidase is the 
commonly used enzyme label and the substrates for peroxidase include 3-amino-9 ethyl 
carbazole (AEC), which gives a red precipitate and 3,3-diaminobenzidine (DAB) which 
results in an intense brown precipitate.
Immunohistochemistry In situ hybridisation
Tissue preparation
Antigen unmasking
a)  high temp and buffers
b)  Enzymatic digestion
Unmasking to target DNA/RNA
a)  dilute acid (e.g HC1)
b)  detergent
c)  proteolytic enzymes
Antibody staining either:- 
1)  Direct method
Hybridisation with labelled probe
or
2)  Indirect method
Post-hybridisation washes
Detection with chromogenic substrate
Figure 1.5 Diagram of immunohistochemistry and in situ hybridisation technique
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Methods for amplification of the detection system have also been adopted to increase 
the sensitivity of IHC.  The most widely used technique is the avidin-biotin complex 
(ABC)  method developed by Hsu et al.  (1981).  It is based  on the high affinity and 
essentially irreversible  interaction between avidin  and biotin.  The technique requires 
pre-incubation of the biotinylated enzyme with the avidin, so that large complexes are 
formed  for  incubation  with  the  biotinylated  secondary  Ab  (see  figure  1.6a).  More 
recently, the application of chain-polymer technology such as DAKO Envision Systems 
has  been  employed.  In  the  Envision  System  the  secondary Ab  is  conjugated  to  the 
enzyme labeled polymer (see figure  1.6b) which contains an average of 10 molecules of 
secondary  Ab  and  70  molecules  of  enzyme,  thereby  increasing  the  sensitivity  of 
detection.
A)  B)
A AA
X
Key
A
first primary Ab (monoclonal) m HRP enzyme
A
secondary primary Ab t polymer (spine molecule)
> -
secondary Ab (anti-mouse) Avidin-biotin enzyme complex
AA  tissue Ag
Figure 1.6 Amplification of detection systems A) The ABC method: the avidin-biotin 
complex reacts with the biotinylated secondary Ab; B) The Envision System: the spine 
molecule which contains an average of 10 molecules of secondary Ab and 70 molecules 
of enzyme (adapted from www.dako.com).
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1.6.5.3  In situ hybridisation
In  situ  hybridisation  (ISH)  is  a  technique  for  localization  of  specific  nucleic  acid 
sequences  in  microscopic  preparations  of  tissues,  cells  or  chromosomes.  It  was 
originally developed in 1969 by Pardue and Gall and (independently) by John et al. and 
is  based  on  the  complementary  binding  of nucleic  acid  probe  to  a  specific  target 
sequence  of DNA  or  RNA.  Hybridisation  has  conventionally been  performed  with 
radioisotopically labeled probes followed by autoradiographic probe detection.  This has 
largely been replaced by non-radioactive probe labeling and detection systems (Rudkin 
and  Stoller,  1977).  ISH  has been  applied  for the  diagnosis  of HCMV  pneumonitis 
(Gleaves et al.,  1989; Solans et al.,  1995), hepatitis (Masih et al.,  1988; Colina et al., 
1995; Paya et al., 1990) and gastroenteritis (Muir et al., 1998).  One of the limitations of 
ISH has been the inability of ISH to discriminate between active infection and latency 
(Ehmst, 1996).  The introduction of probes specific for HCMV BE mRNA, however has 
allowed for the identification of early HCMV infection (Link et al., 1993).
1.6.53.1  The ISH technique
The  principle  steps  of ISH  include:  (1)  preparation  of the  biological  material,  (2) 
pretreatment  of section,  (3)  hybridisation  with  labeled  probe,  (4)  Post-hybridisation 
washes and (5) cytochemical probe detection (see figure  1.5).  Preparation of cells and 
tissue sections for ISH is essentially the same as that described for IHC.  Sections are 
pre-treated (for example with, dilute acids, proteolytic  enzymes  including pepsin and 
proteinase  K  and  non-ionic  detergents  such  as  Triton  X-100  and  saponin)  for  cell 
permeabilisation, thereby unmasking target nucleic acids and facilitating access of the 
probes and cytochemical detection molecules.  The principle of the ISH technique is 
based  largely  on  gel  hybridisation  protocols  for  the  detection  of  DNA  (Southern 
blotting) and RNA (Northern blotting).  The specificity of probe binding is influenced 
by a number of parameters  such as the  composition  of the probe  (G-C  bonds being 
stronger than A-T) and probe length,  the temperature,  the  salt concentration,  and the 
content of formamide (a denaturing agent) in the hybridisation mixture and the post­
hybridisation  washes.  Four  types  of probes  can  be  used  for  ISH:  double  stranded 
complementary  DNA  (cDNA),  single  stranded  cDNA,  RNA  probe  (riboprobe)  and 
oligonucleotides (reviewed in Dirks, 1996).  Probes can be labeled directly (usually with 
fluorescein or fluorochromes) or indirectly where a reporter molecule (such as biotin or 
digoxigenin  (DIG),  introduced chemically or enzymatically,  can be  detected by IHC
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techniques.  Detection  of probe  is  usually  carried  out with  enzyme  conjugated  Abs 
raised against the label (DIG or biotin) (reviewed in Speel, 1999).
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Aims of thesis
1)  To  develop  in  situ  techniques  including  in  situ  hybridisation  and 
immunohistochemistry for the detection of the human p-herpesviruses.
2) To apply these optimized assays to examine the presence of these viruses (viral DNA 
or specific antigens) in organ biopsies from previous prospective studies of liver and 
renal transplant patients, and to investigate the role of these viruses in graft dysfunction, 
including allograft rejection.
3)  To  examine  for  evidence  of both  vascular  (by  C4d  staining)  and  cellular  graft 
rejection in the renal transplant patients and to correlate the presence of rejection with 
HCMV status in the biopsy.
4) To construct a riboprobe specific to a region of the HCMV immediate early-1   gene 
for ISH to investigate HCMV gene expression at the mRNA level in the renal biopsies 
following transplantation.
5)  To  study  HHV-6  integration  into  host  cell  chromosomes  by  the  development  of 
fluorescence in situ hybridisation.
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2.1 Cell culture and virus propagation
Section  2.1  describes  cell  culture  methods  for  the  preparation  of cell  controls  for 
subsequent in situ methods.
2.1.1 Cell culture
MRC-5  and  human  embryonic  lung  (HEL)  fibroblasts  were  grown  in  minimum 
essential medium (MEM) (Invitrogen) supplemented with 10% foetal calf serum (FCS) 
(Labtech  International)  and 2  mM  L-glutamine,  100  IU/ml penicillin and  100  jig/ml 
streptomycin solution (Sigma) in a 75 cm2 tissue culture flask at 37°C.  Once the cells 
reached confluency, the media was removed, and the cell monolayer was washed with 
10 ml phosphate-buffered saline (PBS).  The PBS  was removed and 3  ml  of trypsin 
(0.05%)/EDTA (0.01%)  (Invitrogen)  were added to the flask.  The flask was placed at 
37°C for approximately 3 min until the cells had detached from the surface, and could 
be loosened with gentle tapping.  Ten millilitres of growth medium were then added to 
the flask and mixed.  The cells were then split into two 75 cm2 flasks.  Approximately 5 
ml cell culture was added to each flask and growth media was added to a final volume 
of 30 ml.  The cells were incubated at 37°C for up to a week.  Cells were passaged twice 
weekly.
2.1.2 Virus propagation
The laboratory strain of HCMV, AD 169 was cultured in MRC-5  or HEL cells.  The 
cells were grown to 80-90% confluency in 30 ml growth media in a 75 cm2 flask.  The 
medium was removed, and the cell monolayer was washed with 10 ml PBS.  The PBS 
was removed, and 5 ml of stock AD 169 were inoculated onto the cells and allowed to 
adhere to the cells for 1  hr in a 37°C incubator.  The viral inoculum was removed, the 
cell monolayer was washed with maintenance media (MEM media supplemented with 
5% FBS and Pen/Strep), and replaced with 10 ml fresh maintenance media.  The cells 
were  incubated  in  a  37°C  incubator  for  approximately  1   week  or  until  CPE  was 
observed.  The supernatant containing the virus was then removed and centrifuged at 
400 g for 5  min to remove the cell debris.  The supernatant was aliquoted into 2 ml 
tubes and stored frozen at -70°C.  Another 10 ml maintenance media was added to the 
flask, and the cells were incubated at 37°C for a further 24 hrs.  Viral stock supernatant
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was collected from the cells as described above, until there were no more adherent cells 
visible.
HHV-6B (strain Z29) infected and non-infected Molt-3 cell cultures and HHV-7 (DC 
strain) infected and non-infected Sup T1  cell cultures were obtained from Dr Duncan 
Clark and Edward Tsao, Department of Virology, Royal Free and University College 
Medical School.
2.1.3  Cell preparations
Cells from infected cultures; HCMV (strain AD 169) infected HEL/MRC-5,  HHV-6B 
(strain Z29) infected Molt-3, and HHV-7 (DC strain) infected Sup T1 cells were grown, 
and  harvested  for  use  as  positive  controls  for  optimisation  of  in  situ  techniques. 
Generally, cell cultures were grown until over 50% of cells were infected with virus 
based on visualisation of CPE.  HCMV (strain AD 169) infected MRC-5 cells were also 
grown for 3-4 hrs to limit expression of viral genes to IE only.  Non-infected MRC-5, 
HEL, Molt-3 and Sup T1 cell cultures were used as negative controls.
2.13.1  Fixation of cells to glass slides
Five to  10 ml cells from virus infected and non-infected cultures were  harvested by 
centrifuging at 400 g for 5 min.  The supernatant was removed, and the cell pellet was 
washed in 10 ml PBS three times to remove any serum proteins, before resuspending in 
200  pi  PBS.  The  number  of  cells  was  counted  using  a  haemacytometer  and 
approximately  1x10s cells/50pl  PBS  were  spotted  onto  aminopropyl  tri-ethoxysilane 
(APES) coated glass slides (Applied Biosystems).  The cell suspension was left to air 
dry for approximately  1   hr before fixing in cold 4% paraformaldehyde in PBS for 20 
min.  Fixation helps to reduce nucleic acid loss and preserve cellular morphology.  The 
slides  were  then  washed  twice  in  PBS  for  5  mins  each,  dehydrated  in  increasing 
concentrations of ethanol (25%, 50%, 75% and  100%) and stored at -20°C until ready 
for use.
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2.13.2  Preparation of cell suspensions for paraffin-embedding
Ten to 20 ml of virus infected and non-infected cultures were harvested by centrifuging 
at 400 g for 10 min.  The supernatant was removed, and the pellet was washed in 10 ml 
PBS twice.  The cell pellet was then transferred to a  1.5  ml microfuge tube,  and an 
approximately  equal  volume  of melted  3%  (w/v)  low  melting  temperature  agarose 
(Sigma)  in  IX  TBE buffer (90 mM  Tris-borate,  2mM  EDTA),  cooled to  50°C, was 
added to the pellet and mixed thoroughly by pipetting up and down.  The agarose plug 
was  left  to  harden  for  approximately  30  min  before  transferring  and  wrapping  in 
Biowrap, and then fixing in 4% neutral buffered formalin (CellStor pots; Cellpath pic) 
overnight,  followed  by  paraffin-embedding.  Using  a  microtome  blade  (Leica  RM 
2035),  4  pm  sections  were  cut,  floated  on  distilled  H2O   in  a  37°C  waterbath  and 
mounted  onto  APES-coated  glass  slides.  The  sections  were  then  baked  in  a 
hybridisation oven at 55°C for 48 hr to aid the adhesion of cells onto the slides.
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2.2  Development of immunohistochemistry
Immunohistochemistry  (IHC)  is  a  technique  that  uses  Abs  to  detect,  visualize  and 
localize Ags at the cellular level.  Section 2.2 describes IHC using human p-herpesvirus 
MAbs for the detection of viral specific proteins.  Two amplification detection methods 
were used for the development of IHC; the avidin-biotin peroxidase complex method 
described  in  section  2.2.1,  and  the  ChemMate  Envision  detection  system 
(DakoCytomation Ltd) described in section 2.2.2.
2.2.1 The avidin-biotin peroxidase complex method
The avidin-biotin peroxidase complex method was originally introduced by Hsu et al. 
(1981).  This  patented  procedure  uses  biotinylated  Ab  and  a  preformed  Avidin 
Biotinylated enzyme Complex and has been termed the “ABC” technique.  Avidin is a 
tetramer consisting of four identical subunits of molecular weight  15,  000 Da.  Each 
subunit contains a high affinity binding site for biotin with a dissociation constant of 
approximately 10'15 M.  This affinity for biotin is over one million times higher than that 
of Ab for most Ags, and so unlike Ab-Ag interactions, the binding of avidin to biotin is 
essentially irreversible.  The Vectastain Elite ABC kit (Vector labs) contains Avidin 
DH  and  biotinylated  enzyme,  and  was  used  to  form  ideal  complexes  for 
immunohistochemical staining of the human p-herpesvirus proteins.
2.2.1.1 IHC on paraformaldehyde-fixed cell suspensions
IHC  was  performed  with  MAbs  directed  against  HCMV,  HHV-6  and  HHV-7  on 
respective  paraformaldehyde-fixed  infected  cell  suspensions.  MAb  to  HCMV  late 
protein of 47-55  kDa (MAB8126;  Chemicon International),  MAb to HHV-6B  virion 
protein of 101K (plOl) (MAB8535; Chemicon International), and MAb 5E1 to HHV-7- 
specific phosphoprotein 85 (pp85) (kindly provided by Dr Gabriella Campadelli-Fiume, 
University of Bologna,  Italy (Stefan et al.,  1997) were tested at a range  of dilutions 
(1:100-1:500) on HCMV infected HEL cells, HHV-6B infected Molt-3 cells and HHV- 
7 infected Sup T1 cells respectively.  Non-infected HEL, Molt-3, and Sup T1 cells were 
used as negative controls.
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Using a pap pen (Zymed labs), a circle was drawn around the cell suspension to help 
retain reagents on the glass slide.  The slides were immersed in 100% ethanol and then 
100% methanol.  Endogenous peroxidase (which will produce a reaction product from 
the substrate alone) was blocked by incubating the slides with 1.5% Hydrogen Peroxide 
(30% w/w solution) (Sigma) in  100% methanol (BDH) for 30 min.  The slides were 
then rehydrated through decreasing concentrations of ethanol washes (100%, 75%, 50% 
and 25%) to distilled H2O  for 2 min each.  Primary Ab in first layer diluent (0.3% Triton 
X-100, 2% normal horse serum, 0.01% sodium azide in PBS) was subsequently added 
to  the  sections,  and  the  slides  were  placed  in  a humidified  chamber  for  incubation 
overnight at 4°C.  After overnight incubation in primary Ab, the slides were washed in 
PBS three times for 5 min each.  Secondary biotinylated anti-mouse IgG (Vector labs) 
at 1:100 dilution in second layer diluent (0.3% triton X-100 in PBS) was added to the 
slides, and incubated in a humidified chamber for 50 min at room temp.  The slides 
were washed in PBS three times for 5 min each, and incubated in a third layer complex 
(Vectastain Elite ABC kit, Vector labs) for 1  hr at room temp.  The third layer complex 
was prepared according to the maufacturer’s instructions.  Two drops of reagent A, and 
two drops of reagent B, were added to 5 ml second layer diluent with mixing.  This was 
prepared  30  min  before  use.  After  PBS  washes  three  times  for  5  min  each,  the 
peroxidase substrate was detected using DAB substrate kit (Vector Labs).  Two drops of 
Buffer  Stock  Solution,  4  drops  of DAB  Stock  Solution  and  2  drops  of Hydrogen 
Peroxide were added to 5 ml of distilled H2O, mixing well each time.  The slides were 
incubated  in  DAB  substrate  solution  for  10  min.  DAB  produces  a  reddish  brown 
precipitate in the sections.  The reaction was stopped by washing the slides in distilled 
H2O   for  5  min,  followed by  dehydration  in  increasing  ethanol  concentrations  (25%, 
50%, 75% and  100%).  The slides were air dried, and mounted with UV Loctite 358 
adhesive (Loctite UK Ltd).  The adhesive was applied to the centre of the slide, and a 
glass cover slip was placed on top.  The  slides were  cured by placing  onto  the UV 
transilluminator for 1  min. The slides were subsequently monitored by viewing under a 
light microscope (Olympus BX60).
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2.2.1.2  IHC on formalin-fixed paraffin-embedded cell suspensions
The  same three MAbs  directed against HCMV,  HHV-6  and HHV-7  as  described  in 
section 2.2.1.1 were evaluated by performing IHC on formalin-fixed paraffin-embedded 
cell controls; HCMV infected HEL, HHV-6B infected Molt-3 and HHV-7 infected Sup 
T1 cells respectively.  Negative controls of non-infected HEL, Molt-3 and SupTl  cells 
were included in each staining run.  An additional three MAbs directed against HHV-6 
proteins were also tested.  These include; MAb to HHV-6 early protein p41/38, MAb to 
HHV-6  gp116/64/54  (referred to  as  HHV-6  gB  (Ellinger et al.,  1993),  and MAb  to 
HHV-6B  p98  (also  known  as  MAb  OHV3)  all  obtained  from  Advanced 
Biotechnologies International.  MAb OHV3 reacts with a HHV-6B-specific neutralizing 
epitope on gH (Takeda et al., 1997) and so will be referred to as MAb to HHV-6B gH. 
Preliminary experiments were performed using a range of dilutions (1:50-1:100) of the 
MAbs  to  determine  the  dilution  required  to  detect  human  P-herpesvirus  Ags  in 
formalin-fixed paraffin-embedded virus infected cells, without a background reaction. 
IHC was carried out as described in section 2.2.1.1 with an initial deparaffinization step 
in xylene twice for 15 min at room temp before immersing in 100% ethanol.
2.2.13 Incorporation of an antigen retrieval method into IHC
Staining was refined by incorporating an Ag retrieval method.  Ag retrieval helps break 
the protein cross-links formed by formalin fixation and thereby allowing the availability 
of the  Ag  for interaction with a specific  Ab  to  be  maximized.  Two  methods  were 
evaluated; enzymatic digestion and microwave irradiation.
The MAbs described in section 2.2.1.1 and two additional MAbs directed to the HCMV 
delayed early DNA-binding protein p52 (CCH2 MAb; Dako) (Plachter et al., 1992), and 
to the HCMV IE non-structural protein of 68-72 kDa (MAB8131; Chemicon) were all 
independently  evaluated  at  a  range  of  dilutions  (1:100-1:500)  on  formalin-fixed 
paraffin-embedded cells infected with the respective virus.  Microwave irradiation, or 
an enzymatic digestion step was also incorporated into IHC.  For comparison, IHC with 
no  Ag  retrieval  method  was  performed  in parallel.  Non-infected  cells  were  used  as 
negative controls.
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The sections were deparaffinized twice in xylene for  15  min, endogenous peroxidase 
was blocked as described in section 2.2.1.1  followed by rehydration of the sections to 
distilled H2O.  For enzymatic digestion, slides were incubated at a range of Proteinase K 
(Sigma) concentrations ranging from 2.5  (LLg/ml-10 pg/ml  in Proteinase K buffer (50 
mM Tris-HCl, 5 mM EDTA pH 7.6) for 30 min at 37°C, followed by washes in PBS 
three times for 5 min.  For microwave irradiation, sections were boiled in an 800 watt 
microwave (Hinari) for 5 min in preheated citrate buffer (0.01M citric acid, pH 6.0), and 
cooled for a further 25 min at room temp.  The slides were then washed in PBS three 
times for 5 min each.  After the Ag retrieval step, immunohistochemical detection was 
continued as described in section 2.2.1.1.
2.2.1.4  Incorporation of an avidin biotin block into IHC
Once  the  optimal  concentration  of  MAb,  and  the  Ag  retrieval  method  had  been 
determined, an avidin biotin blocking kit (Vector Labs) for reducing background levels 
was tested.  This blocking kit consists of an Avidin D solution and a Biotin solution. 
Background  may  result  from  some  tissue  sections  binding  avidin,  biotinylated 
horseradish  peroxidase  or  other  Biotin/Avidin  System  components  without  prior 
addition of biotinylated Ab.  This binding may be due to endogenous biotin or biotin- 
binding  proteins,  lectins,  or  non-specific  binding  substrates  present  in  the  section. 
MAbs  directed  against  HCMV  proteins  characteristic  for  each  stage  of  HCMV 
replication;  MAB8131  to HCMV BE protein, CCH2 MAb to HCMV p52,  and MAB 
8126 to HCMV late protein were used for development of IHC with the incorporation 
of an avidin biotin block.  In addition, MAb to HHV-6 gB, MAB8535 to HHV-6B plOl 
and MAb 5E1 to HHV-7 pp85 were also tested.  For comparison, the MAbs were tested 
at  the  same  dilutions  without  the  blocking  step.  Non-infected  cells  were  used  as 
negative  controls.  The  sections  were  deparaffinized,  endogenous  peroxidase  was 
blocked, and an Ag retrieval method was incorporated as previously described.  The 
slides  were  then  incubated  with  10%  normal  horse  serum  in  PBS  with  Avidin  D 
solution (4 drops Avidin D solution per 1   ml  10% normal horse serum in PBS) for 10 
min.  After a brief wash in PBS, the primary Ab diluted in first layer diluent with the 
biotin  solution  was  added  (4  drops  of the  biotin  solution  per  1   ml  of primary  Ab 
solution).  IHC was continued as described in section 2.2.1.1.
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2.2.2  The DAKO ChemMate Envision Detection system
The  application  of  chain-polymer  technology  (Dako  Envision  Systems)  was  also 
employed to increase the sensitivity of the detection systems.  The EnVision detection 
reagent  in  the  DAKO  ChemMate  EnVision  detection  kit,  peroxidase/DAB  (Dako) 
consists  of a  dextran  backbone  to  which  a  large  number  of enzyme  molecules  and 
secondary  Ab  molecules  have  been  coupled.  A  unique  chemistry  is  used  for  the 
coupling reaction, which permits the binding of up to 100 enzyme molecules and up to 
20  Ab  molecules  per backbone.  Endogenous  biotin  also  has  no  affect  on  staining 
results.
The MAbs directed to HCMV described in section 2.2.1.4 were used for development 
of IHC using the DAKO ChemMate Envision Detection system.  IHC was performed 
on  formalin-fixed  paraffin-embedded  MRC-5  cells  infected  with  HCMV  (AD 169). 
Non-infected MRC-5 cells were used as negative controls.
The sections were deparaffinized in xylene twice for  15  min and then rehydrated  in 
decreasing concentrations of ethanol to distilled H2O .  Ag retrieval was performed as 
described  in  section  2.2.1.3.  In  addition,  both  enzymatic  digestion  and  microwave 
irradiation were incorporated.  First, the  sections were boiled in preheated 0.01M citrate 
buffer (pH 6.0) for 5 min in a microwave, cooled for 20 min at room temp followed by 
incubation with 7.5 |ig/ml Proteinase K for 15 min at 37°C.  After washes in PBS three 
times for 5 min, the slides were incubated with HCMV MAbs (1:50 and 1:100 dilution) 
for 30 min at room temp.  After a 5  min wash in PBS,  endogenous peroxidase was 
blocked by incubation with peroxidase blocking solution (Dako) for  10 min, followed 
by  PBS  wash  for  5  min.  The  tissue  sections  were  then  incubated  with  DAKO 
chemMate Envision/horseradish peroxidase  (HRP), rabbit/mouse for 25  min  at room 
temp.  After a 5 min wash in PBS, the DAB-containing Substrate Working Solution (50 
parts of Substrate Buffer with 1  part of DAB chromogen) was added to the sections for 
5 min.  The slides were then washed in H2O  for 5 min, air dried, and mounted in UV 
Loctite 358 adhesive.
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2.2.3 Testing the specificity of the human p-herpesvirus MAbs
The  specificity  and  crossreactivity  of the  immunohistochemical  reactions  with  the 
MAbs  described  in  section  2.2.1.4  were  tested  on  formalin-fixed paraffin-embedded 
cells  infected  with  respective  virus  and  to  each  of the  other  human  p-herpesvirus 
infected and non-infected cell controls.  Methods were as described in section 2.2.1.4 
and 2.2.2).
2.2.4 Subtyping of HHV-7 MAb 5E1
At the time these experiments were carried out the Ab isotype of MAb 5E1  to HHV-7 
pp85 had not been determined.  To characterize the Ab isotype of MAb 5E1, HHV-7 
infected Sup T1  cells were incubated with MAb 5E1, followed by the addition of an 
enzyme conjugated antimouse Ab corresponding to the common mouse isotypes IgGi, 
IgG2a  and  IgG2b,  and  subsequent  immunohistochemical  detection  using  the  ABC 
method.
Formalin-fixed paraffin-embedded HHV-7 infected Sup T1 cells were deparaffinized in 
xylene,  endogenous  peroxidase  was  blocked,  and  the  sections  were  rehydrated  as 
previously described.  The slides were microwaved for 5 min in preheated citrate buffer 
and cooled for a further 25 min followed by washes in PBS three times for 5 min.  MAb 
5E1  was added at  1:100 dilution in first layer diluent and incubated in  a humidified 
chamber at 4°C overnight.  Slides were then washed in PBS three times for 5 min each, 
and  secondary  Ab  (antimouse  IgGi  (AP273),  IgG2a  (AP274)  and  IgG2b  (AP275) 
conjugated with peroxidase (The Binding Site Limited) were added at  1:20 and  1:50 
dilution in second layer diluent for 1  hr at room temp.  Slides were then washed in PBS 
three  times  for  5  min  each  and  detection  was  carried  out  with  DAB  substrate  as 
previously described.  The reaction was stopped by washing the slides in H2O  for 5 min. 
The  sections  were  then  dehydrated,  air  dried  and  mounted  with  UV  Loctite  358 
adhesive.  HHV-6 infected Molt-3 cells incubated with mouse IgG2b to HHV-6 gB was 
used as a positive control.  HHV-7 infected Sup T1  cells incubated without MAb 5E1, 
and non-infected Sup T1 cells were included as negative controls.
99Chapter 2  Materials and  Methods
2.3  Construction of digoxigenin labelled riboprobes for ISH
This  section describes the  synthesis  of digoxigenin (DIG)  labelled riboprobes  (RNA 
probes) specific for each of the (3-herpesviruses for the detection of viral DNA by ISH 
(see figure 2.1).  In section 2.3.1, the generation of HCMV, HHV-6 and HHV-7 DNA 
sequences by PCR is described.  The amplicons were then purified and cloned into the 
polylinker site of the transcription vector pGEM-T Easy which contains a promoter for 
SP6 and T7 RNA polymerases (see sections 2.3.3-2.3.7).  Section 2.3.8 describes the 
linearization  of the  plasmids prior to  the  transcription  reaction  so  that  only discrete 
“run-off  transcripts,  virtually  free  of  vector  sequences  are  obtained.  In  vitro 
transcription incorporating a DIG RNA labelling mix was then carried out with RNA 
polymerases, Sp6 and T7 to generate DIG labelled RNA transcripts.
23.1  Generation of HCMV, HHV-6 and HHV-7 DNA by PCR
The pUC13 plasmid containing the 149 bp insert of HCMV gB gene control sequence 
was  used  as  a  template  for  cloning  into  the  transcription  vector  pGEM-T  Easy 
(Promega).  The  control  sequence  is  identical  to  the  authentic  HCMV  gB  target 
sequence  with  the  exception  of a  2  bp  change  at  bases  77  and  78  of the  149  bp 
sequence  converting the  original  GG to  a TT.  This results  in the  introduction  of a 
unique Hpal restriction site into the  149 bp target sequence (Fox et al.,  1992).  The 
pUC18 plasmids containing the 223  bp insert of HHV-6 unique (U)-67  gene control 
sequence (Clark et al.,  1996), and the  183 bp insert of the HHV-7 U42 gene control 
sequence (Kidd et al.,  1996), with a Smal restriction site in the middle of the sequences, 
were constructed in the same way as that of Fox et al. (1992).  These plasmids were 
used as templates for cloning into the pGEM-T Easy vector.
The control plasmids at a concentration of 108  copies were used as templates for PCR 
amplification.  The primers HCMV gBl  and HCMV gB2, HHV-6C and HHV-6D, and 
HHV-7 MIG and HHV-7 MK4 were used to generate a 149 bp, a 173 bp and a 143 bp 
fragment of HCMV gB, HHV-6 U67, and HHV-7 U42 respectively (see table 2.1).  In 
addition,  DNA  extracted  from  HCMV  (AD 169)  infected  HEL  cells  were  used  as 
template for PCR amplification of a 298 bp sequence of HCMV US28 using primers 
US28F and US28R (Beisser et al., 2001), and cloned into the pGEM-T Easy vector (see 
table 2.1 for US28 primers).
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Gene Primer sequence
HCMVgBl 5’-GAG GAC AAC GAA ATC CTG TTG GGC A -3’
HCMV gB2 5’-GTC GAC GGT GGA GAT ACT GCT GAG G -3’
HCMV US28F 5’-CGT CGG ATT CAA TGC TCC GGC GAT GTT TAC-3’
HCMV US28R 5’-GAA TGG CGA TGA TCA CGG CAA AGA TCC ACC-3’
HHV-6 C 5’-TCC ATT ATT TTG GCC GCA TTC GT-3’
HHV-6 D 5’-TGT TAG GATATA CCGATG TGC GT-3’
HHV-7 MK3 5’-TGC TTT TTG GTT TGT AAA TTC -3’
HHV-7 MK4 5’-GAA TTT ATG GAG TTT GGT CTG -3’
Table 2.1 Primer sequences for HCMV, HHV-6 and HHV-7 PCR
Each reaction was performed in triplicate, in IX PCR buffer containing 2 mM MgCl2, 
200  pM  each dNTP  (dATP,  dGTP,  dCTP,  dTTP)  (Promega),  2.5  U  of HotStar Taq 
DNA Polymerase  (Qiagen) and  100 ng of each primer in a volume of 98 pi made up 
with distilled H2O .  Two microlitres of plasmid template were added, to a final reaction 
volume of 100 pi.  Negative H2O  controls were included to determine the presence of 
any contaminating DNA.  The PCR cycling conditions for HCMV gB are shown below. 
The PCR cycling conditions for HHV-6 U67 and HHV-7 U42 were the same as that of 
HCMV gB, except the annealing temperature was  50°C.  Cycling was performed on a 
Hybaid DNA thermal cycler.
Hot start  95°C  for 15  min  }  1  cycle
Denaturation  94°C  for 30 sec
Annealing  60°C for 30 sec  39 cycles
Extension  72°C for 30 sec
Final extension  72°C for 10 min  }  1  cycle.
The resulting PCR amplicons were detected by electrophoresis on a 3% (w/v) agarose 
gel.
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Figure 2.1 Diagram showing riboprobe in vitro transcription.  Recombinant plasmid 
DNAs were linearized prior to in vitro transcription.  In vitro transcription incorporating 
a  DIG  RNA  labelling  mix  was  carried  out with  RNA polymerases  to  generate  DIG 
labelled riboprobes for ISH.
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2.3.2 Gel preparation and electrophoresis
Three grams of multipurpose agarose (Bioline) in 100 ml of IX TBE buffer was melted 
in a microwave oven.  The gel was allowed to cool to approximately 50°C, before 3 pi 
of ethidium bromide (10 mg/ml,  Sigma) was added.  The gel was poured  into a gel 
casting tray, with a gel comb, and allowed to set.  Once set, the gel comb was removed, 
and the  gel was placed  in an electrophoresis  tank containing  IX  TBE  buffer.  Five 
microlitres of loading dye (0.25% w/v bromophenol blue, 0.25% w/v xylene cyanol FF, 
15% w/v Ficoll (Sigma) in distilled H2O)  were added to 10 pi of each PCR reaction and 
loaded into separate wells, together with the PhiX174//faeIII cut marker (Promega) to 
confirm the size of the amplicons.  DNA was separated by electrophoresis at 100V for 1  
hr and visualised on a UV transilluminator.
23.3  Direct purification of PCR amplification products
Once  the  size  of the  PCR products  had been  confirmed by  gel  electrophoresis,  the 
remainder of the products were purified using the Wizard PCR Preps DNA Purification 
System  (Promega)  according  to  the  manufacturer’s  instructions.  Two  tubes 
(approximately 180 pi) of PCR amplification products were pooled together into a 1.5 
ml eppendorf tube and 100 pi Direct Purification buffer (50 mM KC1, 10 mM Tris-HCl 
(pH  8.8  at  25°C),  1.5  mM  MgCk  0.1%  triton X-100)  was  added  and  mixed.  One 
millilitre of resin was then added and mixed.  The DNA/Resin mix was pipetted into 
the  Syringe  Barrel  and  the  syringe  plunger  was  inserted  slowly,  pushing  the  slurry 
gently into the Minicolumn.  Two millilitres of 80% isopropanol were then syringed 
through the Minicolumn.  The Minicolumn  was centrifuged  at 10 000 g for 2 min to 
dry the resin.  After transferring the Minicolumn to a new eppendorf, 50 pi of nuclease 
free H2O  was applied, and centrifuged at 10 000 g for 30 sec to elute the DNA fragment. 
The concentration of purified DNA was measured spectrophotometry using the Gene 
Quant spectrophotometer (Pharmacia, Biotech) and stored at -20°C for future use.
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2.3.4  Ligation of HCMV, HHV-6 and HHV-7 DNA into the pGEM-T Easy vector 
The purified PCR products  were  cloned into  the  transcription vector pGEM-T  Easy 
using  the  pGEM-T  Easy  Vector  System  I  (Promega).  The  pGEM-T  Easy  vector 
systems  are  convenient  systems  for  the  cloning  of PCR  products.  The  vector  is 
prepared by cutting with EcoRV and adding a 3’ terminal thymidine (T) to both ends. 
The presence of these 3’-T overhangs at the insertion site enhances the efficiency of 
ligation of a PCR product into the plasmid by preventing recircularization of the vector 
and  by  providing  a  compatible  overhang  for  PCR  products  generated  by  certain 
thermostable polymerases such as Taq polymerase.  These thermostable polymerases 
add a single deoxyadenosine, in a template-independent fashion, to the 3’-ends of the 
amplified fragments.
The PGEM-T Easy vector is a high copy number vector that contains T7 and SP6 RNA 
polymerase promoters flanking a multiple cloning region within the a-peptide coding 
region of the enzyme p-galatosidase.  Non-recombinant plasmids produce a functional 
a-peptide  which  leads  to  production  of  a  functional p-galatosidase.  Insertional 
inactivation of the a-peptide results in no p-galatosidase activity and these recombinant 
clones  can  be  directly  identified  by  colour  screening  on  indicator plates  containing 
IPTG (isopropyl-P-D-thiogalactopyranoside) and X-Gal (5-bromo-4-chloro-3-indoyl-p- 
D galactopyranoside).  Therefore bacterial colonies harbouring recombinant clones are 
white, whereas bacterial colonies harbouring non-recombinant plasmids are blue.
The following equation was used to calculate the amount of insert DNA to include in 
the ligation reaction.
X ng of vector x kb size of insert
kb size of vector  x insertivector molar ratio = Y ng insert DNA
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For each insert DNA, ligation reactions with vectoriinsert ratios of 1:1, and  1:3 were 
performed. Each reaction was composed of IX Rapid Ligation Buffer (30 mM Tris-HCl 
(pH 7.8), 10 mM MgCl2, 10 mM DTT, 0.5 mM ATP, 5% polyethylene glycol (50 ng), 3 
Weiss units of T4 DNA ligase, made up to a total volume of 20 pi with  nuclease free 
H20.  Control ligations of the vector alone, and the insert alone, with all the ligation 
reaction components were also included.  Ligation reactions were left at 4°C overnight.
23.5 Transformation of competent E.coli JM109 cells with plasmid DNA
The  ligation  of fragments  with  a  single-base  overhang  can  be  inefficient,  so E.coli 
JM109 high efficiency  competent cells  (Promega)  were used  to  obtain  a reasonable 
number of colonies.  JM109 cells are also compatible with blue/white colour screening 
and standard Ampicillin selection.  Each ligation was transformed  into JM109  cells, 
followed by mini-scale preparation of plasmid DNA.  Frozen competent JM109 cells 
were thawed on ice.  Once the cells had just thawed, 50 pi of cells were added to a 1.5 
ml eppendorf.  Two microlitres of each ligation reaction were added to the cells, mixed 
and placed on ice for 20 min.  The cells were heat shocked at 42°C for 45-50s, followed 
by immediately returning to ice for 2 min.  Nine hundred and fifty microlitres of  room 
temp  Luria  broth  (LB)  (Sigma)  was  added  to  the  tube  and  incubated  in  a  shaking 
incubator at 37°C for  1.5 hr.  One hundred microlitres of the transformed cells were 
plated out onto LB agar plates supplemented with 50 pg/ml Ampicillin (Sigma),  0.5 
mM  IPTG  (Promega),  and  80 pg/ml  X-Gal  (Promega)  to  allow the  selection  of the 
recombinant clones (white colonies).
23.6 Small-scale preparations of plasmid DNA
After overnight incubation at 37°C, the white putative recombinant clones were picked 
and inoculated into 5 ml LB containing 50 pg/ml Ampicillin, and incubated in a shaking 
incubator at 37°C overnight.  The selected clones were also streaked onto LB agar plates 
supplemented with 50 pg/ml Ampicillin and stored at 4°C.  Glycerol stocks were made 
by  adding 200  pi  glycerol  (Sigma)  to  800  pi  of the  overnight bacterial  suspension, 
vortexed  and  snap  frozen  in  an  methanol/dry  ice  bath  and  stored  at  -70°C.  The 
remainder  of  the  overnight  bacterial  suspension  were  used  for  plasmid  DNA 
purification.
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Plasmid  purification  was  performed  using  the  Wizard  Plus  SV  Minipreps  DNA 
Purification  System  (Promega)  according  to  the  manufacturer’s  instructions.  Five 
millilitres  of overnight bacterial culture were pelleted by centrifugation at 10 000 g for 
5 min, and the supernatant discarded.  Two hundred and fifty microlitres of Wizard Plus 
SV Cell Resuspension Solution (50 mM Tris-HCl pH 7.5,  10 mM EDTA,  100 pg/ml 
RNase A)  were added to the cell pellet,  followed by 250 pi of Wizard Plus SV Cell 
Lysis Solution with mixing.  Ten microlitres of Alkaline Protease Solution were then 
added, and the tubes were  incubated at room temperature for 5 min.  Three hundred and 
fifty microlitres of Wizard Plus SV Neutralization solution were added,  followed by 
centrifugation  at 10 000 g for 10 min.  The cleared lysate was then transferred to the 
Wizard Plus SV Minipreps Spin Column, and centrifuged at 10 000 g for 1  min.  After 
discarding  the  flow-through,  750  pi  of Wizard  Plus  SV  Minipreps  Column  Wash 
solution were added to the Spin Column.  The Spin Column was centrifuged twice at 10 
000 g for 1  min discarding the flowthrough each time.  The Wizard Plus SV Minipreps 
Spin Column was transferred to a fresh eppendorf and plasmid DNA was eluted in 100 
pi of nuclease free H2O .
2.3.7 Screening of plasmid clones by restriction endonuclease digestion
The plasmid  DNAs  were  digested  with EcoRl  to  confirm  that  the  clones  contained 
HCMV gB, HCMV US28, HHV-6 U67 and HHV-7 U42 cloned into pGEM-T Easy. 
Three hundred nanograms  of each plasmid DNA were digested with 1U of iscoRI in IX 
buffer H (50 mM Tris-HCl, 0.1 M NaCl, 10 mM MgCl2,  1  mM DTT, pH 7.5 at 37°C) 
(Roche) made up to a final volume of 15 pi with nuclease free H2O .  The reaction was 
incubated at 37°C for 2 hrs, and then analysed on a 3% agarose gel in IX TBE buffer as 
described in section 2.2.2.  The concentration of the plasmid DNA was measured using 
the Gene Quant.  The presence and orientation of the insert was verified by sequencing 
with Ml3  universal  and reverse primers using an in-house  sequencing service at the 
Windeyer Institute, UCL.
M13 Universal 5’ - GTA AAA CGA CGG CCA GT - 3’
M13 Reverse  5* - GTT TTC CCA GTC ACG AC - 3’
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2J.8 Linearization of the plasmids prior to transcription
From the sequencing results, all inserts were found to be cloned into the pGEM-T Easy 
vector in the 5’-3’  orientation.  The restriction enzymes Ncol and Ndel were used to 
digest the plasmid DNAs  in  order to  generate  insert  sequence  for the production  of 
antisense and sense RNA transcripts using in vitro transcription with the respective Sp6 
and T7 RNA polymerase as described in section 2.3.10 (see figure 2.2).
T7 Transcription start
I   *
S '. .. TGTAA  TAOGA  CTCAC  TATAG  GGCGA ATTGG  GCCCG  ACGTC  GCATG  CTCCC  GGCCG CCAJG 
3T.  .. ACATT  ATGCT  GAGTG  ATATC  OCGCT  TAACC  CGGGC  TGC  AG  CGTAC  GA3GG  CCGGC GGTAC
'  T7 Promoter  1   I________ I________ II________ I  I_________II______
A p a  I   A a r 11  S fih  I   flsrZ I  N col
r^cioned insert)
* 5 ^
CGCCG GCGCC CTTAA GCTA  V   / 3TTAGTG  ATCAC TTAAG CGCCG GCGGA CGTCC AGCTG
U   I   I _____I____ N  a,,  11 _____f--------1 „  S m c I  E coR I  S p e  I   fcoRI  I     - I   P srl  Sa/I S srZ  I   ^   B srZ  I
SPB transcription start
CATAT GGGA GAGCT CCCAA CGCGT  TGGAT GCATA GCTTG AGTAT TCTAT AGTGT CACCT AAAT ... 3 
GTATA CCCT CTCGA GGGTT GCGGA ACCTA CGTAT CGAAC TCATA A3ATA TCACA GTGGATTTA ... 5'
I______ I  I________I________________fl_______ I  *  SP6 Promoter  '
N dal  Sac I   SsrX I  N s i\
Figure  2.2  The  promoter  and  multiple  cloning  sequence  of the  pGEM-T  Easy 
vector.  The top strand of the sequence shown corresponds to the RNA synthesized by 
T7 RNA polymerase.  The bottom strand corresponds to the RNA synthesized by Sp6 
RNA polymerase (www.promega.com).
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Ten micrograms of each plasmid DNA  were digested with 50 U restriction enzyme 
{NcollNdel) in IX NE buffer 4 (50 mM potassium acetate, 20 mM Tris acetate, 10 mM 
magnesium acetate, 1  mM DTT, pH 7.9 at 25°C) (New England BioLabs) made up to a 
final volume of 50 pi with nuclease free H2O.  The reaction mixture was digested at 
37°C for 2-3 hr.  Two microlitres  of the digestion reaction, together with 2 pi of the 
uncut plasmid  were  analysed on  a 0.8%  agarose  gel  in  IX  TBE  buffer to  confirm 
complete  digestion  of the  vector.  The  restriction  digestion  must  be  performed  to 
completion as a small amount of undigested plasmid DNA can give rise to very long 
transcripts.
23.9 Phenol extraction and ethanol precipitation of linearized template DNA
After  the  restriction  digest,  the  linearized  template  DNAs  were  purified  by  phenol 
chloroform extraction and ethanol precipitated to avoid RNase contamination.  To each 
digest, an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1)  (Sigma) was 
added, vortexed vigorously for  10 sec and centrifuged at  10  000 g for  15  sec.  The 
upper, aqueous phase was transferred to a fresh  1.5 ml eppendorf, and 0.1  vol of 3 M 
sodium acetate buffer solution (pH 5.2) (Sigma) was added, and vortexed briefly.  Two 
volumes of ice-cold 100% ethanol were then added to the mixture, which was vortexed, 
and placed in a -70°C freezer for at least 30 min.  After centrifuging at 10 000 g for 5 
min the supernatant was discarded.  One ml of room temp 70% ethanol  were added, the 
tube was mixed by inverting several times, and centrifuged at 10 000 g for 5 min.  The 
supernatant was discarded, and the pellet was air dried, before resuspending in 20 pi 
nuclease free H2O .
23.10 In vitro transcription using Sp6 and T7 RNA polymerase
As mentioned previously, the plasmid DNAs digested with Ncol were used to generate 
antisense RNA transcripts using in vitro transcription with Sp6 RNA polymerase, and 
the plasmid DNAs digested with NdeI were used to generate sense RNA transcripts with 
T7  RNA  polymerase.  In  vitro  transcription  was  performed  using  the  riboprobe 
combination system-Sp6/T7 (Promega).
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Each in vitro transcription reaction was performed in a  1.5 ml RNase-free microfuge 
tube (Ambion), and was composed of 1   fig linearized template DNA,  IX transcription 
buffer (40 mM Tris-HCl (pH 7.9), 6 mM MgCh, 2 mM spermidine, 10 mM NaCl), 10 
mM dithiotreitol (DTT), 40 U RNAsin, 20 U RNA polymerase (Sp6 or T7), and  IX 
DIG RNA labelling mix (1  mM ATP,  1   mM CTP,  1   mM GTP, 0.65  UTP, 0.35 mM 
DIG-11-UTP, pH 7.7 (20°C) (Roche)) made up to a final volume of 20 |il with nuclease 
free H2O .  A positive control reaction with pGEM Express Positive control template and 
Sp6 RNA polymerase was also included.  The reaction components were added on ice, 
and after mixing and centrifuging briefly, in vitro transcription was performed for 2 hr 
at 37°C.  After in vitro transcription,  any remaining template DNA was removed by 
adding 2 pi RQ1  RNase-free DNase (1  U/pl) (Promega) to the tube, and incubating at 
37°C for 15 min.  Two microlitres of 0.2 M EDTA (pH 8.0) were then added to the tube 
to stop the reaction.
23.11 Ethanol precipitation of RNA transcripts
To each in vitro transcription reaction, 0.1  vol of 4 M lithium chloride (LiCl) and 2.5 
vol of prechilled 100% ethanol was added to the tube, and placed in a -70°C freezer for 
at  least 30  min.  The tubes  were  centrifuged  at  10  000 g  for  15  min,  to  pellet the 
precipitated RNA.  The ethanol was decanted, and 50 pi of 70% ethanol was added to 
the tube which was inverted several times to wash the pellet.  After centrifuging at  10 
000 g for 5 min, the ethanol was decanted, and the pellet air dried.  The RNA pellet was 
resuspended in 50 pi nuclease free H2O, and 1  pi RNase inhibitor (Promega) was added 
to the tube.  The concentration of RNA was measured using the Gene Quant and the 
riboprobes were stored at -70°C until ready for use.
23.12 Denaturing agarose gel preparation and electrophoresis
The RNA transcripts were  analysed  on  a 3%  denaturing  agarose  gel.  The  gel  was 
prepared by weighing out 3 g of agarose in a 200 ml Duran bottle, and adding 10 ml of 
10X morpholinopropanesulphonic acid (MOPS) buffer (0.2 M MOPS (pH 7.0), 50 mM 
sodium acetate,  0.5  mM  EDTA  (pH  8.0),  and  86  ml  of 0.1%  diethyl pyrocarbonate 
(DEPC)-treated H2O .  DEPC-treated H2O  was prepared by adding 1   ml DEPC to  1   litre 
of distilled H2O.  The H2O   was  shaken  vigorously,  and  left  overnight  at room  temp 
before autoclaving to inactivate the DEPC.  The gel was heated in a microwave oven
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until all the agarose had completely dissolved.  The gel was allowed to cool to 50°C 
before adding 4.8 ml formaldehyde (37% solution, Sigma).  In a fume cupboard, the gel 
was poured into a gel-casting tray, with a gel comb, and allowed to set.  Once set, the 
gel was placed in an electrophoresis tank containing IX MOPS buffer.  Five microlitres 
of  each  transcription  reaction,  together  with  1   pg  RNA  markers  0.28-6.58  kb 
(Promega), were added to 15 |il RNA sample buffer (10 ml formamide (Sigma), 3.5 ml 
formaldehyde  (37%  solution),  and 2  ml  10X  MOPS  buffer)  and  2  pi  RNA  loading 
buffer (50% glycerol,  1   mM EDTA, 0.4% bromophenol blue, and  1   mg/ml ethidium 
bromide) in a 0.5 ml tube.  The tubes were placed in a heating block and denatured at 
60°C for  10 min, before loading into separate wells.  The gel was run at  100V for 30 
min and visualised on a UV transilluminator.
23.13  Spot assay to detect efficiency of digoxigenin labelling reaction
To confirm that the RNA transcripts were sufficiently labelled with DIG, a spot assay 
was performed.  Serial dilutions of the RNA probes (10 ng-0.01  ng/pl RNA) in RNA 
dilution buffer (500 pi of nuclease free H2O, 300 pi 20X Saline-sodium citrate (SSC) 
buffer  and  200  pi  formaldehyde)  were  spotted  onto  Nylon  Hybond  N  membrane 
(Amersham Life Sciences) and air dried for 5 min.  The RNA probes were fixed onto 
the membrane by UV crosslinking.  The membrane was placed face down on a UV 
transilluminator for 20 min.  The membrane was then washed in buffer 1   (0.1  M Tris- 
HCl, 0.1  M NaCl, 2 mM MgCl2, 0.5% Triton-XlOO, pH 7.5) followed by blocking in 
2% normal sheep serum in buffer 1   for 15 min.  The membrane was incubated with an 
anti-DIG Alkaline phosphatase (AP) Ab (Roche) diluted at 1:5000 dilution in buffer 1  
with  1% normal sheep serum for 30 min.  After washes in buffer 2 (0.1  M Tris-HCl, 
0.1M NaCl, 50 mM MgCl2, pH 9.5) for 15 min, detection was carried out using the 5- 
Bromo-4-chloro-3-indoylphosphate/Nitroblue tetrazolium (BCIP/NBT) AP substrate kit 
IV (Vector Labs).  The BCIP/NBT substrate working solution was prepared according 
to the manufacturer’s instructions. Two drops of Reagent 1, 2 drops of Reagent 2, and 2 
drops of Reagent 3 were added to 5 ml 0.1 M Tris-HCl pH 9.5 mixing well each time. 
The membrane was incubated with BCIP/NBT substrate solution and left in the dark for 
approximately 1  hr or until dark purple spots appear in sufficient intensity.  The reaction 
was stopped by rinsing in H20 for 5 min.
110Chapter 2 -  Materials and  Methods
2.4  Development of in situ hybridisation for the detection of human [}- 
herpesvirus DNA
In situ hybridisation (ISH) is a technique that allows the detection of nucleic acid hybrid 
molecules (DNA:DNA, DNA:RNA or RNA:RNA) between the target nucleic acid in 
morphologically  preserved  cells  or  tissues,  and  a  labelled  probe  containing  a 
complementary sequence.  In this section, ISH was developed for the detection of (3- 
herpesvirus DNA using the DIG labelled riboprobes constructed in section 2.3.  The 
ISH method was first tested on 4% paraformaldehyde fixed cell controls (section 2.4.1), 
and this provides a good starting point as it gives adequate morphology and sufficient 
permeability  so  that permeabilisation  steps  are  usually not  required.  ISH  was  then 
carried out on formalin-fixed paraffin-embedded cell controls where optimisation of in 
situ  conditions  was  required  to  achieve  optimal  hybridisation  signals.  Further 
optimisation of the ISH method was carried out on formalin-fixed paraffin-embedded 
liver and renal biopsies (sections 2.4.3 and 2.4.4).  This method was subsequently used 
for  the  detection  of  human  P-herpesvirus  DNA  in  liver  and  renal  biopsies  from 
transplant patients (sections 2.5 and 2.6).
2.4.1 ISH on 4% paraformaldehyde-fixed cell suspensions
The detection of the human P-herpesviruses by ISH using DIG labelled riboprobes was 
tested  initially  on  4%  paraformaldehyde-fixed  cells  from  virus  infected  cultures. 
HCMV gB,  HCMV US28,  HHV-6 U67  and HHV-7 U42  riboprobes  were tested on 
HCMV infected HEL/MRC-5, HHV-6  infected Molt-3,  and HHV-7  infected  Sup T1 
cells, respectively.  Non-infected HEL, Molt-3 and Sup T1 cells were used as negative 
controls.
2.4.1.1 Tissue pre-treatment
All pre-treatment conditions were performed under RNase free conditions when RNA 
probes  were  used.  Disposable  gloves  were  worn  at  all  times,  sterile  glass  and 
plasticware were used, and all solutions were treated with 0.1% DEPC.  Surfaces were 
also  wiped  down  with  RNase  Zap  (Ambion).  The  paraformaldehyde-fixed  cell 
suspensions (see section 2.1.3.1) were rehydrated through decreasing concentrations of 
ethanol into distilled H2O .  The slides were then washed in PBS for 5 min and treated 
with 0.03% triton-XlOO in PBS for  15 min.  The slides were incubated at a range of
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Proteinase  K  (Sigma)  concentrations  ranging  from  0-10  Mg/ml  Proteinase  K  in 
Proteinase  K buffer  (50  mM  Tris-HCL,  5  mM  EDTA  pH  7.6)  for  30  min  at  37°C 
followed by PBS washes three times for 5 min.  The slides were dehydrated through 
increasing concentrations of ethanol and air dried.
2.4.1.2  Hybridisation with DIG labelled riboprobes
Hybridisation was carried out using the GeneAmp  in situ PCR System  1000 (Perkin 
Elmer).  This thermal cycling machine is designed for use with the Perkin Elmer in situ 
PCR Reagent Containment System (includes the in situ PCR 1000 slide assembly tool, 
Amplicover  Discs,  Amplicover  Clips  and  in  situ  PCR  glass  slides  (Applied 
Biosystems)), for containing reagents over tissue specimens mounted on slides.  The 
machine block can incubate the samples  at a constant temperature.  The  slides were 
assembled onto the in situ PCR  1000 slide assembly unit.  The Amplicover clip has 
stainless  steel  sliding  grip  attached  at  either  end  for  gripping  the  slide  to  hold  the 
Amplicover disc in place.
Hybridisation mix consisted of 50% formamide,  10% dextran sulphate,  IX Denhardts 
solution  (0.02%  Ficoll,  0.02%  Polyvinyl  pyrrolidone,  10  mg/ml  RNase-Free  bovine 
serum albumin) (Sigma), 4X SSC,  10 mM DTT,  100 |ig/ml yeast tRNA (Roche),  100 
pg/ml denatured and sheared Salmon sperm DNA (Sigma) and 5 ng of DIG labelled 
riboprobe.  The  salmon  sperm DNA  and DIG  labelled riboprobe were  added to  the 
hybridisation mix immediately before hybridisation.
Fifty microlitres  of the hybridisation mix  were pipetted onto  the  centre  of each cell 
suspension.  The Amplicover clip  and disc was  then  lowered  onto  the  slide  and by 
squeezing the levers on the top of the assembly tool the Amplicover clip and disc were 
secured  onto  the  slide.  The  Amplicover  disc  and  clip  creates  an  airtight  reaction 
chamber to prevent evaporation during hybridisation (or thermal cycling).  The IS 1000 
instrument  was  programmed  for  denaturation  at  95°C  for  5  min  followed  by 
hybridisation at 37°C overnight.
112Chapter 2 -  Materials and  Methods
2.4.13   Post-hybridisation washes
After hybridisation,  the  Amplicover  discs  and  clips  were  dismantled  and  the  slides 
washed in solutions of decreasing salt concentrations (2X SSC twice at 37°C for 15 min, 
IX SSC twice at 37°C for 15 min, 0.2X SSC twice at 37°C for 30 min) to remove the 
excess and non-specifically bound probe and to melt away mismatched hybrids leaving 
only the true hybrids intact for detection.
2.4.1.4  Immunological detection of signal
The slides were washed in buffer 1  (0.1 M Tris-HCl, 0.1 M NaCl, 2 mM MgCh, 0.5% 
Triton XI00, pH 7.5) for 5 min, and incubated in blocking solution (buffer 1  containing 
2% normal sheep serum) for 30 min to remove background.  DIG labelled DNA was 
detected with an anti-DIG AP Ab (Roche).  One hundred microlitres  of AP-labelled 
anti-DIG Ab diluted to  1:200 in buffer 1  with 1% normal sheep serum  were added to 
the slide, and incubated in a humidified chamber at room temp for 2 hr.  The slides were 
further washed in buffer  1   for  10 min followed by buffer 2  (0.1  M Tris-HCl, 0.1  M 
NaCl, 50 mM MgCk, pH 9.5) for 10 min.  Detection of the DIG-labelled RNA:DNA 
hybrid was carried out using the BCIP/NBT AP substrate kit IV as previously described 
in  section  2.2.13.  A  precipitating  dark  purple  reaction  product  (NBT  Formazan)  is 
formed at the site of DIG-labelled hybrid.  The reaction was stopped by washing the 
slides in distilled H2O  for 5 min.  The slides were subsequently air dried and mounted in 
UV Loctite 358 adhesive.
2.4.2  ISH on formalin-fixed paraffin-embedded cell suspensions
ISH  using  DIG  labelled  riboprobes  was  also  tested  on  formalin-fixed  paraffin- 
embedded cells from cultures infected with the respective virus.  HCMV gB, HCMV 
US28, HHV-6 U67 and HHV-7 U42 riboprobes were tested on HCMV infected HEL, 
HHV-6 infected Molt-3 and HHV-7 infected Sup T1  cells respectively.  Non-infected 
HEL, Molt-3 and Sup T1  cells were again used as negative controls.  ISH was carried 
out in the same way as that for paraformaldehyde-fixed cell suspensions (see  section 
2.3.1),  except that slides were  initially deparaffinized in xylene twice  for  15  min  at 
room temp.
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2.4.2.1 Optimisation of protease concentration
For  formalin-fixed  paraffin-embedded  cell  suspensions,  a  range  of  Proteinase  K 
concentrations  ranging  from  0-100  pg/ml  Proteinase  K  in  Proteinase  K buffer were 
tested.  Incubation was carried out at 37°C for 30 min.
2.4.2.2 Optimisation of riboprobe concentration
Once the optimal concentration of proteinase K had been determined, the concentration 
of DIG labelled riboprobe was increased to see whether the hybridisation signal could 
be improved.  A range of DIG labelled riboprobe concentrations (5 ng, 7.5 ng and  10 
ng) in 50 pi of hybridisation mix was tested.  Hybridisations were performed at 37°C 
overnight.
2.4.23  Optimisation of salmon sperm DNA and yeast tRNA concentrations
Once the optimal concentration of DIG labelled riboprobe was determined, a range of 
concentrations of salmon sperm DNA and yeast tRNA (0,  100 pg/ml, and  1   mg/ml) in 
the hybridisation mix was tested.  The  incorporation of these nucleic acids  can help 
reduce non-specific nucleic acid interactions.  Hybridisations were performed at 37°C 
overnight.
2.4.3  ISH on liver biopsies
A liver biopsy which stained positive for HCMV late protein 47-55 kDa by IHC (and 
independently shown to be positive for HCMV p52 protein by IHC conducted by the 
Histopathology Service at the Royal Free Hospital) was used to optimise ISH conditions 
for the detection of HCMV DNA in liver biopsy tissue using DIG labelled HCMV gB 
riboprobe.  Positive  and  negative  controls  consisting  of  formalin-fixed  paraffin- 
embedded HCMV infected and non-infected MRC-5 cells were also included.
2.4.3.1  Optimisation of protease concentration
As mentioned previously the amount of proteolytic treatment varies for different types 
of tissue and must be empirically determined.  A range of Proteinase K concentrations 
ranging  from  2.5-15  pg/ml  were  tested  on  the  liver  biopsies.  The  sections  were 
incubated at 37°C for 30 min
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2.43.2  Optimisation of riboprobe concentration
Once  the  concentration  of proteinase  K  had  been  determined,  hybridisations  were 
performed  using  increasing  riboprobe  concentration  (10  and  20  ng  probe  per 
hybridisation reaction) to determine whether hybridisation signal could be  improved. 
Hybridisations  were performed at 37°C overnight.
2.433 Methods to reduce endogenous alkaline phosphatase
To help reduce non-specific background in the tissue sections caused by endogenous 
alkaline  phosphatase,  two  methods  were  tested.  One  method  involved  treating  the 
sections  in  cold  20%  acetic  acid  for 45  sec  after proteinase  K  treatment  and  PBS 
washes.  Slides were then washed in distilled H2O  for 5 min, dehydrated and air dried. 
The second method involved adding levamisole solution (Vector labs) to the BCEP/NBT 
AP  substrate  solution.  The  sections  were  then  incubated  in  the  substrate  solution 
overnight in the dark as before.  One drop of levamisole solution was added per 5 ml of 
substrate solution.
2.43.4  Modified  ISH  with  recommendations  from  Orion  Molecular  Services, 
Manchester.
ISH using recommendations from Orion Molecular Services, Manchester, were carried 
out to further improve hybridisation signals and reduce background levels.  The slides 
were deparaffmized, and rehydrated to distilled H2O .  The slides were then immersed in 
0.2 M HC1 for 20 min. An acid pre-treatment step was included as acids denature basic 
proteins and in combination with proteolytic treatments can facilitate their removal, thus 
making the target more accessible.  The slides were then treated with 0.01% Triton- 
X100 in PBS for 90 sec, followed by incubation with 7.5 |lg/ml Proteinase K for 30 min 
at 37°C.  After PBS washes three times for 5 min the sections were post-fixed in 0.4% 
paraformaldehyde in PBS for 20 min and washed in distilled H2O  for 5 min.  Sections 
were then treated in cold 20% acetic acid for 45 sec and washed in distilled H2O  for 5 
min.  The slides were dehydrated and air dried.
Hybridisation with a range of concentrations of riboprobe (50 ng,  100 ng and 200 ng) 
were tested.  The hybridisation mix was vortexed briefly and heated at 60°C for 10 min 
in a waterbath to help remove any tertiary structures, and then immediately placed on 
ice.  The hybridisation mix was then warmed to 37°C before pipetting 50 fil onto each
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section.  The slides were denatured at 95°C for 5 min followed by hybridisation at 42°C 
overnight.
Post-hybridisation washes consisted of Wash buffer 1  (0.5X SSC, 1  mM EDTA) for 20 
min at 42°C, Wash buffer 2 (0.15 M NaCl, 5 mM Tris-HCl (pH7.4), 0.5 mM EDTA, 
50% formamide) for 10 min at 42°C, and Wash buffer 3 (0.5X SSC) for 20 min at 50°C 
and wash buffer 3 for 5 min at room temp.  Slides were placed in buffer 1  for 5 min, and 
incubated in blocking solution (buffer 1  containing 2% normal sheep serum) for 30 min. 
Anti-DIG  AP  Ab  diluted  to  1:200  in  buffer  1   with  1%  normal  sheep  serum  was 
incubated for 2 hr in a humidified chamber.  Slides were washed in buffer 1   for 5 min, 
and then in buffer 2 for 5 min.  DIG-labelled DNA was detected using NBT/BCIP AP 
substrate kit IV (Vector labs).  The reaction was stopped by washing in distilled H2O  for 
5 min.  The slides were then air dried and mounted with UV Loctite 358 adhesive.
2.4.4 ISH on renal biopsies
Using the same optimised ISH conditions for the liver biopsies (see section 2.4.3),  10 
formalin-fixed  paraffin-embedded  renal  biopsies  taken  from  transplant  patients 
suspected of graft dysfunction were initially tested for HCMV gB DNA.  To determine 
the  concentration  of protease  required  for  an  optimal  hybridisation  signal  in  renal 
biopsy tissue, a sample which tested positive for HCMV gB DNA was used to test a 
range of Proteinase K concentrations (2.5-15 |ig/ml) incubated at 37°C for 30 min, and 
comparing hybridisation signals.  Positive and negative controls consisting of formalin- 
fixed  paraffin-embedded  HCMV  infected  and  non-infected  MRC-5  cells  were  also 
included.
2.4.5  Testing  the  specificity  of  HCMV,  HHV-6  and  HHV-7  DIG  labelled 
riboprobes
Once the ISH method had been determined, each of the human P-herpesvirus specific 
riboprobes  were  tested  against  formalin-fixed  paraffin-embedded  cells  infected  with 
respective  virus,  and  to  each  of the  other  human  p-herpesviruses  to  test  for  cross- 
reactivity.
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2.4.6  Testing the sensitivity of ISH with a human P-globin riboprobe
The sensitivity of ISH was tested using a p-globin riboprobe.  Human p-globin DNA is 
present as 2 copies per cell, therefore detection of hybridisation signals in human cell 
suspensions using the sense probe (for the detection of DNA and not mRNA) will help 
determine the level of sensitivity of this method.  Section 2.4.6.1-2.4.6.2 describes the 
construction of the human p-globin riboprobe, and section 2.4.6.3 describes ISH with 
this probe.
2.4.6.1  Construction of the human P-globin probe for determining the sensitivity of 
ISH
A human p-globin riboprobe was constructed in the same way as described in section 
2.3.  A  110 bp human P-globin PCR product was amplified using primers PC03  5’ 
ACA CAA CTG TGT TCA CTA GC 3’ and PC04 5’ CAA CTT CAT CCA CGT TCA 
CC 3* (Saiki et al., 1988).  PCR cycling conditions are shown below.
Hot start 
Denaturation 
Annealing 
Extension 
Final extension
95°C for 15 min 
94°C for 30 sec 
50°C for 30 sec 
72°C for 30 sec 
72°C for 10 min
}  1  cycle
39 cycles 
}  1  cycle.
The resulting PCR product was detected by electrophoresis on a 3% (w/v) agarose gel 
as described in section 2.3.2.  The PCR product was then purified and cloned into the 
pGEM-T Easy vector (see section 2.3.3-2.3.7).  Sequencing results showed that the 110 
bp  fragment  of the  human  p-globin  gene  was  cloned  in  the  3’-5’  orientation.  The 
restriction enzymes Ndel and Sphl were used to digest the plasmid DNA (see section 
2.3.8) in order to generate insert sequence for the production of antisense and  sense 
RNA  transcripts  using  in  vitro  transcription  with  T7  and  Sp6  RNA  polymerase, 
respectively.  The linearized plasmid DNA was then purified by phenol extraction and 
ethanol precipitation as described in section 2.3.9.  Plasmid DNA linearized with Ndel 
was  in  vitro  transcribed  with  T7  RNA  polymerase  as  described  in  section  2.3.10. 
However,  Sphl  generates  3*  overhangs  which  can  result  in  extraneous  transcripts. 
Therefore the 3’ overhang must be converted to a blunt end using the 3’-5’ exonuclease
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activity of DNA polymerase  I Large (klenow) Fragment before  in vitro transcription 
with Sp6 RNA polymerase.
2.4.6.2  Conversion of a 3’ overhang to a blunt end
The reaction was composed of 1   pg linearized template DNA,  IX transcription buffer 
(40  mM  Tris-HCl  (pH  7.9),  6  mM  MgCl2,  2 mM  spermidine,  10  mM NaCl),  40 U 
RNAsin, DNA polymerase I Large (Klenow) Fragment (5U/pg) (Promega),  IX DNA 
polymerase buffer (500 mM Tris-HCl (pH 7.2 at 25°C),  100 mM MgS04, 1  mM DTT) 
made up to a final volume of 10 pi with nuclease free H2O.  The reaction mixture was 
incubated  at  22°C  for  15  min,  before  proceeding  to  in  vitro  transcription.  To  the 
reaction mixture,  10 mM DTT, 20 U  Sp6 RNA polymerase,  IX DIG RNA labelling 
mix, made up to a final volume of 20 pi with nuclease free H2O  was added.  In vitro 
transcription was performed for 2 hrs at 37°C.  After in vitro transcription, 2 pi RQ1 
RNase-free  DNase  (1  U/pl)  was  added,  and  incubated  at  37°C  for  15  min.  Two 
microlitres of 0.2 M EDTA (pH 8.0) were then added to the tube to stop the reaction. 
The RNA transcripts were then ethanol precipitated as described in section 2.3.11.  The 
RNA transcripts were analysed in a 3% denaturing agarose gel as described in section 
2.3.12 and a spot assay was performed as described in section 2.3.13.
2.4.63   ISH with DIG labelled human P-globin riboprobe
ISH using the p-globin sense riboprobe was tested on 4% paraformaldehyde-fixed HEL 
cells  using  the  method  described  in  section  2.4.1.1-2.4.1.4,  and  on  formalin-fixed 
paraffin-embedded HEL cells, using optimized ISH conditions (section 2.4.3.4).
2.4.7  Testing  the  sensitivity  of HHV-6  ISH  on  a  lymphoblastoid  cell  line  with 
integrated HHV-6 genome (Vl-LCL)
Once the conditions of ISH were optimised, the sensitivity of ISH using HHV-6 U67 
riboprobe  was  tested  on  a  lymphoblastoid  cell  line  (LCL)  with  integrated  HHV-6 
genome  (Vl-LCL).  Using  a  QC-PCR,  the  HHV-6  load  of Vl-LCL was previously 
shown to be 26 genome copies/cell.  More recently using a real-time HHV-6 Taqman 
assay, the viral load in this cell line was determined as 12 copies/cell (Dr Duncan Clark 
pers. comm.). The Vl-LCL was prepared by Dr Duncan Clark, and was formalin-fixed 
and paraffin-embedded as described in section 2.1.3.2.  Positive and negative controls
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consisting  of HHV-6B  (Z29)  infected  Molt  3  and  noninfected  Molt  3  cells  were 
included.
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2.5  Role of the human ^-herpesviruses in allograft rejection following 
renal transplantation
2.5.1 Renal transplant patients
This study followed on from a prospective study of 52 patients who underwent their 
first renal transplantation between 1st August 1993 and 31st January 1995 (Kidd et al.,
2000).  Inclusion criteria for this present study included at least one diagnostic allograft 
biopsy during the 120-day post-transplant period.  Fine-needle biopsies were only taken 
when a patient was suspected of having renal dysfunction.  Patients were excluded if 
adequate renal tissue was not included (no biopsy performed, n = 16; biopsy too small n 
= 6).  A total of 62 allograft biopsies from 30 renal transplant patients were available for 
study.  In these patients, biopsies were performed at a median of 21  days (range 2 to 
107) after transplantation.  Two or more biopsies were available from 18 patients, with 
a median of 2 (range 1  to 5) biopsies.
2.5.2 Immunosuppressive therapy
Immunosuppressive therapy in the immediate post-transplant period consisted of a triple 
drug regimen (cyclosporine A, azathioprine, prednisolone).  Episodes of histologically- 
identified  acute  rejection  were  treated  with  0.5  or  1   gram  pulse  doses  of methyl 
prednisolone, and if rejection continued a course of ATG was administered.
2.5.3 Renal biopsies
Biopsy  samples  were  routinely  fixed  in 4%  neutral  buffered  formalin  and  paraffin- 
embedded.  Four pm sections were cut and mounted onto APES-coated slides (Applied 
Biosystems).  The slides were placed in a hybridisation oven and baked at 55°C for 48 
hrs.  Morphological classification of the renal allograft biopsies were conducted by Dr 
Michael Jarmulowicz, pathologist at the  Royal  Free  and University College Medical 
School,  and  followed  the  Banff ’93-95’  working  classification  (Solez  et  al.,  1993; 
1996).
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2.5.4 Cell controls
Formalin-fixed  paraffin-embedded  cells  from  infected  cultures  of  HCMV  (strain 
AD169) infected HEL fibroblasts, HHV-6B (strain Z29) infected Molt-3  and HHV-7 
(strain DC) infected SupTl T cell lines were used as positive controls for ISH and IHC. 
Non-infected  cell  cultures  were  used  as  negative  controls.  Formalin-fixed paraffin- 
embedded  human  leukaemic  cell  line  HL60,  and  HL60  cells  treated  with  10  pM 
etoposide  (kindly  provided  by  Dr  Ranmohan  Wickremasinghe,  Department  of 
Haematology,  Royal  Free  and  University  College  Medical  School),  were  used  as 
positive controls for in situ detection of apoptosis.
2.5.5 ISH on renal biopsies
ISH using DIG labelled riboprobes were used to test each renal biopsy for HCMV gB, 
HHV-6 U67 and HHV-7 U42 DNA by ISH.  Ten renal biopsies positive for HCMV gB 
DNA were also tested for HCMV US28 DNA by ISH to confirm results.  Two renal 
biopsies  which tested negative  for HCMV  gB  DNA were  also  included  as  negative 
controls.  The slides were deparaffinized in xylene twice for  15  mins at room temp, 
followed  by  rehydration  of the  tissue  in  decreasing  concentrations  of ethanol  in  to 
distilled H2O .  The slides were then immersed in 0.2 M HC1 for 20 mins, and washed in 
distilled H2O  for 5 mins.  The slides were then treated with 0.01% Triton-XlOO in PBS 
for 90 secs, followed by incubation with 7.5 pg/ml Proteinase K in Proteinase K buffer 
(50 mM Tris-HCL, 5 mM EDTA pH 7.6) for 30 mins at 37°C, and washes in PBS three 
times for 5 mins.  Sections were post-fixed in 0.4% paraformaldehyde for 20 mins and 
washed in distilled H2O  for 5 mins, followed by immersion in cold 20% acetic acid for 
45  secs.  The slides were washed in distilled H2O  for 5  mins and dehydrated through 
increasing concentrations of ethanol and air dried.  For each renal sample, hybridisation 
with  HCMV  gB,  HHV-6  U67,  and  HHV-7  U42  riboprobe  was  carried  out.  Fifty 
nanograms of DIG labelled riboprobe were added to 50 pi hybridisation mix containing 
50% formamide, 10% dextran sulfate, IX Denhardts solution, 4X SSC, 10 mM DTT,  1  
mg/ml  yeast  tRNA  and  1   mg/ml  denatured  and  sheared  Salmon  sperm  DNA.  A 
negative reagent control with hybridisation mixture, but without probe, was performed 
in parallel for each sample.  The hybridisation mix was vortexed briefly and heated at 
60°C for  10 mins in a waterbath, and then placed on ice.  Fifty microlitres  of probe 
mixture was pipetted onto each section and denatured at 95°C for 5 mins followed by
121Chapter 2 -  Materials and  Methods
hybridisation at 42°C overnight.  Post-hybridisation washes consisted of 4X SSC for 5 
mins at room temp, Wash buffer 1  (0.5X SSC, 1  mM EDTA) for 20 mins at 42°C, Wash 
buffer 2 (0.15M NaCl, 5mM Tris-HCl (pH7.4), 0.5 mM EDTA, 50% formamide) for 10 
mins at 42°C, and Wash buffer 3  (0.5X SSC) for 20 mins at 50°C and for 5 mins at 
room temp.  Slides were washed  in buffer  1   (0.1  M  Tris-HCl,  0.1  M NaCl,  2  mM 
MgCh,  0.5%  Triton  XI00,  pH  7.5)  for  5  mins,  and  incubated  in  blocking  solution 
(buffer  1   containing  2%  normal  sheep  serum)  for  30  mins.  Anti-DIG  AP  Ab  was 
diluted to 1:200 in buffer 1  with 1% normal sheep serum was incubated for 2 hours in a 
humidified chamber.  Slides were further washed in buffer  1   for 5 mins followed by 
buffer 2  (0.1  M Tris-HCl,  0.1  M NaCl,  50 mM  MgCl2,  pH  9.5)  for 5  mins.  DIG- 
labelled  RNA-DNA  hybrids  were  detected  using  NBT/BCIP  AP  substrate  kit  IV 
(Vector labs).  The reaction was stopped by washing in distilled H20 for 5 mins.  The 
slides were air dried, and mounted with UV Loctite 358 adhesive.
2.5.6  HCMV-specific IHC
Ten renal biopsies positive for HCMV gB DNA by ISH were tested for the presence of 
HCMV proteins characteristic for each temporal stage of replication using the following 
mAbs: MAB8131 directed to the HCMV EE protein; MAb CCH2 directed HCMV p52 
(Plachter et al.,  1992); MAB8126 to HCMV late protein.  Two immunohistochemical 
staining  methods  were  used.  The  ABC  system  (Elite  ABC  kit,  Vector  Labs)  as 
described  in  section  2.2.1  was used with  the  three  HCMV  MAbs,  and  the  DAKO 
chemMate Envision detection  system (Dako)  as  described in  section 2.2.2  was used 
with  two  HCMV  MAbs  (MAB8131  and  MAb  CCH2).  The  sections  were 
counterstained  with  Hematoxylin  (Gill’s  Formula)  (Vectorlabs).  Sections  were 
incubated in Hematoxylin for  1-5  mins followed by rinsing in running tap H20 until 
rinse H20 was clear.  The slides were then dipped 10 times in acid rinse solution (2 ml 
glacial acetic acid in 98 ml 70% ethanol) followed by  10 dips in tap H20.  The slides 
were then incubated in bluing solution (1.5 ml ammonium hydroxide (Sigma) in 98.5 ml 
70%  ethanol)  for  1   min  followed  by  10  dips  in  tap  H20  and  dehydrated  through 
increasing concentrations of ethanol.  The specificities of these Abs were confirmed by 
using isotype matched control mouse mAbs (Dako).  Five renal biopsies negative  for 
HCMV gB DNA by ISH were also included as negative controls.
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2.5.7 In situ detection of active caspase-3
To investigate whether apoptosis  is  associated with the presence of HCMV  in renal 
biopsies,  10 samples positive for HCMV gB DNA by ISH were stained with an anti­
active caspase-3 mAb (C92-605; Pharmingen) (Dukers et al., 2002a).  Caspase-3 is a 
cysteine  protease  that plays  a  central  role  in  apoptosis.  The  presence  of activated 
caspase-3 is a sensitive and specific marker of apoptosis (Dukers et al., 2002b).  The 
slides were deparaffinized, endogenous peroxidase was blocked, and the sections were 
microwaved in Citrate buffer as previously described  in  section 2.2.1.  The  sections 
were  then  incubated  with  10%  normal  goat  serum  in  PBS  with  the  avidin  biotin 
blocking kit as mentioned in section 2.2.1.4.  The anti-active caspase-3  Ab was then 
added to the sections at a 1:500 dilution in first layer diluent and incubated overnight at 
4°C in a humidified chamber.  Immunohistochemical detection was carried out, and the 
sections were counterstained with hematoxylin as described in section 2.5.6.  For each 
sample,  staining with diluted normal goat serum was  included as a negative control. 
Human  leukaemia  cell  line  HL-60  cells,  with  and  without  the  treatment  of  10  pM 
etoposide, an inducer of apoptosis, was used as positive controls.
2.5.8 In situ detection of C4d
All  renal  biopsies  were  tested  for  the  presence  of Ab  mediated  rejection  using  a 
polyclonal  peptide-specific  anti-C4d  antibody  (C4dpAb;  Biomedica)  (Regele  et  al.,
2001).  Immunohistochemical staining using the DAKO chemMate Envision detection 
system was performed as described in section 2.2.2.  The sections were incubated with 
C4dpAb  (4  jig/ml)  in  polyclonal  Ab  diluent  (0.3%  Triton  X-100,  2%  normal  goat 
serum, 0.01% sodium azide in PBS) for 30 mins at room temp.  For each experiment, a 
renal allograft biopsy positive for C4d staining, and a renal allograft biopsy negative for 
C4d staining was included.  A liver allograft biopsy was also included as a negative 
control.  For 20  samples  which  stained  positive  for  C4d,  normal  rabbit  IgG  serum 
(Sigma)  diluted  to  the  same  concentration  as  the  anti-C4d  Ab  was  included  as  a 
negative control.
2.5.9 Statistical analyses
Statistical comparison between the groups was done using the X2 and Fisher’s exact 
tests.
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2.6  Investigation of HCMV gene expression in renal biopsies
To investigate HCMV gene expression in the renal biopsies of the transplant recipients, 
a DIG labelled riboprobe specific to a region of the HCMV BE-1  was constructed for 
ISH.  The IE-1, also referred to as the major IE gene, is the first gene to be expressed 
following the entry of the HCMV into the cell, and requires no prior protein synthesis 
for its expression (LaFemina and Hayward, 1983).  Since BE gene expression can occur 
during an abortive or productive infection, development of a HCMV IE-1 probe will be 
useful to detect HCMV in various states of infection.
2.6.1 Construction of HCMV immediate early (IE) riboprobes
HCMV IE riboprobe was generated by subcloning a HCMV IE-1 region of cDNA into 
the pGEM-T Easy vector, followed by in vitro transcription to generate both sense and 
antisense  RNA  transcripts.  The  antisense  probe  is  a  complementary  strand  to  the 
mRNA, and should hybridise to a region on the target mRNA.  The sense probe should 
not hybridise, since it is the same sequence as the target mRNA.
2.6.1.1 Extraction of RNA from HCMV infected HEL cells
HEL cells infected with HCMV for 4 hrs, and uninfected HEL cells were cultured in 75 
cm2 flasks as described in section 2.1.1, and 2.1.2.  Total RNA was then extracted using 
TRIzol reagent (GibcoBRL).  The medium was first discarded from the HEL cells, and 
6  ml  TRIzol  was  added  to  the  cell  monolayer.  The  cells  were  lysed  by  repetitive 
pipetting.  The cell lysate was transferred to  1.5 ml RNase-free tubes (6 tubes of 1   ml 
cell lysate) and heated at 70°C on a heating block for 10 min to facilitate dissociation of 
RNA from the cell debris/nucleoprotein complexes.  The tubes were left to cool to room 
temp, and then 0.2  ml chloroform was  added to  each tube.  The tubes  were  shaken 
vigorously  for  15  sec,  and  left to  stand  at  room  temp  for  3  min.  The  tubes  were 
centrifuged at 10 000 g for 15 min.  After centrifugation, the mixture was separated into 
a  lower red phenol-chloroform phase,  an  interphase  and  a colourless  upper  aqueous 
phase.  Five  hundred  microlitres  of the  aqueous  phase  were  transferred  to  a  fresh 
RNase-free tube and 0.5 ml isopropanol were added to precipitate the RNA.  The tubes 
were left at room temp for 10 min, and then centrifuged at 10 000 g for 10 min to pellet 
the  RNA.  The  supernatant  was  discarded,  and  the  pellet  was  air  dried  before
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resuspending in 50 pi RNase-free H2O .  The tubes were incubated at 55°C for 10 min, 
and stored at -80°C.  The concentration of RNA was measured using the GeneQuant.
2.6.1.2 RQ1 RNase-Free DNase treatment of RNA
The RNA sample was treated with RQ1  RNase-Free DNase (DNase I)  (Promega) to 
remove any residual DNA.  Each reaction was composed of 20 pg RNA in IX Reaction 
buffer (40 mM Tris-HCl (pH 8.0),  10 MgS04,  1   mM CaCl2), 20 U RQ1  RNase-Free 
DNase,  made up  to  a  final  volume  of 50  pi  with nuclease  free  H20.  The  reaction 
mixture was incubated at 37°C for 30 min.  One microlitre of RQ1 DNase Stop solution 
(20 mM EDTA, pH 8.0) was added to terminate the reaction.  The tubes were incubated 
at 65°C for 10 min to inactivate the DNase.
2.6.1.3 Reverse transcription (RT)-PCR
Extracted  RNA  was  reverse  transcribed  for  generation  of cDNA  template  for  PCR 
amplification.  PCR amplification was carried out using HCMV IE-1 primers IEP3D 5’ 
CCA GAC TCA GCT GAC TGT TAA CCT CCT TCC 3’ and IEP2AII 5’ ATG GAG 
TCC  TCT  GCC AAG AGA AAG ATG GAC  3’  (Kondo  et al,  1994).  These  two 
primer  pairs  span  exon  2-3  (see  figure  2.3),  so  that  amplification  of  potentially 
contaminated genomic  DNA  sequences would produce PCR products that are  larger 
(263  bp)  than  the  expected  mRNA  product  (151  bp),  as  intron  sequences  that  are 
excised during RNA processing would be included in the genomic DNA.
cDNA was synthesized using random hexamer primers (Perkin Elmer), and Omniscript 
reverse transcriptase (Promega).  Two micrograms of RNA were reversed transcribed in 
IX PCR buffer II (50 mM KC1,  10 mM Tris-HCl, pH 8.3), 0.5 mM of dNTPs,  10 U 
RNase inhibitor, 4 U Omiscript RT, and 2.5 pM random hexamer primers made up to a 
final volume of 20 pi in nuclease free H20.  Each reaction component was added on ice. 
The RT reaction was incubated at 37°C for  1   hr,  and inactivated by 95°C  for 3  min, 
followed by rapid cooling on ice.  PCR was performed in IX PCR buffer containing 2 
mM MgCl2, 200 pM each dNTP, 1.25 U of HotStar Taq DNA Polymerase and 100 nM 
of each primer in a volume of 45 pi made up with nuclease free H20.  Five microlitres of 
cDNA (0.1  pg/pl) were added to each reaction.  Negative controls of HCMV infected 
HEL RNA with no RT step, uninfected HEL cDNA, and distilled H20 were included.
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The PCR cycling conditions previously described by Kondo et al  (1994) are shown 
below.  Cycling was performed on a Hybaid DNA thermal cycler.
2.6.1.4 Gel preparation and electrophoresis
The resulting PCR amplicons were detected by electrophoresis on a 3% (w/v) agarose 
gel in IX TBE buffer as described in section 2.3.2.  Visualisation of the gel showed the 
presence of primer dimers, and contaminating genomic DNA products (263 bp), as well 
as the expected cDNA product (151  bp), therefore purification of the  151  bp product 
from agarose was performed, instead of direct purification from the tubes as previously 
described.
2.6.1.5 Purification of cDNA amplification product from agarose gel
The remaining volume of cDNA product (approximately 40 pl/tube) was run on a 3% 
(w/v) low-gelling point agarose gel in IX TBE buffer.  The bands were visualised under 
long or medium U.V light to minimise exposure of DNA to the light, and the  151  bp 
fragment was excised from the agarose gel with a sterile scapel blade.  The excised band 
was then purified from the agarose gel using the Qiaquick gel extraction kit (Qiagen) 
according to the manufacturer’s instructions.  Six volumes of buffer QG was added to 1  
volume of agarose gel (approximately 300 pi) in a  1.5 ml eppendorf tube.  The tubes 
were placed in a 50°C waterbath until the gel slice had completely dissolved.  One gel 
volume of isopropanol was added to the tube and mixed briefly.  The gel mixture was 
applied to the QIAquick column and centrifuged at  10 000 g for  1   min.  The flow­
through was discarded, and 0.5 ml of Buffer QG was added.  After centrifugation at 10 
000  g  for  1   min,  0.75  ml  of Buffer  PE  was  added.  The  QIAquick  column  was 
centrifuged twice at 10 000 g for 1  min, discarding the flow-through each time.  DNA 
was  eluted  by  adding  50  pi  of  nuclease-free  H2O   to  the  QLAquick  column  and 
centrifuging at 10 000 g for 1  min.
Denaturation
Annealing
Extension
Final extension
Hot start 95°C for 15 min  }  1  cycle
94°C for 1  min 
62°C for 1  min  30 cycles 
72°C for 2 min
72°C for 10 min  }  1  cycle.
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Figure 2.3.  Primers used for the analysis of sense and antisense IE-l/IE-2 region 
transcripts (adapted from Kondo and Mocarski,  1995).  Highlighted primers were 
used for the generation of HCMV IE-1 riboprobe.
2.6.1.6 Cloning of HCMV IE-1 into the pGEM-T Easy vector
After  PCR  purification,  the  HCMV  IE-1  DNA  was  ligated  to  pGEM-T  Easy  as 
described  in  sections  2.3.4,  and  transformed  into  competent  E.coli  JM109  cells  as 
described in sections 2.3.5.
2.6.1.7 Small-scale preparations of plasmid DNA
The recombinant clones were selected and purified with the QIAprep Spin Miniprep kit 
(Qiagen)  according to  the  maufacturer’s  instructions,  instead  of the  Wizard Plus  SV 
Minipreps DNA Purification System (Promega) as described in section 2.3.6, as it was 
recommended  that  the  QIAprep  Spin  Miniprep  kit  gives  better  quality  and  yield  of 
plasmid DNA.
Five mililitres of overnight bacterial culture was pelleted by centrifuging at 10 000 g for 
5 min.  The supernatant was discarded, and the bacterial pellet was resuspended in 250 
pi of Buffer PI.  Two hundred and fifty microlitres of Buffer P2 was added, followed 
by addition  of 350  pi  of Buffer N3.  After centrifuging  at  10  000 g for  5  min,  the 
supernatant  was  transferred  to  a  QIAprep  column  in  a  2  ml  collection  tube,  and 
centrifuged at  10  000 g for  1   min.  The  flow-through was  discarded,  and 0.5  ml  of
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Buffer PB was added and centrifuged for 1  min, followed by a second wash in 0.75 ml 
of Buffer PE and centrifuging again for 1   min, discarding the flow-through each time. 
DNA was  eluted by adding  50  pi  of nuclease-free  H2O   to  the QIAprep  column and 
centrifuging at 10 000 g for 1  min.
2.6.1.8  Screening of plasmid clones by restriction endonuclease digestion
The plasmid DNA was digested with EcoRl to  confirm that the clone contained the 
HCMV IE-1  gene in pGEM-T Easy (as described in section 2.3.7).  Once confirmed, 
the plasmid was sequenced in house at the Windeyer Institute, UCL.  Sequencing results 
showed that  the  HCMV  IE-1  gene  was  cloned  in  the  3’-5’  orientation,  and  so  the 
plasmid was linearized with NdeI and Ncol as described in section 2.3.8.  After phenol 
chloroform extraction and ethanol precipitation of the linearized plasmid as described in 
section 2.3.9, in vitro transcription with T7 and Sp6 RNA polymerase on Nde  I and Ncol 
linearized plasmids was carried out to  generate  antisense  and  sense RNA transcripts 
respectively, as described in section 2.3.10.
2.6.2  Optimisation of ISH for the detection of HCMV IE mRNA
Using previously optimised conditions for HCMV gB, HCMV US28, HHV-6 U67 and 
HHV-7 U42 riboprobes, ISH using the HCMV IE-1 antisense riboprobe was carried out 
on formalin-fixed paraffin-embedded MRC-5 cells infected with HCMV (AD 169) for 4 
hr for the detection of HCMV IE mRNA.  However, background was a problem so re­
optimisation of ISH conditions was performed.
2.6.2.1  Reducing background by acetylation in 0.25%  acetic anhydride in 0.1  M 
triethanolamine
To  help  reduce  tissue  stickiness  which  can  cause  background,  the  sections  were 
acetylated in 0.25% acetic anhydride in 0.1 M triethanolamine, pH 8.0.  The slides were 
deparaffinized, rehydrated and treated with 0.2 M HC1 for 20 min, followed by 0.01% 
Triton-XlOO  in  PBS  for  90  sec.  After  incubation  with  5  pg/ml  Proteinase  K  in 
Proteinase K buffer for 30 min at 37°C, and washes in PBS three times for 5 min, the 
sections were post-fixed in 0.4% paraformaldehyde in PBS for 20 min.  The slides were 
then washed in PBS for 5 min, followed by incubation in 0.25% acetic anhydride in 0.1 
M triethanolamine, pH 8.0 twice for 10 min each.  Acetic anhydride was added to 0.1 M 
triethanolamine immediately before use.  The slides were then plunged into 20% cold
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acetic acid for 45 sec, followed by 5 min wash in distilled H2O.  The sections were then 
dehydrated, and air dried.
2.6.2.2  Optimising hybridisation conditions
The  following  hybridisation  conditions  were  tested;  hybridisation  at  37°C  overnight 
with 5 ng and 10 ng antisense riboprobe; hybridisation at 42°C overnight with 5 ng, 10 
ng, 25 ng and 50 ng antisense probe per 50 |il hybridisation mix.  Hybridisation with the 
corresponding sense probe was performed in parallel and was used as a control for non­
specific hybridisation.
2.6.23  Incorporation of RNase A digestion to remove single stranded (unbound) 
probe
To help reduce background, RNase A digestion was incorporated after hybridisation to 
remove any single stranded RNA probe.  After pretreatment of sections, hybridisation 
was carried out at 42°C overnight with 50 ng antisense riboprobe.  The sections were 
then washed in 4X SSC for 5 min, wash buffer 1  for 20 min at 42°C, and wash buffer 2 
for 10 min at 42°C.  The sections were equilibrated in RNase A buffer (500 mM NaCl, 
10 mM Tris,  1   mM EDTA, pH  8.0)  for 5  min,  followed by incubation  in 25  jig/ml 
RNase A for 10, 20 and 30 min at 37°C.  After washes in RNAse A buffer three times 
for 5 min, the sections were washed in wash buffer 3  for 20 min at a range of temp 
(37°C,  42°C,  45°C  and  50°C).  Immunological  detection with  anti  DIG  AP  Ab  was 
performed as previously described.
2.63  Detection of HCMV IE mRNA expression in renal biopsies by ISH
Ten HCMV gB DNA positive samples were tested for HCMV mRNA expression using 
HCMV  IE  antisense  riboprobe.  The  samples  were  pretreated  in  the  same  way  as 
described  in  section  2.5.5.  An  acetic  anhydride  step  was  also  incorporated  after 
proteinase K digestion and PBS washes (see section 2.6.2.1).  Hybridisation with 50 ng 
HCMV IE-1  antisense riboprobe was carried out at 42°C overnight.  For each sample, 
hybridisation with the HCMV IE-1  sense probe was included as a negative control.  A 
previously  tested  HCMV  gB  DNA  negative  renal  biopsy  was  included  in  each 
experimental run.  After hybridisation, the sections were washed in 4X SSC for 5 min, 
followed by Wash buffer 1  for 20 min at 42°C, Wash buffer 2 for 10 min at 42°C, and
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RNAse A buffer for 5 min at room temp.  The sections were then incubated in 25 (Xg/ml 
RNase A for 30 min at 37°C, followed by washes in RNAse A buffer three times for 5 
min.  A further wash in 0.5X SSC for 30 min at 42°C and then for 5 min at room temp 
was carried out.  Immunological detection of the in situ reaction was then carried out as 
described in section 2.5.5.
2.6.4  In situ hybridisation with a human P-actin riboprobe to determine quality of 
mRNA in tissues
A human  p-actin  antisense  riboprobe  (Roche)  was  used to  determine  the  quality of 
mRNA in the renal biopsies.  The p-actin riboprobe had been in vitro transcribed in the 
presence of digoxigenin-UTP.  The transcript has a length of 588 bases, of which 550 
bases are complementary to the 5’ region of human-p actin mRNA (Ponte et al., 1984).
2.6.4.1 Detection of p-actin mRNA on 4% paraformaldehyde fixed HEL cells
ISH with the human P-actin probe was carried out initially on 4% paraformaldehyde- 
fixed  HEL  cells  using the  same  method  as  described  in  section  2.3.1.  A  negative 
control incorporating RNAse treatment to degrade cellular RNA was also included to 
check that hybridisation signals were mRNA specific.  RNase was incorporated after 
proteinase  K  treatment  and  PBS  washes.  The  sections  were  treated  with  1   mg/ml 
RNase A in DNase buffer at 37°C for 1  hr.  After 5 min wash in PBS, the sections were 
postfixed in cold 0.4% paraformaldehyde in PBS for 20 mins.
2.6.4.2 Detection of P-actin mRNA on formalin-fixed paraffin-embedded cells
ISH using the p-actin probe was also tested on formalin-fixed paraffin-embedded HEL 
cells as described in section 2.4.4.  Hybridisation using a range of concentrations of 
probe (50 ng, 25 ng, and 5 ng per reaction) were tested.  Controls consisting of cells 
treated  with  DNAse  I  (O.lU/pl)  for  1   hr  at  37°C,  and  cells  treated  with  RNase  A 
(1 mg/ml and 0.1 mg/ml) for 1  hr at 37°C after proteinase K digestion and PBS washes 
were also run in parallel.  In addition, 10 pi RNase inhibitor (40U/ pi) was added to the 
hybridisation mix to help further inhibit any RNases.
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2.6.4.3  Detection  of  P-actin  mRNA  on  formalin-fixed  paraffin-embedded  renal 
biopsies
Five renal  biopsies  were  initially tested with  P-actin  riboprobe using the  same  ISH 
method as described in section 2.4.4.  Results were difficult to interpret as background 
staining was very high.  To help reduce background levels an acetic anhydride step was 
incorporated during pre-treatment of sections (see section 2.6.2.1).  Hybridisation using 
a  lower  concentration  of probe  (5  ng  per  reaction)  was  also  carried  out  at  42°C 
overnight.  Ten renal biopsies (5  HCMV  gB  DNA positive  and  5  HCMV gB  DNA 
negative renal biopsies) were again tested.  For each sample, an RNAse treated sample 
was run in parallel to ensure hybridisation signals were mRNA specific.
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2.7  Role  of human  ^-herpesviruses  in  allograft  rejection  following 
liver transplantation
2.7.1 Liver transplant patients
This study utilised a sub-section of 60 patients enrolled on a prospective  study who 
underwent their first liver transplantation between  1st August  1993  to  11th  October 
1995 (Griffiths et al., 1999a).  Protocol liver biopsies of the donor liver were obtained at 
the time of transplantation; on days 5,  10,  15  and 25  after transplantation;  whenever 
liver dysfunction occurred and after antirejection treatment.  Inclusion criteria for this 
present study was the availability of at least one fine needle biopsy taken near the time 
of PCR positivity in blood for any of the human p-herpesviruses (median -2.5, range - 
33 to +8 days) during the 120-day post-transplant period.  Those patients who had more 
than one  PCR positive  blood  sample  for the  same  human  P-herpesviruses,  biopsies 
taken nearest the time of maximum virus load were selected.  In addition, consecutive 
liver biopsies were taken for 4 patients.  Patients were excluded if adequate tissue was 
not included (biopsy too small n =  17).  A total of 54 allograft biopsies from 30 liver 
transplant patients were available for study.
2.7.2 Liver biopsies
Biopsy  samples  were  routinely  fixed  in  4%  neutral-buffered  formalin  and  paraffin- 
embedded.  Four pm sections were cut and mounted onto APES-coated slides.  The 
slides were placed in a hybridisation oven and baked at 55°C for 48 hrs.
2.7.3 Cell controls
Formalin  fixed  paraffin  embedded  cells  from  infected  cultures  of  HCMV  (strain 
AD 169)  infected  Human  Embryonic  lung  (HEL)  fibroblasts,  HHV-6B  (strain  Z29) 
infected  Molt-3  and  HHV-7  (strain  DC)  infected  SupTl  T  cell  lines  were  used  as 
positive controls for ISH and IHC.  Non-infected cell cultures were used as negative 
controls.
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2.7.4 IHC on liver biopsies
IHC was performed using human p-herpesvirus MAbs specific for the late proteins of 
these viruses; MAB 8126 (Chemicon International) directed to the HCMV late protein 
of MW 47-55 kDa; MAb directed against HHV-6 glycoprotein gpl 16/64/54 (Advanced 
Biotechnologies),  and  MAb  5E1  directed  against  HHV-7  phosphoprotein  85  (pp85) 
(kindly provided by Dr Gabriella Campadelli-Fiume).  The specificities of these Abs 
were confirmed by testing isotype matched control mouse mAbs against human IgG 
(lgGl,  X931;  IgG2a,  X943;  IgG2b,  X944;  Dako)  in  positive  cases.  All 
immunohistochemical stainings were performed using the ABC system as described in 
section 2.2.1.
2.7.5 ISH on liver biopsies
ISH using DIG labelled riboprobes were used to test each liver biopsy for HCMV gB, 
HHV-6 U67 and HHV-7 U42 DNA, respectively.  ISH was performed as that described 
in section 2.4.5.  A negative reagent control with hybridisation mixture,  but without 
probe, was also performed in parallel for each sample.
Ten liver biopsies which tested positive for HCMV gB DNA by ISH were also tested 
for HCMV US28 DNA to compare hybridisation signals with HCMV gB.  Five HCMV 
gB DNA negative biopsies were included as negative controls.
2.7.6 Statistical analyses
Statistical comparison between the groups was done using the X2 and Fisher’s exact 
tests.
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2.8  HHV-6 Fluorescence in situ hybridisation
Fluorescence  in  situ  hybridisation  (FISH)  was  conducted  in  collaboration  with  Dr 
Elisabeth  Nacheva,  Dr  Diana  Brazma,  and  Dr  Paul  Sinclair,  Department  of 
Haematology, Royal Free and University College Medical School.  Three individuals 
were identified with abnormally high HHV-6 loads, a characteristic of viral integration 
into host cell chromosomes; a healthy individual (VI) with consistently high HHV-6 
viral loads in the PBMCs which remained constant over a 10-month period (Clark et al., 
1996), a stem cell donor with a viral load of 8xl06 HHV-6 genomes/ml of blood, and 
the sibling recipient who was initially HHV-6 PCR negative following transplantation 
who  subsequently  became  positive  at  the  time  of  engraftment  and  developed  an 
abnormally high viral load which remained constant.  The PBMCs of VI and the stem 
cell donor were immortalized by infection with EBV to give rise to LCLs (conducted by 
Dr Duncan Clark.  (Silveira et al., 2002).  Attempts to generate an LCL from the stem 
cell recipient were unsuccessful as B cell  counts were very low in peripheral blood. 
FISH was developed using HHV-6  specific probes to look for integration of HHV-6 
viral sequences into human chromosomes of these individuals.
2.8.1  Development  of FISH  using  direct  labelling  of a  HHV-6  specific  plasmid 
probe
2.8.1.1 Direct labelling of a HHV-6 plasmid probe with SpectrumOrange by nick 
translation
The HHV-6 probe is a plasmid (pZVH14) (kindly provided by Professor Ruth Jarrett, 
University  of Glasgow,  UK)  (Josephs  et  al.,  1986)  containing  an  8.7  kb  HindiII 
fragment of HHV-6 DNA.  This probe was labelled with SpectrumOrange using the 
Vysis nick translation kit (Abbot Labs).  The following components were added to a 0.5 
ml microfuge tube on ice: 1  pg extracted plasmid DNA, nuclease free H2O  made up to a 
volume of 17.5 pi, 2.5 pi SpectrumOrange (0.2 mM), 5 pi dTT (0.1 mM),  10 pi dNTP 
mix (0.3 mM dCTP, 0.3 mM dATP, 0.3 mM dGTP), 5 pi  1  OX nick translation buffer 
(500 mM Tris-HCl, pH 7.2,  100 mM MgS04,  1   mM DTT), and  10 pi nick translation 
enzyme  (DNA  pol  I,  DNase  I  in  50%  glycerol,  50  mM  Tris-HCl,  pH  7.2,  10  mM 
MgS04,  0.1  mM DDT,  0.5  mg/ml nuclease-free BSA  (bovine  serum albumin).  The 
tube was then vortexed, and centrifuged briefly, before incubating at  15°C  for  14 hr. 
The reaction was stopped by heating at 70°C for 10 min, and then chilled to 4°C
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2.8.1.2 Ethanol precipitation of the probe
The following components were added to a 0.5 ml microfuge tube: 5 |il probe (100 ng), 
10 pi Human Cot-1  DNA (10 pg, Invitrogen),  1.5 pi sodium acetate (pH 5.2), and 2.2 
vols 100 % ice cold ethanol.  The tube was then vortexed briefly, and placed at -80 °C 
for at least 30 min.  After centrifuging at 12 000 g for 15 min, the ethanol was decanted, 
and the pellet was resuspended in 30 pi of prewarmed (37°C) hybridisation buffer for 30 
min or until pellet fully dissolved.  The probe was stored at -80°C until ready for use.
2.8.1.3 Cell line preparation
Cells  were  cultured by Dr Duncan  Clark.  The  optimal  seeding  density  for  LCL  is 
lxl06/ml.
2.8.1.4 Harvesting cells and preparation of slides
Cells from the tissue culture flasks were transferred to  a falcon tube.  One hundred 
microlitres of colcemid (10 pg/ml, Invitrogen) were added to  10 ml cells (LCL), and 
incubated at 37°C for 60 min.  The cells were then centrifuged at 400 g for 10 min, and 
the  supernatant  was  removed.  The  cell  pellet  was  then  resuspended  in  10  ml  of 
hypotonic KC1 prewarmed to 37°C, and incubated at room temp for 20 min.  The cells 
were then centrifuged at 400 g for 10 min, and the supernatant was removed.  The cell 
pellet  was  loosened  by  gentle  tapping  of the  tube,  and  with  simultaneous  mixing 
approximately 1  ml of ice cold fixative (3 parts of methanol and  1  part of acetic acid) 
was added drop wise to the cells.  A further 7 ml of fixative was then added to the cells 
and mixed well by inverting the tube several times.  The tube was then centrifuged at 
400 g for 10 min, and the supernatant removed.  Again the cell pellet was loosened and 
5 ml of fixative was added to the cells and mixed.  After centrifuging for a further 10 
min, the supernatant was removed and the fixative was added until the cell suspension 
was slightly cloudy.  Using a glass Pasteur pipette, 2 drops of the cell suspension were 
dropped  onto  a  cold  wet  slide.  The  slide  was  tilted  to  allow  the  metaphase 
chromosomes  to  run  along  the  length  of the  slide.  The  slide  was  then  air  dried 
overnight at room temp.
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2.8.1.5 Staining of metaphase chromosomes
The slides were incubated in 2X SSC at 37°C for 1  hr.  Twenty microlitres of RNAse 
working solution (10 mg/ml  in 2X  SSC) were then applied to the target region, and 
covered with a coverslip.  The slides were then incubated in a well-humidified chamber 
at 37°C for 30 min.  Any remaining enzyme was removed by rinsing the slides in PBS. 
The slides were then incubated in 0.005% pepsin in  10 mM HC1 at room temp for 10 
min, followed by incubation in  10 mM MgCk in PBS at room temp for 5 min.  The 
slides were dehydrated by immersing in increasing concentrations of ice-cold ethanol 
(70%,  80%  and  100%)  for  2  min  each,  and  then  air  dried  at  room  temp.  After 
denaturing the slides in prewarmed 70% formamide in 2X SSC at 72°C for 2 min, the 
slides were dehydrated by immersing in increasing concentrations of ice-cold ethanol 
and air dried at room temp.
2.8.1.6 Hybridisation of probes to the metaphase chromosomes
The probe solution (prepared in section 2.8.1.2) was denatured for 5 min in a 72-73°C 
waterbath, followed by annealing at 37°C for at least 1  hr.  Ten microlitres of the probe 
solution were then added to each slide.  The slides were covered with a coverslip and 
sealed with rubber cement glue.  The slides were then incubated in a well-humidified 
chamber at 37°C overnight.
2.8.1.7 Washing and counterstaining
The seal and coverslips were removed from the slides.  The slides were then placed in a 
prewarmed coplin jar with 0.4X SSC/0.3% IGEPAL at 72-73°C for 5 min, followed by 
2X SSC/0.1% IGEPAL washes twice at room temp for 2 min.  Thirty microlitres of 
propidium  iodide  and  diamino-2-phenylindole  (DAPI)  diluted  1:100  in  Vectashield 
mounting  medium  (Vector  labs)  was  then  added  to  each  slide  to  counterstain  the 
chromosomes.  The slides were covered with a coverslip,  and the edges were  sealed 
with clear nail varnish.  The  slides were placed  in  a box  and  left to  mature  at 4°C 
overnight.
2.8.1.8 FISH analysis
Fluorescence imaging of metaphase chromosomes utilised a SmartCapture FISH station 
(Digital Scientific).
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2.8.2 Development of FISH using indirectly labelled HHV-6 plasmid probe
The  HHV-6  plasmid probe  (pZVH14)  was  indirectly  labelled  using biotin-16-dUTP 
(Roche)  by nick  translation  using  the  same  method  as  described  in  section  2.8.1.1. 
SpectrumOrange (0.2mM) was replaced with biotin dUTP (0.2mM).  The probe was 
then ethanol precipitated as described in section 2.8.1.2.  Metaphase chromosomes were 
prepared using cells prepared in section 2.8.1.4.  Staining of metaphase chromosomes 
was carried out as described in section 2.8.1.5.  The probe solution was then denatured 
and annealed as described in section 2.8.1.6.  Hybridisation of metaphase chromosomes 
was carried out in a well-humidified chamber at 37°C for 24 and 48 hr.  The seal and 
coverslips  were  then  removed  from  the  slides.  The  slides  were  then  placed  in  a 
prewarmed coplin jar with 0.4X SSC/0.3% IGEPAL at 72-73°C for 2 min, followed by 
2X  SSC/0.1%  IGEPAL at room temp  for 2  min.  After  gently tapping  the  slides to 
remove any excess liquid, 100 pi of 3% BSA in 4XSSCT (0.05% triton in 4XSSC) was 
added to each slide, covered with parafilm and incubated at room temp for 20 min to 
block non-specific hybridisation signals.  The slides were then washed in 4XSSCT for 5 
min at room temp, and 30 pi of fluorescein isothiocynate (FITC) labelled avidin was 
added  to  each  slide.  The  slides  were  covered  with  parafilm  and  incubated  in  a 
humidified chamber at 37°C  for  15  min.  After washing the  slides  in 2X  SSC/0.1% 
IGEPAL for 2 min at room temp, 30 pi of DAPI counterstain was added to each slide. 
The slides were covered with a coverslip and the edges were sealed with a clear nail 
varnish.  The slides were placed in a box and left to mature in the dark at 4°C overnight.
2.8.3 Development of FISH using a cocktail of HHV-6 specific plasmids
This work was done in collaboration with Dr Nacheva, Dr Brazma, and Dr Hoe Nam 
Leong (Centre for Virology).  A cocktail of eight plasmids containing between 9 and 
16kb  inserts  of the  HHV-6  genome  (non-overlapping)  (see  table  2.2)  were  used  as 
probes  for FISH  (7 plasmids were kindly provided by Dr  Scott  Schmid,  Centers  for 
Disease Control, Atlanta (Lindquester et al.,  1996) and PZVH14 (see fig 2.4).  These 
HHV-6 plasmids were combined and labelled with SpectrumGreen dUTP (Roche) using 
nick translation as described in section 2.8.1.1.  FISH was performed using the same 
methods as described in sections 2.8.1.
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HHV-6 plasmid probe Z29 base position size (kb)
BamHI C (pH6Z-102) 131777-144687 12.9
Clal B (pH6Z-604) 110637-126162 15.5
Clal D (pH6Z-606) 12977-22098 9.1
Hindlll C (pH6Z-204) 137525-149857 12.3
Hindlll E (pH6Z-205) 69994-78900 8.9
Sail D (pH6Z-816) 81792-93695 11.9
Sail G (pH6Z-802) 99666-108679 9
pZHV14 43854-52568 8.7
Table 2.2 HHV-6 specific plasmid probes for FISH
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Figure 2.4 HHV-6 (Z29) restriction map showing genomic locations of cloned fragments (adapted from Lindquester et al., 1996).
Highlighted areas show HHV-6 plasmids used for HHV-6 FISH.  All plasmids used were non-overlapping except for BamHI C (pH6Z-102) 
and Hindlll C (pH6Z-204).  Abbreviations: 101K 101 KDa major antigenic protein; MTP major tegument protein ; MDBP major DNA- 
binding protein; ori origin of DNA replication; gH glycoprotein H ; OBP origin-binding protein ; UDG uracil-DNA glycosylase; PR 
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Chapter 3 - Development of i n   s i t u  techniques for the 
detection of the human P-herpesviruses in biopsy material.
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3.1  Introduction
HCMV,  the  prototype  member  of the  p-herpesvirinae,  has  a  major  impact  on  the 
immunocompromised including the recipients of solid organs and bone marrow as well 
as AIDS patients.  HCMV causes a range of disease manifestations, ranging from a mild 
non-specific  viral  syndrome  to  severe  end  organ  disease  (hepatitis,  pneumonitis, 
encephalitis,  retinitis or gastrointestinal  ulceration).  Among  SOT recipients,  several 
risk factors have been identified for the potential  development of HCMV  end-organ 
disease.  These include primary infection  (Betts  et al.,  1977), viraemia (Kidd et al., 
1993) and peak viral load (Cope  et al.,  1997a;  1997b;  Hassan-Walker et al.,  1999). 
Over the years, a series of prospective studies using QC-PCR have been employed to 
define the quantitative natural history of HCMV infection in different post-transplant 
patient  groups  (Cope  et  al.,  1997a;  1997b;  Hassan-Walker  et al.,  1999;  Gor  et  al., 
1998).  These  studies  provide  evidence  that  HCMV  load  is  actually  the  major 
determinant of HCMV disease and that primary infection, and viraemia are prognostic 
because they identify patients destined to have high viral loads.
Modem tests including DEAFF, shell vial, antigenemia and qualitative PCR assays have 
been used for routine monitoring of HCMV in blood.  Studies have shown that PCR or 
antigenemia assays are important in providing prognostic information in post-transplant 
patients (Meyer-Konig et al.,  1995; Caballero et al.,  1997; Manez et al.,  1996).  In our 
centre (Department of Virology, Royal Free and University College Medical  School, 
Royal  Free  Campus)  qualitative  PCR  is  used  for the  routine  monitoring  of HCMV 
DNaemia,  and  pre-emptive  therapy  is  recommended  whenever  a  patient  has  two 
consecutive positive bloods (Griffiths et al.,  1999b).  Recently, a quantitative Taqman 
assay has superceded the quantitative PCR assay.  Whilst the measurement of HCMV in 
the blood is a reliable indication of the degree of viraemic dissemination, it does not 
address the questions relating to viral involvement in disease pathogenesis at the tissue 
level.  At present HCMV end-organ involvement is routinely diagnosed by biopsy, with 
the histologic identification of cytomegalic inclusion bodies in routine H and E stained 
tissue biopsies.  This is a highly specific, but rather insensitive method (Mattes et al., 
2000).  As a result more sensitive in situ methods including IHC and ISH have been 
developed.
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The detection of HCMV Ags with MAbs using IHC has provided a rapid and more 
sensitive method compared to detection of inclusion bodies for the diagnosis of HCMV 
infection in immunocompromised patients (Niedobitek et al., 1988; Sacks and Freeman, 
1984; Paya et al.,  1990).  ISH has also been shown to be specific and more sensitive 
compared with typical histological  criteria for the  diagnosis  of HCMV pneumonitis, 
hepatitis  or  encephalitis  in  the  immunocompromised  host  (Myerson  et  al.,  1984; 
Naoumov et al., 1988; Masih et al., 1988; Musiani et al., 1994).
In addition to direct end-organ involvement, HCMV has been associated with indirect 
effects  including  accelerated  atherosclerosis,  increased  predisposition  to  other 
opportunistic  infections,  and  allograft  rejection  in  SOT  patients  (Rubin,  1989). 
Similarly,  the  other  members  of the  human  P-herpesviruses,  HHV-6  and  HHV-7 
(Frenkel et al.,  1990;  Salahuddin et al.,  1986), have also been  implicated in disease 
pathogenesis in the immunocompromised.  Case reports and retrospective studies have 
shown  that  both  HHV-6  and  HHV-7  are  associated  with  a  range  of  disease 
manifestations  in  transplant  recipients.  These  include  encephalitis,  hepatitis  and 
pneumonitis (Singh and Paterson, 2000; Ward et al.,  1989; Chan et al.,  1997).  More 
importantly, these two viruses have also been associated with indirect effects including 
increasing the occurrence of HCMV disease and allograft rejection (Desjardin et al., 
1998; Osman et al., 1996; Griffiths et al., 1999a; Kidd et al., 2000).
In prospective  studies  conducted at our centre  in  renal  and  liver transplant patients, 
qualitative and quantitative PCR were used to detect and measure HCMV, HHV-6 and 
HHV-7  loads  in  the  blood  (Griffiths  et  al.,  1999a;  Kidd  et  al.,  2000). 
Clinicopathological analyses showed that both HHV-6 and HCMV were independently 
associated with biopsy proven rejection in the liver transplant patients (Griffiths et al, 
1999a), whereas in the renal transplant patients, HHV-7 was associated with increased 
episodes of graft rejection (Kidd et al., 2000).  One of the main aims of this thesis was 
to extend these prospective studies by utilising in situ techniques for the detection of 
these viruses directly in organ biopsies taken from the patients in the original cohorts to 
examine the pathogenic role of these viruses at the tissue level (see chapters 4 and 5).
The objectives of this chapter were therefore to develop specific,  and more sensitive 
methods for in situ detection of human p-herpesvirus infected cells in tissue biopsies.
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This  chapter  describes  the  construction  of DIG-labelled  riboprobes  specific  for  the 
detection of HCMV gB, HCMV US28, HHV-6 U67, and HHV-7 U42 DNA in renal 
and liver biopsies.  To further investigate HCMV gene expression in the renal biopsies a 
DIG  labelled  riboprobe  directed  against  HCMV  IE-1  gene  transcripts  was  also 
developed.  Preliminary experiments were also carried out to identify MAbs suitable for 
the  detection  of HCMV,  HHV-6  and  HHV-7  proteins  by  IHC  on  formalin-fixed 
paraffin-embedded  culture  infected  cells.  MAbs  directed  against  HCMV  proteins; 
HCMV IE protein, HCMV p52, and HCMV late protein, characteristic for each stage of 
HCMV replication were tested.  The detection of HHV-6 specific proteins in HHV-6B 
infected cells were also tested using a range of MAbs directed to HHV-6A p41, HHV- 
6B plOl, HHV-6B gH and HHV-6 gB.  At present,  only MAb  5E1  directed against 
HHV-7 pp85 (kindly provided by Dr Gabriella Campadelli-Fiume) has been found to 
maintain their reactivity in formalin-fixed paraffin-embedded tissues making it suitable 
for immunohistochemical detection of HHV-7.
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3.2  Results
3.2.1 Immunohistochemistry (IHC)
3.2.1.1  IHC  using  the  avidin-biotin  complex  (ABC)  detection  method  on 
paraformaldehyde-fixed ceU preparations
IHC using MAb directed to HCMV late protein, HHV-6B plOl, and MAb 5E1 to HHV- 
7 pp85 were evaluated on paraformaldehyde-fixed HCMV infected MRC-5, HHV-6B 
infected Molt 3, and HHV-7 infected Sup Tl  cells, respectively (section 2.2.1.1).  The 
ABC detection method was developed by Hsu et al.  (1981) and is based on the high 
affinity  and  essentially  irreversible  interaction  between  avidin  and  biotin.  The 
technique requires pre-incubation of the biotinylated enzyme with the avidin,  so that 
large complexes are formed for incubation with the biotinylated secondary Ab.
MAb to HCMV late protein and MAb 5E1  to HHV-7 pp85 at a 1:500 dilution showed 
strong positive staining of HCMV infected MRC-5, and HHV-7 infected Sup Tl  cells 
respectively (figure 3.1).  The DAB substrate produces a brown precipitate at the site of 
Ag detection.  The intensity of staining increased with a 1:200 and 1:100 dilution of the 
MAbs, however, there was also an increase in background level.  Therefore, optimal 
staining  of  these  two  MAbs  was  determined  to  be  at  a  1:500  dilution  on 
paraformaldehyde-fixed cell preparations.  A small number of positively stained HHV- 
6B infected cells were observed with MAb to HHV-6B plOl  at a  1:200 dilution.  A 
further increase to a  1:100 dilution increased the staining intensity and the number of 
positively stained HHV-6B infected cells detected.  Therefore, optimal staining of MAb 
to HHV-6B plOl was determined to be at a 1:100 dilution on paraformaldehyde-fixed 
HHV-6 infected Molt-3 cells (figure 3.1).
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Figure 3.1 Immunohistochemical detection of the human p-herpesvirus proteins on 
paraformaldehyde-fixed  cell  preparations.  A)  Staining  of HCMV  infected  MRC-5 
cells and B) Negative control  showing no staining in MRC-5 cells with MAB8126 to 
HCMV late protein (1:500 dilution); C) Staining of HHV-6B infected Molt-3 cells and 
D) Negative control showing no staining in Molt-3  cells with MAB8535  to HHV-6B 
plOl  (1:100 dilution);  E)  Staining of HHV-7  infected  Sup  Tl  cells  and  F) Negative 
control  showing no  staining  in  Sup Tl  cells with MAb  5E1  to  HHV-7  pp85  (1:500 
dilution).
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3.2.1.2  IHC using the ABC  method on formalin-fixed paraffin-embedded culture 
infected cells
Formalin-fixation followed by tissue processing for paraffin embedding is the routine 
method  for  preservation  of  tissue  biopsy  for  microscopic  analysis.  Therefore, 
preliminary experiments were carried out on a range of human P-herpesvirus MAbs to 
determine the sensitivity and specificity on formalin-fixed paraffin-embedded culture 
infected cells.  The same MAbs described above, and an additional three MAbs directed 
to HHV-6 proteins; HHV-6 gB, HHV-6B gH and HHV-6  A early protein p41/38, were 
initially tested at a range of dilutions by IHC (section 2.2.1.2).
Positive staining was observed in HCMV infected MRC-5 cells with MAb to HCMV 
late protein at 1:200 and 1:500 dilution (figure 3.2), and in HHV-7 infected Sup Tl cells 
with MAb 5E1 to HHV-7 pp85 at 1:200 and 1:500 dilution (figure 3.3).  No staining of 
HHV-6B  infected Molt-3  cells was  detected with MAb  to  HHV-6B  pi01,  and with 
MAb to HHV-6A p41/38 even at a 1:50 dilution.  A small number of positively stained 
HHV-6B infected cells were observed with MAb to HHV-6B gH at a 1:50 dilution but 
the  intensity  of  staining  was  weak,  and  background  levels  were  high.  Positive 
cytoplasmic staining was observed in a small number of HHV-6B infected Molt-3 cells 
with MAb to HHV-6 gB at 1:100 dilution.
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Figure 3.2 Immunohistochemical detection of HCMV late protein with MAB8126 
(1:500  dilution)  in  formalin-fixed  paraffin-embedded  MRC-5  cells  infected  with 
HCMV (AD 169).
Figure 3.3 Immunohistochemical detection of HHV-7 pp85 with MAb 5E1 (1:500 
dilution) in formalin-fixed paraffin-embedded Sup Tl cells infected with HHV-7.
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3.2.1.3  Incorporation of an antigen retrieval method
The principle of Ag retrieval is to break the protein cross-links formed by formalin-or 
paraformaldehyde-fixation,  and  thereby  unmasking  hidden  antigenic  sites.  This 
technology was reported by Shi et al. (1991) and uses a combination of high temp and 
buffers of different pH  (the most commonly used is  0.1M Citrate buffer, pH 6.0) to 
retrieve or unmask the Ag in formalin-fixed paraffin-embedded tissues.  Recently, Ag 
retrieval has also been applied to non-heating methods, including enzymatic digestion 
(Shi, 2001).  Proteinase K treatment after fixation can be used to increase access to Ags, 
especially nuclear Ags.
Two Ag retrieval methods, proteolytic enzyme digestion, and heating in a microwave 
oven in Citrate buffer (as described in section 2.2.1.3), were incorporated into IHC.  For 
each Ag retrieval method, MAbs directed to human P-herpesvirus late proteins (HCMV 
late protein, HHV-6 pi01  and HHV-7 pp85), and an additional two MAbs directed to 
the  HCMV  IE  protein  and  to  HCMV  p52  were  tested  at  a  range  of dilutions,  and 
staining  intensities  were  compared  on  formalin-fixed  paraffin-embedded  culture 
infected cells.
Ag retrieval by microwaving  or enzymatic  digestion  with Proteinase  K  significantly 
improved the intensity of immunohistochemical staining with the MAbs tested, except 
with MAb to HHV-6A p41/38 which remained negative as expected as this MAb  is 
HHV-6 variant A specific.  The number of virus-infected cells detected also increased. 
Five pg/ml Proteinase K for 30 mins at 37°C was sufficient for immunohistochemical 
staining  on  formalin-fixed  paraffin-embedded  cells,  and  any  further  increase  in 
proteinase K concentration did not significantly improve staining.
Optimal staining with MAbs to HCMV IE protein and to HCMV p52 were observed at 
1:50 dilution with proteinase K digestion.  Figure 3.4A shows detection of HCMV IE 
protein in HCMV infected MRC-5 cells.  Figure 3.4B shows detection of HCMV p52 in 
the nucleus and cytoplasm of HCMV infected MRC-5 cells.  Although the number of 
HCMV  infected  MRC-5  cells  detected  with  the  two  MAbs  at  1:200  dilution  was 
increased with microwaving, background levels were higher and intensity of staining 
was less than that observed with proteinase K digestion.  With MAb to  HCMV late 
protein (1:200 dilution) and MAb 5E1 to HHV-7 pp85 (1:500 dilution) optimal staining
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of respective HCMV infected MRC-5 and HHV-7 infected Sup T1  cells was observed 
with microwaving.  Optimal staining was achieved at a  1:100 dilution (with Proteinase 
K digestion) and at a 1:200 dilution (with a microwaving step) with MAb to HHV-6 gB, 
and HHV-6B plOl (see figure 3.5 and 3.6).
Figure 3.4  Immunohistochemical  detection  of HCMV  proteins  in  formalin-fixed 
paraffin-embedded  MRC-5  cells  infected  with  HCMV  (AD 169).  A)  HCMV  IE 
protein with MAB8131; and B) HCMV p52 with CCH2 MAb at 1   in 50 dilution, with 
Proteinase K digestion.  Arrows indicate staining in MRC-5 cells infected with HCMV.
149Chapter 3- Development of in situ techniques for detection of human ^-herpesviruses in biopsy material
A and B) Staining of HHV-6B pi01 
with  MAB8535  (1:200  dilution) 
(see  arrows)  in  HHV-6B  infected 
Molt-3  cells.  C)  Negative  control 
showing no staining of Molt-3 cells
Figure  3.6  Immunohistochemical  detection  of  HHV-6B  plOl  in  formalin-fixed 
paraffin-embedded  Molt-3  cells  infected  with  HHV-6B  (strain  Z29),  with  the 
incorporation of a microwaving step.
Positive  staining was  observed  with  MAb  to  HHV-6B  gH  at  1:50  dilution  with  the 
incorporation  of either  Ag  retrieval  methods  but  background  levels  were  high  (see 
figure 3.7).  MAb to HHV-6B gH was found not to be as sensitive and specific as that 
of MAb to HHV-6 gB  and MAb to HHV-6B pi01.  Overall,  incorporation of an Ag 
retrieval method significantly improved immunohistochemical staining of the human p- 
herpesvirus proteins.  Generally, slightly higher background staining was observed with 
microwaving than with proteinase K digestion, and a higher concentration of MAb was 
required to  achieve  optimal  staining  when  proteinase  K was  incorporated  in  IHC  as 
compared to microwaving.
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Figure  3.7  Immunohistochemical  detection  of  HHV-6B  gH  in  formalin-  fixed 
paraffin-embedded  Molt-3  cells  infected  with  HHV-6B  (strain  Z29),  with  the 
incorporation of Proteinase K treatment.  A) Staining with HHV-6B gH MAb (1:50 
dilution).  B) Negative control showing no staining of Molt-3 cells.
3.2.1.4  Incorporation of an avidin biotin block into IHC
One potential problem in an  EHC system which utilizes the  interaction of biotin with 
avidin (and streptavidin) is the binding of labelled avidin (streptavidin) to endogenous 
biotin.  Biotin is present in a variety of tissues, with high concentrations in the brain, 
spleen, kidney, liver and  lung tissues, hence excessive background staining and false- 
positive reactivity can occur.  Therefore, to help reduce this background staining which 
was also most apparent when IHC was performed with a microwaving step, an avidin 
biotin blocking step was included as described in section 2.2.1.4.
IHC  incorporating a microwaving step and an avidin biotin block was tested using a 
range  of  MAbs  directed  to  the  human  P-herpesvirus  proteins;  HCMV  IE  protein, 
HCMV p52,  HCMV late protein,  HHV-6  gB,  HHV-6B plOl,  and HHV-7 pp85  at a 
1:100 and  1:200 dilution, on formalin-fixed paraffin-embedded cells infected with the 
respective  virus.  The  incorporation  of the  avidin  biotin  blocking  kit  significantly 
reduced background levels for staining with MAb to HCMV late protein, MAb to HHV- 
6 gB, MAb to HHV-6B plOl  and to MAb 5E1  to HHV-7 pp85  (see figure 3.8).  All 
four MAbs gave good staining intensities at 1:200 dilution with low background.  MAb 
to HHV-6 gB  gave slightly better staining intensities and lower background levels as 
compared to MAb to HHV-6B p 101.  Immunohistochemical staining of MAb to HCMV
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IE  protein,  and  MAb  to  HCMV  p52  was  most  optimal  at  1:50  dilution,  with  the 
incorporation of proteinase K, and an avidin biotin block.  Although the avidin biotin 
block did reduce background staining when a microwaving step was incorporated into 
IHC,  the  staining  intensity  of these  two  MAbs  was  not  as  strong  as  observed  with 
proteinase K digestion.
Figure 3.8 Immunohistochemical detection of HHV-7 pp85 in HHV-7 infected Sup 
T1 cells with MAb 5E1 at 1:200 dilution.  A) Incorporation of an avidin biotin block. 
B) No avidin biotin block in IHC.
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3.2.1.5  IHC using the Dako chemMate Envision detection system on formalin-fixed 
paraffin-embedded cells
The  application  of chain  polymer  technology  (Dako  chemMate  Envision  detection 
system)  to  improve  the  sensitivity  of IHC  detection  was  also  tested.  This  system 
consists of a peroxidase-labelled dextran coupled with secondary Ab molecules directed 
against rabbit and mouse Igs.  The same MAbs described in section 2.2.14 were tested 
on formalin-fixed paraffin-embedded  culture  infected cells  (see  section  2.2.2).  This 
detection  system  has  the  advantage  in  that  staining  results  are  not  affected  by 
endogenous biotin.
IHC using the ABC method gave good staining with MAbs to HCMV IE protein and to 
HCMV p52 when protease digestion was incorporated for Ag retrieval.  However, with 
the Dako chemMate envision system, optimal staining of these two MAbs was only 
achieved when a combination of both protease digestion and microwaving were used 
(figure 3.9).  Incubation with either of these two MAbs at 1:50 and 1:100 dilution for 30 
mins  gave  good  staining  intensities,  and  the  number  of infected  cells  detected  was 
greater  than  that  using  the  ABC  system.  With  MAb  to  HCMV  late  protein, 
microwaving in 0.01 M citrate buffer (pH 6.0) gave optimal staining.  The addition of 
protease  treatment  did  not  significantly  improve  staining.  No positive  staining was 
observed with 30 min incubation with MAb to HCMV late protein at  1:50 or  1:100 
dilution.
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A
Figure  3.9  Immunohistochemical  detection  of HCMV proteins  in  formalin-fixed 
paraffin-embedded MRC-5 cells infected with HCMV (ADI 69) using the DAKO 
chemMate Envision detection kit.  A and B) HCMV IE protein with MAB8131; and C 
and D) HCMV p52 with CCH2 MAb at 1  in 50 dilution.
3.2.1.6  Specificity of the MAbs
The specificity and crossreactivity of the immunohistochemical reaction with the MAbs 
described  in  section  2.2.1.4  were  determined  by  testing  each  MAb  against  their 
respective virus  and to the  other human  p-herpesvirus  infected and non-infected cell 
controls.  All MAbs tested reacted specifically with the respective virus,  and did not 
display cross-reactivity to the heterologous virus.  No positive staining was observed for 
non-infected cells (results not shown).
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3.2.1.7 Subtyping of HHV-7 MAb 5E1
At the time these experiments were carried out the Ab isotype of MAb 5E1 to HHV-7 
pp85 had not been determined.  To characterize the Ab isotype of MAb 5E1 to HHV-7 
pp85,  detection  was  carried  out  using  peroxidase  conjugated  antimouse  Abs 
corresponding to the common mouse isotypes IgGi, IgG2a and IgG2b (see section 2.2.4). 
Figure  3.10  shows positive  staining of MAb  5E1  to pp85  with mouse  isotype  IgGi, 
therefore  IgGi  is  the  Ab  isotype.  MAb  5E1  to  HHV-7  pp85  has  since  been  made 
commercially  available  by  Advanced  Biotechnologies  International,  USA,  and  the 
isotype has been confirmed to be IgGi.
MAb 5E1 staining with A) IgGi; B) 
IgG2a; C) IgG2b (X200 Mag).
Figure 3.10 Subtyping of HHV-7 mAb 5E1  on formalin-fixed paraffin-embedded 
HHV-7  infected  Sup  T1  cells  using  peroxidase  conjugated  anti-mouse  Abs 
corresponding to common mouse isotypes.
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3.2.2 In situ hybridisation (ISH) for detecting ^-herpesvirus DNA
3.2.2.1 PCR amplification of HCMV gB, HHV-6 U67 and HHV-7 U42
A series of PCRs were  set up to amplify HCMV gB, HHV-6 U67  and HHV-7 U42 
control  sequences  as  described  in  section  2.3.1.  The  HCMV  gB,  HHV-6  U67  and 
HHV-7 U42 control sequences differs from the wild-type HCMV gB, HHV-6 U67 and 
HHV-7 U42 target sequence by the presence of a restriction endonuclease site in the 
middle of the sequence (Fox et al.,  1992; Clark et al.,  1996; Kidd et al.,  1996).  The 
PCR amplification products were separated by 3% agarose gel electrophoresis (figure
3.11  and 3.12) and amplification products of 149 bp, 173 bp and 143 bp were observed, 
corresponding  to  the  predicted  size  of HCMV  gB,  HHV-6  U67  and  HHV-7  U42 
sequences, respectively.
3.2.2.2 Cloning of the HCMV gB, HCMV US28, HHV-6 U67 and HHV-7 U42 into 
pGEM-T Easy
Since PCR amplification produced clear specific bands of the expected size for HCMV 
gB, HHV-6 U67 and HHV-7 U42, the remainder of the PCR products were subjected to 
direct PCR purification as described in section 2.3.3.  The HCMV gB, HHV-6 U67 and 
HHV-7 U42 purified amplicons were then ligated into pGEM-T Easy (1:1  molar ratio) 
(section 2.3.4).  The 298 bp amplification product of HCMV US28 was also ligated into 
pGEM-T Easy.  Each ligation reaction was transformed into competent E.coli JM109 
cells as described in section 2.3.5.
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Figure  3.11  PCR  amplification  of HCMV  gB  sequence.  Lanes  1   and  6)  0.5  jig
PhiX174//faeIII Markers;  2-4)  108 copies of HCMV gB plasmid control;  5) Negative 
control-H20
1  234567  8 9  1 0
194 bp —  
118 bp —
Figure 3.12 PCR amplification of HHV-6 U67 and HHV-7 U42 sequences.  A)
Lanes  1   and  10) 0.5  |ig PhiX174/i/aeIII Markers; 2-4)  108  copies of HHV-6 U67 
plasmid  template;  6-8)  108  copies  of HHV-7  U42  plasmid  template;  5  and  9) 
Negative control-H20.
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3.2.2.3  Screening of the putative recombinant clones by restriction enzyme analysis
White  putative  recombinant  clones  were  selected,  plasmid  DNAs  were  extracted 
(section  2.3.6),  and  analysed  by  restriction  endonuclease  digestion  with EcoRl  (see 
figure 3.13).  The presence of HCMV gB, HCMV US28, HHV-6 U67 and HHV-7 U42 
in these  clones  was  further  confirmed by DNA  sequencing with  M13  universal  and 
reverse primers.  From the sequencing results, all inserts were found to be cloned into 
the pGEM-T Easy vector in the 5’-3’ orientation.
1  2  3  4  5
194 b p -
Figure 3.13 EcoRl restriction digests of HCMV gB, HHV-6 U67 and HHV-7 U42 
plasmid  DNA.  Lanes  1   and  5)  0.5  fig  PhiX174//fa  III  Markers;  2)  300  ng  EcoRl 
digested  HCMV  gB  plasmid  DNA;  3)  300 ng EcoRl  digested  HHV-6  U67  plasmid 
DNA; and 4) 300 ng EcoRl digested HHV-7 U42 plasmid DNA
159Chapter 3- D evelop m en t o f in situ techniques for detection o f hum an  P-herpesviruses  in biop sy m aterial
3.2.2.4  Linearization of plasmid DNAs with restriction enzyme for the production 
of “run-off’ transcripts
Once  the  HCMV  gB,  HCMV US28,  HHV-6 U67  and HHV-7  U42  inserts had been 
successfully cloned into pGEM-T Easy, the recombinant plasmids were linearized with 
restriction  enzymes  to  generate  “run-off’  transcripts.  The  plasmid  DNAs  were 
linearized with restriction enzymes, Ndel or Ncol (section 2.3.8).  These two restriction 
enzymes were chosen as they have only one restriction site in the pGEM-T Easy vector, 
and no restriction site in the inserts.  In addition, they do not leave a 3’ overhang on the 
template,  which  can  result  in  extraneous  transcripts  that  contain  sequences 
complementary to the expected transcript as well as sequences corresponding to vector 
DNA.  A  0.8% agarose  gel  was  used to  confirm that the  restriction  digest had been 
performed to  completion  (see  figure  3.14)  as  a  small  amount  of undigested  plasmid 
DNA  can  give  rise  to  very long transcripts.  The  linearized  DNA  was  subsequently 
extracted, and precipitated (section 2.3.9) for in vitro transcription.
1 2 3 4   5 6 7 8 9   1 0  1 1
4000 b p - 
3000 b p -
2000 b p -
Figure  3.14  Linearization  of HCMV  gB,  HHV-6  U67  and  HHV-7  U42  plasmid 
DNA with Ncol or Ndel.  Lanes 1  and 11) 0.5 jag 1  kb DNA ladder; 2, 5 and 8) 300 ng 
HCMV  gB,  HHV-6  U67  and  HHV-7  U42  plasmid  DNA;  3,  6  and  9)  300  ng Ncol 
digested  HCMV  gB,  HHV-6  U67  and  HHV-7  U42  plasmid  DNA;  4)  300  ng Ndel 
digested HCMV gB, HHV-6 U67 U42 and HHV-7 U42 plasmid DNA.
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3.2.2.5 Generation of HCMV, HHV-6 and HHV-7 RNA transcripts
Since  HCMV  gB,  HCMV  US28,  HHV-6  U67  and  HHV-7  U42  were  cloned  into 
pGEM-T Easy in the 5’-3’  orientation,  in vitro transcription was performed using T7 
and Sp6 RNA polymerase on Ndel and Ncol linearized DNAs, to generate sense and 
antisense  transcripts,  respectively (2.3.10).  The  RNA  transcripts  were  subsequently 
ethanol  precipitated  (section  2.3.11)  and  analysed  on  a  3%  denaturing  agarose  gel. 
Figure 3.15 shows in vitro transcription of; HCMV gB template DNA with Sp6 and T7 
RNA  polymerase  giving  rise  to  the  expected  band  sizes  of  255  bp  and  250  bp 
respectively; HHV-6 U67 template with Sp6 and T7 RNA polymerase giving rise to the 
expected band sizes of 279 bp and 274 bp respectively; HHV-7 U42 template with Sp6 
and T7 RNA polymerase giving rise to the expected band sizes of 249 bp and 244 bp 
respectively.  In vitro transcription of HCMV US28 template DNA with Sp6 and T7 
RNA  polymerase  gave  rise  to  the  expected  band  sizes  of  404  bp  and  399  bp, 
respectively (results not shown).
3.2.2.6 Spot assay to confirm DIG labelling of RNA transcripts
A spot assay was performed as described in section 2.3.13 to ensure RNA transcripts 
were efficiently labelled with DIG (results not shown).
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1  2  3  4  5  6  7  8
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Figure  3.15  In  vitro  transcription  of HCMV  gB,  HHV-6  U67  and  HHV-7  U42 
template DNA with Sp6 and T7 RNA polymerase to generate antisense and sense 
RNA transcripts.  Lanes 1  and 8) 1  pg RNA Markers; 2-7) 5 pi of HCMV gB, HHV-6 
U67  and  HHV-7  U42  transcription  reaction  with  T7  and  Sp6  RNA  polymerase 
respectively.
3.2.2.7  ISH on 4% paraformaldehyde-fixed cell preparations
Using ISH, DIG labelled riboprobes specific for HCMV gB, HCMV US28, HHV-6 U67 
and  HHV-7  U42  were  evaluated  for  detecting  the  presence  of HCMV,  HHV-6  and 
HHV-7 DNA respectively, in paraformaldehyde-fixed cell controls (see section 2.4.1). 
HCMV gB, HCMV US28,  HHV-6 U67  and HHV-7 U42 DNA were  localised in the 
nuclei of HCMV infected HEL, HHV-6  infected Molt 3, and HHV-7  infected SupTl 
cells  respectively  (results  not  shown).  Hybridisation  signals  were  observed  as  dark 
purple spots within the nucleus of infected cells.  Pre-treatment of paraformaldehyde- 
fixed cell preparations with no proteinase K or low concentrations of Proteinase K (2.5- 
10 pg/ml) for 30 mins at 37°C was sufficient for probe penetration to the target.  Too 
high a concentration of Proteinase K (50-200 pg/ml) resulted in over-digestion of the 
cells and lower hybridisation signals.
•*
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3.2.2.8  ISH on formalin-fixed paraffin-embedded culture infected cells
ISH with each of the DIG labelled riboprobes (HCMV gB, HCMV US28, HHV-6 U67 
and HHV-7 U42) was used to determine optimal hybridisation conditions on formalin- 
fixed paraffin-embedded culture infected cells.  This was determined by independently 
varying the concentration of: proteinase K (section 2.4.2.1); riboprobe (section 2.4.2.2); 
and salmon sperm DNA and yeast tRNA (section 2.4.2.3) in the hybridisation mixture. 
Proteinase K (2.5-5 pg/ml) at 37°C for 30 mins was sufficient for probe penetration to 
the  target.  An  increase  in  Proteinase  K  concentration  to  100  pg/ml  resulted  in 
overdigestion of the cells and lower hybridisation signals.  Once the optimal Proteinase 
K concentration was  determined,  the concentration  of riboprobe  in the  hybridisation 
mixture was increased from 5 to  10 ng riboprobe per 50 pi of hybridisation mix.  Five 
nanograms  of  riboprobe  gave  good  hybridisation  signals  with  relatively  low 
backgrounds.  Riboprobe concentrations of 7.5 ng and 10 ng were too high and resulted 
in non-specific  staining  of cells.  Once  the  optimal  concentration  of riboprobe  was 
determined, the concentration of salmon sperm DNA and yeast tRNA was increased to 
1  mg/ml per hybridisation reaction.  One mg/ml of each nucleic acid per hybridisation 
reaction gave good hybridisation signals and the level of non-specific background was 
reduced.  The exclusion of nucleic acids in the hybridisation mixture resulted in much 
higher  background  levels  (results  not  shown).  Figure  3.16  shows  localisation  of 
HCMV, HHV-6 and HHV-7 DNA in the nucleus of formalin-fixed paraffin-embedded 
cells infected with the respective virus.  Formalin-fixed paraffin-embedded cell controls 
were  treated  with  2.5  pg/ml  Proteinase  K  at  37°C  for  30  min.  Hybridisation  was 
performed at 37°C  with 5  ng riboprobe  and  1   mg/ml  salmon  sperm DNA and yeast 
tRNA incorporated per hybridisation reaction.
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Figure  3.16  Detection  of human  (3-herpesvirus  DNA  in  formalin-fixed  paraffin- 
embedded  culture  infected  cells  by ISH.  A positive reaction  is  indicated by dark 
purple spots within the nuclei of infected cells.  A) and B) HCMV gB DNA in HCMV 
infected HEL cells;  C)  shows HCMV US28 DNA in HCMV infected HEL cells;  D) 
Negative control  showing no staining of HEL cells.  E) and F) HHV-6 U67  DNA in 
HHV-6B infected cells; G) Negative control showing no staining in Molt-3 cells.  H and 
I) HHV-7 U42 in HHV-7 infected Sup T1 cells; I) Negative control showing no staining 
in Sup T1 cells
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3.2.2.9  Optimisation of ISH on formalin-fixed paraffin-embedded liver biopsies
To  optimise  ISH  conditions  for the  detection of the human  (3-herpesviruses  in liver 
biopsies, a biopsy which tested positive for HCMV late protein 47-55 kDa by IHC (and 
independently shown to be positive for HCMV p52 by the Histopathology Diagnostic 
Service  at  the  Royal  Free  Hospital)  was  used.  The  level  of proteolytic  treatment 
required  to  obtain  optimal  hybridisation  signals  and  to  maintain  adequate  cellular 
morphology in the  liver biopsy tissue was  empirically determined by incubating the 
tissue section at a range of proteinase K concentrations (2.5-15 pg/ml) at 37°C for 30 
min,  and  comparing  hybridisation  signals  with  the  HCMV  gB  riboprobe.  Optimal 
hybridisation signal was observed in the liver biopsy treated with 7.5 pg/ml proteinase 
K.  Cellular  morphology  was  also  preserved.  Liver  biopsies  treated  with  lower 
concentrations of proteinase K gave positive hybridisation signals but positive signals 
were weaker.  Liver biopsies treated with more than  10  pg/ml proteinase K did not 
significantly improve hybridisation signals and cellular morphology was less intact.
Once  the  optimal  proteinase  K  concentration  was  determined  to  be  7.5  pg/ml, 
hybridisation was again carried out at 37°C with an increasing concentration of probe 
(10 ng and 20 ng) in the reaction to see whether hybridisation signals could be further 
improved.  Non-specific background staining was however a problem.  Two methods, 
acetic  acid  treatment  and  levamisole  were  incorporated  into  the  ISH  protocol  (see 
section 2.4.3.3) to help reduce background which may have been caused by endogenous 
alkaline phosphatase.  Sections treated in cold 20% acetic acid for 45  sec gave much 
lower background levels than those incubated with levamisole.
ISH incorporating recommendations from Orion Molecular Services, Manchester, was 
used to further reduce background levels and improve hybridisation signals (see section 
2.4.3.4).  An  acid  pre-treatment  step  was  used  to  denature  basic  proteins  and  in 
combination with proteolytic treatment can be used to facilitate their removal and thus 
making the target more accessible.  After proteinase K treatment, sections were post­
fixed in 0.4% paraformaldehyde in PBS for 20 min to help prevent further loss of target 
sequences  and disintegration  of the  tissue.  Hybridisation  with  increasing  riboprobe 
concentration  was  carried  out  at  42°C  overnight  to  help  improve  the  hybridisation 
signal.  Post hybridisation washes were also more stringent to increase specificity of the 
probe  hybridisation  and  to  reduce  background  associated  with  non-specific
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hybridisation.  ISH  using  these  recommendations  significantly  reduced  background 
levels previously observed in the liver biopsies.  Hybridisation signals were also further 
improved when hybridisation was carried out at 42°C overnight with 50 ng HCMV gB 
riboprobe.  Using this optimised method, liver biopsies from transplant patients were 
tested for human p-herpesvirus DNA, and the results are presented in chapter 5.
3.2.2.10 Optimisation of ISH on formalin-fixed paraffin-embedded renal biopsies
Using the same optimised ISH conditions as for the liver biopsies,  10 formalin-fixed 
paraffin-embedded  renal  biopsies  taken  from  transplant  patients  suspected  of graft 
dysfunction were initially tested for HCMV gB DNA.  Of the 10 renal biopsies tested, 5 
were positive for HCMV gB DNA.  One of these HCMV gB DNA positive samples 
was then used to determine the proteinase K concentration required for efficient probe 
penetration  to  target  nucleic  acids  in  renal  biopsy  tissue.  The  renal  biopsy  was 
pretreated  with  a  range  of  concentrations  of  Proteinase  K  (2.5-15  |4,g/ml)  and 
hybridisation signals were compared.  As with liver biopsy tissue, renal biopsy treated 
with  7.5  fig/ml proteinase  K for 30  min  at 37°C  gave  optimal  hybridisation  signals 
together with good preservation of cellular morphology (results not shown).
3.2.2.11 Specificity of the HCMV gB, HCMV US28, HHV-6 U67 and HHV-7 U42 
riboprobes
HCMV gB, HCMV US28, HHV-6 U67 and HHV-7 U42 DIG labelled riboprobes were 
tested against formalin-fixed paraffin-embedded cells infected with respective virus and 
to each of the other human  (3-herpesviruses to test for cross-reactivity.  None  of the 
riboprobes reacted with the heterologous viruses, and non-infected cell controls stained 
negative (results not shown).
3.2.2.12 Construction of a human p-globin riboprobe to determine the sensitivity of 
ISH
Using PCR  a human  (3-globin  sequence was  amplified  (see  section  2.4.6.1)  and the 
resulting amplicon was separated by 3% agarose gel electrophoresis.  Figure 3.17 shows 
an amplification product of 110 bp corresponding to the predicted size of the human (3- 
globin  sequence.  The  remainder  of the  PCR  product  was  subjected  to  direct  PCR 
purification, and cloned into the pGEM-T Easy vector (section 2.4.6.1-2.4.6.2).
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Figure 3.17 PCR amplification of a 110 bp human P-globin sequence Lanes 1  and 6) 
0.5 pg PhiX174//faeIII Markers; 2-4) 100 ng of human DNA; 5) Negative control-t^O
A  white  putative  recombinant  clone  was  selected,  plasmid  DNA  was  extracted  and 
analysed by restriction digestion with EcoRl to show that the  110 bp human (3-globin 
sequence had been cloned  into pGEM-T  Easy (figure 3.18).  The plasmid DNA was 
also sequenced with M l3  universal and reverse primers to confirm the correct insert. 
The sequencing results showed that the insert was cloned into the pGEM-T Easy vector 
in the  3’-5’  orientation.  Therefore, the plasmid DNA was  linearized  with restriction 
enzymes Ndel and Sphl (see figure 3.19) for subsequent in vitro transcription with T7 
and  Sp6  RNA  polymerases,  respectively  to  generate  antisense  and  sense  RNA 
transcripts  for  ISH.  Figure  3.20  shows  in  vitro  transcription  of the  human p-globin 
template DNA with T7  and Sp6 RNA polymerases to give rise to  the  expected band 
sizes of 211 bp and 221  bp, respectively.  A spot assay was performed as described in 
section 2.3.13 to ensure RNA transcripts were labelled with DIG.
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1  2  3
Figure 3.18 EcoRl restriction digest of human P-globin plasmid DNA. Lane  1) 
0.5  pg PhiX174///aeIII Marker; 2) 300 ng human p-globin plasmid DNA; 3) 300 
ng EcoRl digested human p-globin plasmid DNA.
1  2  3  4  5
Figure  3.19  Linearization  of human  P-globin  plasmid  DNA  with  Ndel  and 
Sphl.  Lanes  1   and 5) 0.5 pg PhiX174//faeIII Marker; 2) 300 ng human p-globin 
plasmid DNA; 3) and 4) 300 ng Ndel and Sphl digested human P-globin plasmid 
DNA
169Chapter 3-  D evelop m en t o f  in situ techniques for d etection o f  hum an  (3-herpesviruses in biopsy m aterial
1 2   3  4
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Figure 3.20 In vitro transcription of human P-globin template DNA with Sp6 and 
T7 RNA polymerase to generate sense and antisense RNA transcripts.  Lanes 1  and 
5) 1  pg RNA Markers; 2 and 3) 5 pi of P-globin transcription reaction with T7 and Sp6 
RNA polymerase, respectively.
3.2.2.13 ISH with DIG labelled human p-globin riboprobe
A human P-globin riboprobe was constructed as described in section 2.4.6.3 to test the 
sensitivity of ISH.  Human P-globin DNA is present as 2 copies per cell, therefore using 
the human p-globin sense probe which will only detect DNA (and no mRNA), the level 
of sensitivity of hybridisation can be determined.  No positive hybridisation signal was 
observed  on  4%  paraformaldehyde  fixed  HEL  cells  or  on  formalin-fixed  paraffin- 
embedded HEL  cells with this probe using optimised  ISH  conditions.  This  suggests 
that the ISH method is not sensitive enough to detect down to single copy levels.
3.2.2.14 Determining the level of sensitivity of HHV-6 ISH using a lymphoblastoid 
cell line with integrated HHV-6 genome (Vl-LCL)
The sensitivity of ISH using HHV-6 U67 riboprobe was tested on a lymphoblastoid cell 
line with integrated HHV-6 genome (Vl-LCL).  Depending on the QC-PCR used, Vl- 
LCL was found to contain 12 or 26 genome copies per cell (results not shown).  Positive 
staining of HHV-6 infected cells were detected by ISH.  However, not all cells stained 
positive (see figure 3.21).
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Figure 3.21  HHV-6 ISH on formalin fixed paraffin  embedded Vl-LCL.  Positive 
nuclear staining observed in >50% of cells.
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3.2.3 In situ hybridisation (ISH) for detecting HCMV gene expression
3.2.3.1  Generation of HCMV IE-1 cDNA by RT-PCR
Cultures of HEL cells infected with HCMV were harvested 4 hrs after infection.  RNA 
was  extracted  (section 2.6.1.1),  treated with RQ1  RNase-Free  DNase  to  remove  any 
residual DNA (section 2.6.1.2), and subsequently used as template for the synthesis of 
cDNA  by  reverse  transcription  (section  2.6.1.3).  PCR  amplification  with  primers 
IEP3D and IEP2AII were used to generate a HCMV IE-1 gene transcript (Kondo et al., 
1994).  These two primer pairs  span exon 2-3,  so that amplification of contaminating 
genomic  DNA  yields  a  substantially  larger product  (263  bp)  than  the  expected  IE-1 
gene  transcript  (151  bp).  Figure  3.22  shows  separation  of the  PCR  amplification 
products  by  3%  agarose  gel  electrophoresis.  The  expected  151  bp  product 
corresponding  to  the  IE-1  transcript  was  observed  together  with  the  presence  of 
contaminating genomic DNA (263 bp).  Therefore, the PCR products were subjected to 
low-gelling point agarose gel electrophoresis, and the band corresponding to the size of 
HCMV IE-1 (151 bp) was excised from the gel and purified (section 2.6.1.5).
310 bp
194 bp 
118 bp
Figure 3.22 PCR amplification with primers HCMV IEP3D and IEP2AII.  Lanes 1  
and  12)  0.5  pg  PhiX174//faeIII  Markers;  2-7)  0.5  pg  HCMV  cDNA;  8)  0.5  pg 
uninfected HEL cDNA; 9) 0.5 pg HCMV RNA (no RT step);  10) 0.5 pg HCMV RNA 
with no DNase treatment and no RT step, and 11) H2O .
1  2  3  4  5  6  7  8  9  10  11  12
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3.2.3.2 Cloning of the HCMV IE-1 gene into pGEM-T Easy
The HCMV  IE-1  purified  amplicon was  then ligated  into pGEM-T  Easy (1:1  molar 
ratio)  as  described  in  sections  2.3.4.  The  ligation  reaction  was  transformed  into 
competent E.coli JM109 cells (section 2.3.5).  A white putative recombinant clone was 
selected and purified as described in section 2.5.7.
3.2.33 Restriction enzyme analysis of the putative recombinant clone
The plasmid DNA was  extracted and analysed by restriction  enzyme  digestion with 
EcoRl  as  described  in  section  2.3.7.  The  digest  showed  that  the  clone  selected 
contained the HCMV IE-1  gene insert (figure 3.23).  This was further confirmed by 
DNA sequencing with M13 universal primers.  The results showed that the HCMV IE-1 
gene was cloned into the pGEM-T Easy vector in the 3’-5’  orientation.  The plasmid 
DNA was then linearized with Ndel and Ncol restriction enzyme (see figure 3.24), and 
in vitro transcribed with T7 and Sp6 RNA polymerase to generate antisense and sense 
RNA  transcripts  respectively.  Die  RNA  transcripts  were  subsequently  ethanol 
precipitated and analysed on a 3% denaturing agarose gel.  Figure 3.25 shows in vitro 
transcription  of  HCMV  IE-1  template  DNA  with  Sp6  and  T7  RNA  polymerase 
promoter giving rise to the expected band sizes of 257 bp and 252 bp, respectively.  In 
vitro  transcription  of the  pGEM  Express  Positive  control  template  with  Sp6  RNA 
polymerase  was  included  giving  rise  to  the  expected  band  sizes  of  1,787  bp  and 
2,566bp.
3.2.3.4  Spot assay to confirm DIG labelling of RNA transcripts
A spot assay showed the RNA transcripts were efficiently labelled with DIG.
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Figure 3.23 EcoW restriction digest of HCMV IE-1 plasmid DNA Lanes  1   and 4) 
0.5  pg  PhiX174//faeIII  Markers;  2)  300  ng  HCMV  IE-1   plasmid  DNA;  3)  300  ng 
EcoRl digested HCMV IE-1 plasmid DNA
Figure  3.24  Restriction  digests  of  HCMV  IE-1  plasmid  DNA.  Lane  1)  0.5  pg 
PhiX174///<3eIII  Marker;  2)  300  ng  HCMV  IE-1  plasmid;  3)  300  ng  Ncol  digested 
HCMV IE1 plasmid DNA; 4) 300 ng NdeI digested HCMV IE-1 plasmid DNA
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Figure 3.25 In vitro transcription of HCMV IE-1 template with Sp6 and T7 RNA 
polymerase  promoter  to  generate  sense  and  antisense  RNA  transcripts, 
respectively.  Lanes  1   and  7)  1   pg  RNA  Markers;  2  and  3)  5  pi  of HCMV  IE-1 
transcription  reaction  with  Sp6  RNA  polymerase;  4  and  5)  5  pi  of  HCMV  IE-1 
transcription  reaction  with  T7  RNA  polymerase  6)  pGEM  Express  Positive  control 
template with Sp6
3.2.3.5  Optimisation  of  ISH  for  the  detection  of  HCMV  IE-1  mRNA  in  cells 
infected in vitro
The  detection  of HCMV  IE-1  mRNA  by  ISH  was  initially  tested  on  formalin-fixed 
paraffin-embedded  cells  infected with HCMV for 4 hrs.  The HCMV  IE-1  antisense 
riboprobe is the complementary strand to the mRNA target and was used for detection 
of HCMV  IE-1  gene transcript.  The  sense probe is the  same  sequence  as  the target 
mRNA and consequently should not bind to the target mRNA.  The HCMV IE-1  sense 
riboprobe  was  therefore  used  as  a  negative  control  for  mRNA  detection.  ISH  was 
carried out using optimised conditions for HCMV gB, HCMV US28, HHV-6 U67 and 
HHV-7 U42 riboprobes as described in section 2.4.3.4.  However, background staining 
was  high  and  so  conditions  for  ISH  were  re-optimised.  Acetylation  of the  tissue 
sections  was  incorporated  into  the  pre-treatment  steps  (see  section  2.6.2.1)  to  help 
increase  specific  hybridisation  signals  and  reduce  background  hybridisation.  Non­
specific  staining was however,  still  observed,  therefore  hybridisation conditions were 
re-tested  (see  section  2.6.2.2).  RNase  A  digestion  for  varying  times  (see  section 
2.6.2.3)  was  also  incorporated post-hybridisation.  RNase  A degrades  any remaining 
single stranded RNA probe (which can contribute to background), whereas the double
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stranded RNA-RNA hybrids remain as they are RNase resistant.  Stringency washes at a 
range of temp in wash buffer 3 were also tested (see section 2.6.2.3).  Optimal positive 
hybridisation signals were observed with 50 ng riboprobe and when hybridisation was 
carried out at 42°C overnight.  However, an RNase A (25 fig/ml) digestion step for 30 
mins at 37 °C post-hybridisation was also required to help reduce non-specific staining. 
Furthermore,  stringency washes in wash buffer 3  for 30 mins at 42°C after RNase A 
digestion helped improve background staining.  Figure 3.26 shows detection of HCMV 
IE-1  mRNA  by  ISH  on  formalin-fixed  paraffin-embedded  HEL  cells  infected  with 
HCMV.  Specific  cytoplasmic  hybridisation  was  only  detected  when  antisense 
riboprobe  was  employed  (no  hybridisation  was  detected  with  the  sense  probe) 
suggesting RNA is being detected.  No hybridisation was detected in the non-infected 
cells confirming that the HCMV IE-1  antisense riboprobe specifically hybridised to its 
respective RNA.
Figure 3.26 Detection of HCMV IE-1 mRNA in formalin-fixed paraffin-embedded 
MRC-5  cells infected with  HCMV.  A) Positive cytoplasmic  staining was observed 
with HCMV IE-1 antisense riboprobe.  B) No staining with corresponding sense probe.
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3.3 Discussion and Conclusions
This chapter describes the development of two methods, ISH and IHC for the detection 
of HCMV,  HHV-6  and  HHV-7  infection  in  formalin-fixed  paraffin-embedded  cell 
controls, and the optimisation of the HCMV ISH for detection of viral DNA and in liver 
and renal biopsies.
Historically,  hybridisation  was  conventionally  performed  with  probes  labelled  with 
radioactive isotopes, which follows the detection of sequence specific nucleic acid by 
autoradiographic  analysis.  This  has  now  largely  been  replaced  by  the  use  of 
biotinylated, DIG and electrochemiluminescent labels, facilitating the application of this 
technique without the use of radioisotopes.
DIG  labelled  riboprobes  specific  to  HCMV  gB,  HHV-6  U67  and  HHV-7  U42 
sequences (Fox et al.,  1992; Clark et al., 1996; Kidd et al., 1996) were constructed for 
ISH.  These sequences have been amplified by our diagnostic PCR assays for HCMV, 
HHV-6  and  HHV-7  and  are  highly  conserved  regions.  HCMV  gB  (UL55)  is  an 
abundant component of the virion  envelope,  and elicits neutralizing Abs  in  infected 
humans.  HHV-6 U67  gene codes for a product of unknown function,  although it is 
conserved between variants A and B.  The HHV-7 target sequence encodes an amino 
acid sequence highly homologous to that of the HHV-6 U42 gene.  U42 is homologous 
to ICP27 of HSV (Gompels et al., 1995).  In addition, a DIG labelled riboprobe specific 
to  a  sequence  of HCMV  US28  gene  (Beisser  et al.,  2001)  was  also  constructed  to 
compare hybridisation signals to that of HCMV gB.  The HCMV US28 gene, a GPCR, 
has an important function in immune evasion.  It acts as a broad specificity p chemokine 
receptor and can act as a coreceptor for the uptake of HIV (Pleskoff et al.,  1997).  In 
addition, it has been demonstrated that the expression of HCMV US28 in SMCs in the 
presence of MCP-1  and RANTES promoted SMC migration (Streblow et al.,  1999). 
US28-mediated  SMC  migration  thereby  provides  evidence  linking  HCMV  to  the 
acceleration of vascular diseases (Streblow et al.,  1999).  ISH using the DIG labelled 
riboprobes was  found to be  specific  for the  detection of HCMV  gB,  HCMV US28, 
HHV-6 U67 and HHV-7 U42 DNA in formalin-fixed paraffin-embedded cells infected 
with respective virus.  In order to determine the level of sensitivity of ISH, a riboprobe 
specific for a 110 bp sequence of human P globin was constructed.  The human p globin 
gene is present at 2 copies per cell, therefore the human P globin sense probe which will
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only detect DNA and no mRNA was used to show whether the level of sensitivity of the 
technique reached single copy levels.  No hybridisation signal was observed suggesting 
that the detection of DNA in situ does not approach single-copy levels.  Other studies 
have found ISH detection limits on tissue sections to be in the range of 10-20 copies of 
mRNA or viral DNA per cell (Hoefler et al., 1986; Speel et al.,  1995).  Using an EBV- 
transformed lymphoblastoid cell line with  12-26 copies of integrated HHV-6 genome 
(Vl-LCL), ISH with the HHV-6 U67 riboprobe was also carried out to determine the 
level  of  sensitivity  of  HHV-6  ISH.  Although  positive  hybridisation  signals  were 
detected, not all cells stained positive.  This is most likely due to the level of viral DNA 
in the cells being at the limit of the assay’s sensitivity.  There is no known cell line with 
integrated HCMV or HHV-7 genome, therefore the sensitivity of ISH with HCMV gB, 
HCMV US28 and HHV-7 U47 riboprobes could not be determined.
In  this  chapter,  a  DIG  labelled  HCMV  IE-1  riboprobe  was  also  constructed  for 
investigating HCMV gene expression.  HCMV can establish productive, persistent or 
latent infections.  During a productive infection, expression of HCMV genes occurs in a 
temporally regulated manner leading to the transcription of IE (a), E (p) and L (y) genes 
(Spector et al.,  1990).  Transcription of the HCMV IE genes is under the control of the 
major IE promoter (MEEP).  This single MIEP controls the expression of two genetic 
elements, designated IE-1 and IE-2.  The IE-1 transcript measures approximately 2.0 kb 
(Jahn et al.,  1984) and the protein is 68-72 kDa (Stinski et al.,  1983).  The IE-1  genes 
are the first to be transcribed following entry of the virus into the host cell and their 
transcription  is  independent  of de  novo  synthesis  of viral  proteins  (LaFemina  and 
Hayward,  1983).  Therefore, a riboprobe directed against the IE-1  gene transcript for 
RNA  ISH  was  used  for  investigating  HCMV  in  various  states  of infection  in  renal 
allograft biopsies (results described in chapter 4).
Using IHC, the sensitivity and specificity of a range of MAbs for the detection of the 
human  P-herpesvirus proteins in formalin-fixed paraffin-embedded cell  controls were 
evaluated.  Three MAbs  directed to HCMV proteins characteristic for each temporal 
stage  of replication  were  used;  MAB8126  to  HCMV  late  protein;  MAb  CCH2  to 
HCMV p52; and MAB8131  to HCMV IE protein.  CCH2 MAb reacted with HCMV 
infected cells giving an intense nuclear and/or cytoplasmic staining pattern.  CCH2 has 
been found to label “owl’s eye” cells and morphologically normal cells in human tissue
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sections with widespread HCMV infection (Niedobitek et al., 1988).  The epitope of the 
CCH2  MAb  has  been  mapped  to  the  UL44  reading  frame  of the  HCMV  genome 
(Plachter  et  al.,  1992).  Intense  cytoplasmic  staining  was  observed  in  fibroblasts 
infected with HCMV with MAB8126 to HCMV late protein which is indicative of a 
productive infection.
The presence of HHV-6-specific proteins was detected in HHV-6B (strain Z29) infected 
Molt-3 cells using a range of MAbs directed to HHV-6A p41/38 (originally described as 
detecting both variants),  HHV-6B plOl  (MAB  8535), HHV-6B  gH,  and HHV-6 gB. 
The HHV-6 early protein p41 is encoded by the U27 gene which is conserved in HHV- 
6A and HHV-6B and shows strong homology with the HCMV UL44 gene coding for 
the  ICP36  family of early-late-class phosphoprotein (Chang and  Balachandra,  1991). 
HHV-6  p41  is  a  DNA-binding protein  and  a putative  DNA  polymerase  stimulatory 
factor (Agulnick et al.,  1993).  Challoner et al.  (1995) observed p41  expression using 
MAb  to  p41/38  in  oligodendrocytes  of  MS  patients  but  not  of  controls,  thereby 
suggesting  an  association  of  HHV-6  with  the  etiology  or  pathogenesis  of  MS. 
However, there is data indicating that the two proteins, p41  and p38, recognised by the 
MAb to p41/3 8 are not both encoded by the viral genome.  The protein p38 is likely to 
be of cellular origin, since the sequence of a peptide fragment of p38 (Iyengar et al., 
1994) shows a strong similarity to human p-actin (protein AAH02409 in GenBank) but 
lacks  homology  to  the  ORFs  in  HHV-6.  Recently,  Xu  et al.  (2001)  identified  the 
epitope of HHV-6 p41 responsible for the exclusive reactivity of the MAb to p41/3 8 to 
a nuclear Ag in HHV-6A but not in HHV-6B.  These findings explain the absence of 
immunohistochemical staining observed with HHV-6 p41/38 in HHV-6B (strain Z29) 
infected  cells.  Cytoplasmic  staining  of  HHV-6B  plOl  structural  Ag  in  HHV-6B 
infected cells is indicative of an active infection.  The 101 kDa apparent molecular mass 
(101K) virion protein has been identified as the major immunoreactive virion protein of 
HHV-6B (strain Z29) (Yamamoto et al.,  1990; Pellet et al.,  1993).  The gene encoding 
the  HHV-6B  101K was  described  as  the  homolog  of HCMV  phosphorylated  virion 
tegument  protein,  ppl50.  Neipel  et  al.  (1992)  have  identified  homology  between 
strongly  immunoreactive  virion  proteins  encoded  by  HCMV  and  HHV-6  A  strain 
U1102, ppl50 and pi00, respectively.
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In the herpesvirus  family,  several  glycoproteins,  which are components  of the virion 
envelope,  play critical roles  in viral  infection,  including attachment, penetration,  and 
cell-to-cell  spread.  The  amino  acid  sequence  of gB  is  highly  conserved  among the 
members  of the  herpesvirus  family  (Pereira,  1994)  and  gB  is  essential  for  virion 
penetration into cells (Little et al., 1981).  gH plays an important role in virion entry and 
cell-to-cell spread (Babic et al.,  1996).  Detection of HHV-6 gB and HHV-6B gH Ags 
were observed in the cytoplasm of Molt-3 cells infected with HHV-6B.  MAb to HHV- 
6B  gH  was  found  to  be  the  least  sensitive  for  immunohistochemical  detection  of 
formalin-fixed paraffin-embedded Molt-3 cells infected with HHV-6B, whilst MAb to 
HHV-6 gB gave the best staining intensities with low background levels, therefore MAb 
to HHV6 gB will be used for the detection of an HHV-6 productive infection in biopsy 
material.
At present, only MAb 5E1  directed to HHV-7 pp85 is available for the immunological 
detection of HHV-7 in formalin-fixed paraffin-embedded tissues.  MAb 5E1 directed to 
HHV-7  specific  pp85  was  sensitive  and  specific  for  the  detection  of formalin-fixed 
paraffin-embedded  Sup  T1  cells  infected  with  HHV-7.  IHC  studies  to  date  have 
surprisingly not used an isotype control for MAb 5E1 (Kempf et al., 1997;  1998; 2000). 
Mab 5E1 was therefore subtyped and identified as IgGl.  MAb 5E1 does not crossreact 
with HHV-6 and hence recognizes an HHV-7-specific epitope (Foa-Tomasi et al., 1994; 
1996; Stefan et al., 1997).  pp85 is encoded by the U14 gene (Stefan et al.,  1997), and is 
a  highly  immunogenic  complex  of proteins  (Foa-Tomasi  et  al.,  1994;  1996)  which 
localises to the outer layers of the virion tegument (Stefan et al., 1997).  As it is directed 
to a structural component of the virion, a positive reaction is indicative of active viral 
infection (Stefan et al., 1997).
In summary, the results described in this chapter demonstrate that ISH, and IHC can be 
used for the detection of HCMV, HHV-6 and HHV-7 DNA and proteins in formalin- 
fixed paraffin-embedded  culture  infected  cells.  More  importantly,  ISH  using a  DIG 
labelled  riboprobe  specific  to  HCMV  was  optimised  for  the  detection  of  HCMV 
infected  cells  in  biopsy  material.  Thus,  these  methods  could  now  be  applied  to 
investigate the involvement of these viruses in disease pathogenesis post-transplant at 
the tissue level.
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Chapter 4 - Role of the human ^-herpesviruses in allograft 
rejection following renal transplantation
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4.1  Introduction
Over  the  past  decade,  substantial  progress  has  been  made  in  understanding  the 
pathogenesis of HCMV disease after organ allotransplantation.  The source of HCMV 
can  be  the  recipient  (reactivation  of latent  infection)  or  the  donor  (causing  primary 
infection  if  the  recipient  is  HCMV  seronegative  or  reinfection  if  the  recipient  is 
seropositive).  Serial measures of HCMV viral load in the blood of recipients of renal 
(Kidd et al., 2000), liver (Griffiths et al.,  1999a) or cardiac transplants demonstrate that 
HCMV is frequently detected posttransplant at a median of six weeks.  In some patients, 
viral load increases allowing HCMV to cross a putative blood -  organ barrier and cause 
end organ disease manifest as enteritis, hepatitis, retinitis or pneumonitis (Griffiths and 
Emery, 1997).  These are collectively termed the “direct effects” of HCMV because the 
virus  can  be  seen  directly  in  biopsies  of  the  infected  organ  using  classical 
histopathological techniques to visualise “owl’s eye inclusions” (Smith, 1959; Macasaet 
et  al.t  1975).  Placebo-controlled  trials  demonstrate  that  these  direct  effects  can  be 
prevented through the use of antiviral prophylaxis with GCV (Goodrich et al.,  1991; 
1993;  Winston  et  al.,  1993;  Boeckh  and  Bowden  1995)  or VACV  (Lowance  et al., 
1999).  Alternatively,  patients  can  be  monitored  for  laboratory  evidence  of HCMV 
infection  and  treated  with  GCV  before  disease  develops  (pre-emptive  therapy) 
(Goodrich et al.y  1991; Einsele et al.,  1995).
In addition to end-organ disease, HCMV is associated with a variety of other medical 
conditions  (graft  rejection,  immunosuppression,  atherosclerosis)  collectively  termed 
“indirect  effects”  (Rubin,  1989)  because  the  virus  is  not  seen  histopathologically  in 
affected organs.  Evidence for a causal role for HCMV in these conditions is based upon 
clinical observations in individual patients, statistical association with HCMV disease 
and/or HCMV infection in cohorts of patients as well as the results of clinical trials of 
antiviral agents (Grattan et al.,  1989; Loebe et al.,  1990; von Willebrand et al.,  1986; 
Fietze et al.,  1994;  Reinke  et al.,  1994;  Valantine  et al.,  1999;  Rubin et al.,  2000). 
Specifically,  the trial  of Lowance et al.  (1999) randomised 208  HCMV  seronegative 
patients to receive prophylaxis with VACV or placebo for ninety days after transplant of 
a  seropositive  kidney  and  reported  that  the  incidence  of biopsy-proven  acute  graft 
rejection was decreased by 50% among those receiving VACV.  This finding, coupled 
with supporting evidence from animal models of allotransplantation in the presence of
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animal  CM  Vs  with/without  GCV  therapy,  strongly  indicated  that  CMV  was  an 
unrecognized major contributor to acute graft rejections (Lemstrom et al., 1995; 1997).
Evidence against a causal role for HCMV in triggering acute graft rejection comes from 
several sources.  First, not all clinical cohort studies report a statistical association with 
HCMV (Dickenmann et al., 2001; Sherlock et al., 1991; Teixeira et al., 2000; Boyce et 
al.,  1988).  Second,  in  the  Lowance  study,  a parallel  group  of 408  renal  transplant 
patients who were HCMV seropositive pre-transplant did not demonstrate a beneficial 
effect of VACV prophylaxis on the incidence of biopsy-proven graft rejection.  Third, 
other investigations have reported that HHV-6, and/or HHV-7 are also associated with 
graft rejection and with HCMV end organ disease (Griffiths et al.,  1999a; Kidd et al., 
2000; Osman et al., 1996; Desjardin et al., 1998; Ratnamohan et al., 1998).  HHV-6 and 
to  a  lesser  extent  HHV-7,  are  susceptible  in  vitro  to  drugs  which  inhibit  HCMV 
including  GCV  (De  Clercq  et  al.,  2001).  It  remains  possible  therefore  that  the 
beneficial  effects  of antiviral prophylaxis on acute graft rejections  may be  operating 
through inhibition of these newer (3-herpesviruses and/or inhibition of HCMV.
To  address  this  complex  situation  QC-PCR  assays  were  previously  applied  to 
quantitatively measure the viral load of each of these three (3-herpesviruses in transplant 
patients (Kidd et al, 2000; Griffiths et al.,  1999a).  In the study by Kidd et al. (2000) 
QC-PCR  was  used  to  detect  active  p-herpesvirus  infections  in  the  120  day  period 
following  renal  transplantation.  Detailed  clinicopathological  analyses  were  also 
conducted to reveal symptoms, signs or syndromes associated with these viruses in this 
setting.  HCMV  was  found  to  be  the most  commonly detected virus  post-transplant 
(58%  of  patients)  followed  by  HHV-7  (46%)  and  HHV-6  (23%).  The  median 
maximum viral loads for HCMV was also significantly higher than those for HHV-6 
(p=0.01) and HHV-7 (P>0.0001), and a trend for HHV-7 viral load to be greater than 
HHV-6 (p=0.08).  It was also revealed that in those patients with graft rejection, HHV-7 
was associated with more episodes of rejection (p=0.02).  There was also a significant 
increase in HCMV disease occurring in patients with HCMV and HHV-7 coinfection 
compared to those with HCMV infection only (p=0.04).  Therefore HHV-7 should be 
further investigated  as  a possible  co-factor  in the development of HCMV  disease  in 
renal transplant patients and may potentially exacerbate graft rejection.  The work  in 
this  chapter  is  an  extension  of this  prospective  study,  whereby  in  situ  techniques
183C hapter 4  R ole  o f  hum an  (3-herpesviruses  in  renal  allograft  rejection
including  ISH  and  IHC  (developed  in  chapter  3)  were  used  to  detect  these  viruses 
directly in renal biopsies taken from the patients in the original  cohort who required 
biopsy to investigate the cause of graft dysfunction.  It is reasoned that,  if the in situ 
detection  of HCMV  was  associated  statistically  with  standardised  histopathological 
criteria of rejection in the  same biopsies, the hypothesis that HCMV was a cause  of 
biopsy-proven graft rejection would be accepted.  In contrast, if HCMV was detectable 
in  biopsies  but  was  not  associated  with  graft  rejection,  the  hypothesis  that  HCMV 
infection causes graft dysfunction which mimics rejection clinically would be accepted. 
Furthermore, the detection of HHV-6 and/or HHV-7 in the biopsies would determine 
whether these viruses were also involved in the graft rejection process.  HCMV gene 
expression  was  also  investigated  in  the  renal  allograft  biopsies  using  a  riboprobe 
directed against the HCMV IE-1 gene transcript for RNA ISH (developed in chapter 3).
In renal (and cardiac) transplantation, high levels of AECAs have been demonstrated in 
HCMV infected transplant recipients (Toyoda et al.,  1997;  1999).  These AECA have 
been  proposed  to  play  an  important  role  in  the  development  of humoral  allograft 
rejection after transplantation and could result in reduced long-term allograft survival 
(Yard  et  al.,  1993;  Fredrich  et  al.,  1999).  Ab-mediated  rejection  occurs  in 
approximately 25-50% of biopsy-confirmed acute renal allograft rejection (Lederer et 
al.,  2001;  Regele et al.,  2001;  Mauiyyedi et al.,  2002; Nickeleit et al.,  2002), has  a 
poorer prognosis  than  cellular rejection  and requires  a more  aggressive  and targeted 
antirejection therapy (Nickeleit et al., 2002).  In recent years the deposition of C4d in 
the PTC of the renal graft has emerged as an attractive marker of Ab-mediated injury 
and an important diagnostic criterion (Collins et al.,  1999; Koo et al., 2004).  In this 
chapter, evidence of both humoral (using a polyclonal peptide anti-C4d Ab (C4dpAb; 
Biomedica)  (Regele  et  al.,  2001)  and  cellular  graft  rejection  were  also  examined 
because each of these has been associated in different series with HCMV infection.
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4.2  Results
4.2.1  Detection of P-herpesvirus DNA by ISH in renal biopsies
Sixty two renal biopsies from 30 patients obtained from a previous prospective study of 
52 patients who underwent their first renal transplantation between 1st August 1993 and 
31st January 1995 (Kidd et al., 2000) were available for in situ detection of the human 
p-herpesviruses.  In these patients,  biopsies were  performed at a median  of 21  days 
(range 2 to  107) after transplantation.  Two or more biopsies were available from  18 
patients, with a median of 2 (range 1  to 5) biopsies.  Using optimised ISH conditions for 
the renal biopsies (see  section 2.4.4),  each renal  sample was  stained  for HCMV  gB, 
HHV-6  U67  and  HHV-7  U42  DNA  using  DIG  labelled  riboprobes  constructed  in 
section 2.3.  HCMV gB DNA was detected in 21/30 (70%) renal transplant patients and 
32/62  (52%)  biopsies.  All  renal  biopsies  from  these  patients  were  reviewed  by  Dr 
Michael  Jarmulowicz, pathologist at the Royal  Free  and University College  Medical 
School.  Table 4.1  shows the detection of HCMV gB DNA by ISH together with the 
serological status of these patients.
HCMV serostatus CMVE5H+ CMVISH- Total
D+R+ 11 2 13
D+R- 3 1 4
D-R+ 5 3 8
D-R- 1 2 3
D?R+ 1 1 2
21 9 30
Table 4.1 HCMV serostatus and the detection of HCMV DNA by ISH
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HCMV gB DNA was detected in 8 of 12 patients with only one biopsy and in at least 
one biopsy in 13 of 18 patients with 2 (n =10), or more (n = 8) biopsies.  The detection 
of HCMV in the renal biopsy was frequently seen early during the post-transplantation 
course.  HCMV gB DNA was detected in 19/30 (63%) biopsies taken during 1-19 days 
(d),  in  5/13  (38%) biopsies  taken during 20-39  d,  and  in  8/19  (42%)  biopsies  taken 
during 40-120 d post-transplant.  Of the 18 patients with 2 or more biopsies, the median 
time to first HCMV gB DNA positive biopsy by ISH was  19 d (range 5  to 90) post­
transplant  compared  to  32  d  (range  2  to  107)  post-transplant  for  HCMV  gB  DNA 
negative biopsies.  Detection of HCMV gB DNA in the renal biopsies was widespread 
(Figure 4.1).
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Figure 4.1  Renal biopsies from transplant recipients showing detection of HCMV 
gB DNA by ISH.  Patient 1: A and B) HCMV gB DNA and C) No probe.  Patient 2: D) 
and E) HCMV DNA by  ISH.  Patient  3:  F)  HCMV  DNA by  ISH.  Arrows  indicate 
positive nuclear staining for HCMV.
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Table  4.2  shows  HCMV  gB  DNA  in  various  structures  of the  renal  allografts.  A 
scoring system for HCMV ISH staining intensities included strong positive staining of 
HCMV DNA as indicated by +++, moderate staining by ++ and weak staining by + (Dr 
Michael  Jarmulowicz).  HCMV  gB  DNA  was  found predominantly  in  the  epithelial 
cells of the distal convoluted tubules (DCT) and the proximal convoluted tubules (PCT) 
with strong to moderate  staining.  Endothelial  cells  also  stained positive  for HCMV 
DNA with moderate to slight staining intensities.  Other renal  structures that stained 
positive for HCMV gB DNA include the loop of Henle and podocytes, and to a lesser 
extent mesangial cells.  The presence of HHV-6 or HHV-7 DNA was not detected in 
any of the renal biopsies by ISH.
C W W m l s M a R S oooxDiopaes intensity of staining
distal convoluted tubules 32 +++■/++
proximal convoluted tubules 13 ++/+
podocytes 13 ++/+
mesangial cells 3 +
loop of Henle 5 ++/+
endothelial cells 5 ++/+
Table 4.2 HCMV gB DNA in various renal structures
Ten renal biopsies positive for HCMV gB DNA were also stained for HCMV US28 
DNA by ISH to confirm hybridisation results.  All  10 HCMV gB DNA positive renal 
biopsies also stained positive for HCMV US28 DNA.  The two gB DNA negative renal 
biopsies also stained negative for HCMV US28 DNA.  The pattern of staining detected 
for  HCMV  US28  DNA  was  very  similar to  that  of HCMV  gB  DNA,  although  the 
intensity of staining for HCMV gB  DNA was  slightly stronger.  Figure 4.2  shows a 
comparison of positive hybridisation signals for HCMV gB and US28 DNA.
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Figure 4.2  Renal biopsy showing comparison of hybridisation signals for HCMV 
gB  and  US28  DNA  by  ISH.  A)  HCMV  gB  DNA,  B)  HCMV  US28  DNA  and C) 
negative  staining  with  HHV-6  U67  probe.  Arrows  indicate  positive  hybridisation 
signals.
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4.2.2  Correlation of HCMV ISH results with HCMV DNAemia
Twenty of the 30 renal transplant recipients had HCMV DNA detected in the blood by 
PCR.  Of those,  15 (75%) also HCMV DNA detected in their renal biopsies.  Eight of 
those (53%) had at least one biopsy where HCMV DNA was detected within 2 weeks of 
virus detection in the blood.  Of the remaining 7 patients, 3 patients had only one biopsy 
available, and in all three cases the biopsy was taken more than 2 weeks before HCMV 
DNA was found in the blood by PCR.  In the patients with more than one biopsy, in one 
patient both biopsies taken on day 8 and day 85 post-transplantation were HCMV DNA 
positive by ISH and the virus was detected in the blood on day 50 post-transplantation. 
Two  patients  had  HCMV  DNA  detected  in  an  initial  biopsy,  but  the  virus  was  not 
detected in  a follow-up  biopsy which was taken more  than  1   month  after virus was 
detected in the blood.  In one patient who had 4 consecutive biopsies, HCMV DNA was 
detected in 2 biopsies taken on day 5 and day 12, but not in the biopsies taken on days 
31  and 35 post-transplantation.  HCMV was also detected in the blood of this patient 
after 59 days post-transplantation.
Of the 21 patients with HCMV DNA detected in at least one of their biopsies, 6 (29%) 
had no HCMV DNA detected in their blood within 3 months post-transplantation.  Of 
those 6 patients, 4 patients had only one biopsy available, one patient had 3 consecutive 
biopsies taken on day 45, day 72 and day 90 post-transplantation and virus was detected 
in the latter two biopsies.  Another patient had two biopsies taken on day 2 and day 8 
post-transplantation and HCMV DNA was detected in the latter biopsy by ISH.  Four 
patients had no HCMV DNA detected in their biopsies or in blood by PCR.
4.23 HCMV serostatus and HCMV disease
Twenty three of the 30 (77%) recipients were HCMV seropositive pretransplantation. 
Of those,  17  (74%)  had  HCMV  detected  in  their  biopsy  by  ISH.  In  7  HCMV 
seronegative recipients, 4 (57%) had HCMV gB DNA detected in their biopsy by ISH 
suggesting virus transmission from the donor kidney.  All four patients had poor graft 
outcome within 5 years post-transplantation and are now deceased.  Ten of the 30 (33%) 
patients  developed  HCMV  disease.  This  was  more  common  in  the  HCMV  D+/R- 
serogroup:  3  (75%)  of 4  patients  developed  HCMV  disease  versus  5  (38%)  of  13 
patients  and  1   (13%)  of  8  patients  in  the  D+/R+  and  D-/R+  HCMV  serogroups, 
respectively.  One of 2 patients where the serogroup status was incomplete developed
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CMV  disease.  Nine  of the  10  (90%)  patients  who  developed  HCMV  disease  had 
HCMV gB DNA detected in at least one of their biopsies by ISH, with all PCR positive 
in blood.  Of 20 patients who did not develop HCMV disease, HCMV gB DNA was 
detected in the biopsies of 12 (p = .08805).
4.2.4  Correlation of HCMV ISH results with histological rejection
Renal  biopsies  positive  for  HCMV  gB  DNA  by  ISH  were  examined  to  determine 
whether histological rejection was more frequent in these biopsies.  HCMV DNA was 
detected in  16/30 (53%) biopsies with no rejection or borderline ‘suspicious’ rejection, 
and 16/32 (50%) biopsies with acute histological rejection (p = .793).  Table 4.3 shows 
the morphological features of acute rejection in the renal biopsies.  In analysis restricted 
to only those biopsies with acute histological rejection classified by the Banff ‘93-95’ 
scoring system (Solez et al.,  1993;  1996), the detection of HCMV DNA by ISH was 
also not significantly associated with any type of acute histological rejection (interstitial 
or vascular), or with any histological parameter attributable to acute allograft rejection 
including glomerulitis, interstitial inflammation, tubulitis or intimal arteritis.
Histology AM nfc-M nrinrr HCMV DNA in renal biopsies p-value
Yes No
No rejection, n (%) 16/62 (28) 7/16 (44) 9/16(56)
Borderline rejection, n (%) 14/62 (23) 9/14 (64) 5/14 (36)
Acute rejection, n (%) 32/62 (52) 16/32 (50) 16/30 (50) 0.793
Banff 1,n(% ) 13/27 (48) 7/13(54) 6/13 (46)
Banff 2, n (%) 14/27 (52) 6/14 (43) 8/14 (57) 0.568
Glomerulitis, n (%) 5/37 (14) 1/5  (20) 4/5 (80) 0.169
Interstitial inflammation, n (%) 35/37 (95) 18/35 (51) 17/35 (49) 0.257
Tubulitis, n (%) 35/37 (95) 17/35 (49) 18/35 (51) 0.987
Intimal arteritis (v1, v2), n (%) 14/37 (38) 6/14 (43) 8/14 (57) 0.362
Table 4.3 HCMV DNA by ISH and histopathology
192C   hapter 4  R ole o f hum an  (3-herpes\ iruses  in  renal  allograft  rejection
4.2.5 Clinico-pathological analyses
Clinicopathological details of graft and patient survival were available for 28 patients. 
Patient  survival  (within  10  yrs  post-transplantation)  was  64%,  of which  12  of  18 
patients (67%) had HCMV DNA detected in their graft by ISH.  Of the  10 deceased 
patients,  8  (80%) had HCMV DNA  detected  in the  graft by ISH.  One  patient died 
within  1   month  post-transplantation  with  HCMV  pneumonitis,  and  this  patient  had 
HCMV DNA detected in the graft and in the blood by ISH and PCR, respectively.  It 
should  be  emphasized  that  these  patients  had  biopsies  taken  because  of  graft 
dysfunction, hence the poorer than usual survival.  However, the association of HCMV 
DNA by ISH with patient survival did not reach statistical significance (p = .268).
Comparing the detection of HCMV DNA by ISH with graft survival, it was observed 
that of the 28 patients, only 9 (32%) had grafts that were still functioning up to  10 yrs 
post-transplantation, of which 5 (55%) had HCMV DNA detected in the graft by ISH. 
Of the  19 patients with poor graft outcome  (patients put on dialysis),  15  (79%)  had 
HCMV DNA detected in the graft by ISH.  Although there was a trend towards the 
detection  of HCMV  DNA  by  ISH  with  poor  graft  outcome,  this  did  not  achieve  a 
statistical significance (p = .2007).
4.2.6 C4d staining in allograft biopsies
C4d staining was used to analyse the incidence of acute humoral rejection in the renal 
transplant  patients  biopsied  during  120d  post-transplantation  for  suspected  renal 
dysfunction.  Figure 4.3  shows  capillary deposition of complement fragment  C4d  in 
graft biopsies.  Three types of staining patterns were observed; C4d-H- indicates strong 
widespread  staining (involving >50%  of interstitial  capillaries),  C4d+  indicates  focal 
staining, and C4d- absent staining of interstitial capillaries.  Twenty nine of 62 (47%) 
biopsies had C4d-positive  staining detected in the  endothelial  cells  of PTC  and  6  of 
these (21%) PTC positive biopsies (10% of all biopsies) also had endothelial staining 
for C4d in the glomeruli.  No biopsy showed C4d glomerular staining in the absence of 
C4d in PTC.  Of the 29 C4d-positive biopsies, strong diffuse C4d staining was found in 
10 (34%) of these biopsies (16% of all biopsies).
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Nineteen of 30 (63%) transplant patients had at least one biopsy that stained positive for 
C4d.  Of the 19 patients,  12 patients had two (n = 6) or more (n = 6) allograft biopsies. 
In nine patients, initial C4d staining in endothelial capillaries did not change in follow- 
up biopsies (6 patients had all C4d negative biopsies and 3 patients had C4d positive 
staining in both biopsies).  In 2 patients, initial biopsy was negative for C4d staining but 
one or more subsequent biopsies was scored positive (appearance of peritubular C4d 
deposits).  A loss of peritubular C4d staining was observed in 7 patients.  Detection of 
capillary deposition of C4d was mainly during early time course, the median time to 
first C4d-positive biopsy was 13 (range, 7 to 64) d post-transplantation.
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Figure 4.3  Renal biopsy from a patient showing diffuse C4d staining in endothelial 
cells.  A) peritubular capillaries B) glomeruli. C) IgG control.
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Table 4.4 shows C4d deposition and histopathology.  In biopsies with peritubular C4d 
deposits, acute rejection was more common (18/29, 62%) than in C4d negative biopsies 
(14/33, 42%), although not statistically significant (p = .1225).  In biopsies with C4d 
positive staining, Banff type II (vascular) rejection was more common than Banff type I 
(interstitial) rejection (p = 0.034).  A statistical association between C4d staining and 
intimal  arteritis  (p  =  .0045),  characteristic  of type  II  rejection  was  also  found.  No 
significant association was found between C4d staining and other histological features 
of acute  rejection  including  glomerulitis,  interstitial  inflammation,  and  tubulitis.  In 
biopsies  with  peritubular  C4d  deposits,  the  detection  of  HCMV  DNA  was  more 
common (18/29, 62%) than in C4d- biopsies (14/33, 42%) although this difference was 
not statistically significant (p = .1225).
A M  Biopsies C4d in PTC p-value
Yes No
No rejection, n (%) 
Borderline rejection, n (%) 
Acute rejection, n (%)
16/62 (28) 
14/62 (23) 
32/62 (52)
6/16 (38) 
5/14 (36) 
18/32 (56)
10/16 (63) 
9/14 (64) 
14/32 (44) 0.123
Banff 1, n (%) 
Banff 2, n (%)
13/27 (48) 
14/27 (52)
5/13 (38) 
11/14(79)
8/13 (62) 
3/14(21) 0.034
Glomerulitis, n (%)
Interstitial inflammation, n (%) 
Tubulitis, n (%)
Intimal arteritis (v1, v2), n (%)
5/37 (14) 
35/37 (95) 
35/37 (95) 
14/37 (38)
3/5  (60) 
16/35 (46) 
16/35 (46) 
11/14(79)
2/5 (40) 
19/35 (54) 
19/35 (54) 
3/14(21)
0.585
0.135
0.135
0.0045
Table 4.4 shows C4d deposition and histopathology.
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4.2.7 Detection of HCMV specific proteins by IHC
Three MAbs (as described in section 2.5.6) were used to detect HCMV-specific proteins 
expressed at different stages of replication.  There was no detection of the three HCMV 
Ags by IHC in the 10 renal biopsies which had tested positive for HCMV DNA by ISH.
4.2.8 Detection of active caspase 3 by IHC
Evidence  of apoptosis  was  also  investigated  in  renal  biopsies  infected  with  HCMV 
DNA  using  a  MAb  directed to  the  active  form  of caspase-3  (Pharmingen).  Active 
caspase-3  was  observed  in  both  induced  and  non-induced  HL60  cells  (positive 
controls).  Approximately  50-60%  of etoposide  treated  HL-60  cells  showed  active 
caspase-3 staining most of them with clear apoptotic morphology.  In non-induced cells 
only a few positive cells were detected.  Figure 4.4 shows nuclear and/or cytoplasmic 
staining of active  caspase-3  in HL60  cells  treated with etoposide.  Active  caspase-3 
staining was not found in any of the 10 renal biopsies tested.  One renal biopsy showed 
a  few  active  caspase  3-positive  cells,  as  indicated  by  cytoplasmic  and/or  nuclear 
staining.  However, the number of positively stained cells was less than 5% and so was 
scored negative (see figure 4.5).
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Figure 4.4 Detection of active caspase-3  in etoposide treated  HL60 cells.  Arrows 
indicate brown nuclear localised staining and/or cytoplasmic staining of active caspase- 
3 positive cells.
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Figure 4.5 Apoptosis in a HCMV gB DNA positive renal biopsy.  Only a few cells 
stained positive for active caspase-3 (see arrows).
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4.2.9  ISH with HCMV IE-1 antisense riboprobe on renal biopsies
To determine the presence of HCMV DE-1 mRNA in the renal biopsies from transplant 
patients,  10 renal biopsies previously shown to contain HCMV gB DNA by ISH were 
stained with the HCMV IE-1 antisense riboprobe.  For each sample, hybridisation with 
the corresponding sense probe was included as a negative control.  A HCMV gB DNA 
negative renal biopsy was included in each experimental run.  Of the  10 renal biopsies 
tested,  only  two  biopsies  showed  some  positive  HCMV  IE-1  mRNA  hybridisation 
signals.  Cytoplasmic staining was found predominantly in the renal tubules, however, 
this was detected in <5% of the whole biopsy (results not shown).
The lack of positive hybridisation signals detected in the renal biopsies with the HCMV 
EE-1 antisense riboprobe maybe due to either low levels of HCMV IE-1 gene transcript 
in these biopsies which are not detectable by ISH,  or it may reflect  a problem with 
tissue preparation or the tissue itself or the technique.  If the quality of the tissue is poor 
and RNA is degraded it will be very difficult to obtain satisfactory results with ISH. 
Therefore, to address these issues, a labelled riboprobe complementary to an abundant 
“housekeeping  gene”  such  as  p-actin  was  used  to  test  the  quality of the  tissue  and 
mRNA within the tissue.  Positive hybridisation signals will be detected if mRNA  is 
present  within  the  tissue,  whereas  an  absent  or  low  signal  suggests  tissue  RNA 
degradation.
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4.2.10  ISH  with  p-actin  antisense  riboprobe  (Roche)  on  4%  paraformaldehyde- 
fixed human cell suspensions
ISH  with  the  p-actin  antisense  riboprobe  was  initially  carried  out  on  HEL  cell 
suspensions that had been fixed in 4% paraformaldehyde for 20 mins at 4°C.  These 
cells were fixed for a short period of time to minimize mRNA degradation.  The ISH 
conditions used were the same as that described in section 2.3.1.  HEL cells treated with 
RNase were  included as  a negative  control  to  confirm  that the hybridisation  signals 
were  mRNA  specific.  Positive  hybridisation  signals  were  detected  on  these  cells 
(results not shown).
4.2.11  ISH with  P-acttn  antisense riboprobe (Roche) on  formalin-fixed  paraffin- 
embedded human cell suspensions
ISH  with  the  p-actin  antisense  riboprobe  was  then  carried  out  on  formalin-fixed 
paraffin-embedded HEL cells.  Hybridisation was carried out at 42°C overnight with 50 
ng, 25 ng and 5 ng probe.  HEL cells treated with RNAse A (0.1 and 1  mg/ml), and cells 
treated with DNAse I (O.lU/pl) as described in section 2.6.4.2 were also included to 
confirm  the  specificity  of  the  reaction.  RNAsin  was  also  incorporated  into  the 
hybridisation  mix  to  further  inhibit  any  RNases  which  may  degrade  the  riboprobe. 
Positive hybridisation signals were detected with this probe at all concentrations tested, 
with  stronger  signals  detected  as  concentration  of probe  increased  (see  figure  4.6). 
Positive  hybridisation  signals  were  detected  when  cells  were  treated  with  DNase 
(degrades  DNA),  but  not  when  cells  were  treated  with  RNase  (0.1  or  1   mg/ml) 
confirming that hybridisation is RNA specific.
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4.2.12  ISH with p-actin antisense riboprobe on formalin-fixed paraffin-embedded 
renal biopsies
Five renal biopsies were initially tested with P-actin antisense riboprobe using the same 
in situ hybridisation method as described  in  section 2.4.4.  Results were  difficult to 
interpret as background staining was very high.  To help reduce background levels an 
acetic  anhydride  step was  incorporated  during  pre-treatment  of sections  (see  section 
2.6.2.1).  Hybridisation using a lower concentration of probe (5 ng per reaction) was 
also carried out at 42°C  overnight.  Ten renal biopsies  (5  HCMV gB  DNA positive 
biopsies from section 4.2.1, and 5 HCMV gB DNA negative renal biopsies) were again 
tested.  For each sample, a negative control consisting of the same sample treated with 
RNAse was run in parallel to ensure hybridisation signals were mRNA specific.  Non­
specific background staining was still too high for five biopsies.  Two biopsies showed 
positive mRNA hybridisation signals.  Detection of mRNA was not uniform, but more 
localised in the renal biopsy (see figure 4.7).  mRNA was predominantly detected in the 
renal tubules.  RNase treated biopsies stained negative indicating hybridisation to be 
RNA specific.  Three biopsies showed very little mRNA detection, if any.
202Chapter 4 -   Role o f human P-herpesviruses in renal allograft rejection
A
O -
-■V  i  .■*  %
< ? • ^   -
r--% .  i
J
'X
V  -
C >
Figure 4.7 Detection of human P-actin mRNA in renal biopsies by ISH.  Patient  1: 
A) Positive human P-actin mRNA hybridisation and B) no staining in the same section 
treated with RNase.  Patient 2: C) Positive p-actin mRNA hybridisation and B) shows 
no staining in the same section treated with RNAse.
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4.3 Discussion and Conclusions
Using  QC-PCR,  previous  prospective  studies  conducted  in  our  department  have 
reported  an  association  between  HCMV  infection  and  graft  rejection  in  transplant 
recipients (Kidd et al., 2000; Griffiths et al.,  1999a).  HHV-6 and HHV-7  infections 
were also linked to graft rejection in different transplant populations.  However to fully 
understand the pathological role of these viruses in allograft rejection detection of these 
viruses must be made at the tissue level.  The occurrence of HCMV inclusions in renal 
tissue  examined  by light  microscopy provide  direct  evidence  of tissue  invasiveness. 
However, these inclusions are detected in <1% of transplant biopsies of patients with 
HCMV  disease  (Kashyap  et  al.,  1999).  In  this  study  ISH  and  IHC  techniques 
(developed in chapter 3) were therefore used to further investigate the incidence and the 
pathogenesis of these viruses in renal biopsies taken from a previous  cohort of renal 
transplant patients suspected of graft dysfunction (Kidd et al., 2000).
HCMV DNA was detected by ISH in a significant proportion of biopsies from patients 
with renal  allografts.  Approximately 50% of these renal biopsies  had HCMV DNA 
detected, and within a majority of these biopsies detection was widespread with up to 
50%  of HCMV  DNA  positive  kidney  cells  observed.  In  a  previous  study  HCMV 
genomes were documented in up to 41% of routine allograft biopsies by ISH technique 
(Ulrich et al.,  1986).  The biopsies containing HCMV DNA were not more likely to 
show graft rejection so the hypothesis that HCMV is a frequent trigger of rejection was 
rejected.  This finding is similar to another study where in situ detection of HCMV was 
not found to be significantly associated with acute rejection (Andersen et al.,  1990). 
Instead,  it  is  proposed  that  CMV  infection  of the  graft  causes  post  transplant  graft 
dysfunction which mimics rejection clinically and which can be prevented by antiviral 
prophylaxis such as that used by Lowance et al. (1999).  In support of this conclusion, 
in  most  of our  cases  the  donor  had  serological  evidence  of past  HCMV  infection 
consistent with the donor origin of HCMV exactly as seen by Lowance et al.  (1999). 
Since no biopsy contained HHV-6 or HHV-7 DNA using ISH of similar sensitivity the 
role of these  P-herpesviruses  in graft rejection or dysfunction  is also rejected.  This 
finding is in contrast to the situation in the blood where HHV-7 DNA was detected by 
PCR  in  these  patients  with  rejection.  HHV-7  was  also  associated  with  increased 
episodes of rejection (Kidd et al., 2000).
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Several  studies  have  demonstrated  that  various  cell  types  in  the  kidney,  including 
mesangial cells, glomerular epithelial cells, endothelial cells and tubular epithelial cells 
can be infected by HCMV in vitro (Ustinov et al.,  1991; Heieren et al.,  1988a;  1988b) 
and in vivo (Payton et al.,  1987; Bissinger et al., 2002; Hendrix et al.,  1997).  In the 
present study, HCMV DNA was also found to be widely distributed in a variety of cell 
types,  although  tubular epithelial  cells  were  most  frequently positive,  this  finding  is 
similar to other studies (Ulrich et al., 1986; Hendrix et al., 1997).
Results in this chapter suggest a trend towards the presence of HCMV DNA in the graft 
as detected by ISH and the long-term outcome among the renal transplant recipients, 
however, this did not achieve statistical significance which is a reflection of low patient 
numbers.
In this  chapter ISH  was used to detect the  presence  of (3-herpesvirus DNA  in renal 
allografts  using  riboprobes  specific  for  HCMV,  HHV-6  and  HHV-7.  A  riboprobe 
directed to HCMV IE-1 gene transcript (developed in chapter 3) was also used to further 
examine for HCMV gene expression in these biopsies.  HCMV IE-1  gene transcripts 
were not detected in the renal allografts by RNA ISH.  p-actin transcripts were only 
detected in  some renal  allografts.  P-actin mRNA  in these biopsies were  not  evenly 
distributed but focal and random.  These results suggest that the renal allografts may not 
be suitable for looking at mRNA (and therefore no HCMV IE-1  gene transcripts) since 
RNA degradation is likely to have occurred resulting in no, or low abundance of p-actin 
transcripts  detected.  Therefore,  although  HCMV  gB  DNA  was  found  in  the  renal 
allografts, the type of HCMV infection could not be established by ISH.  To further 
discriminate between a latent or productive infection, IHC was utilised to identify for 
viral Ags.  The failure to detect HCMV Ags shows that HCMV expression was at a low 
level  and  explains  why  this  phenomenon  has  not  been  described  previously  by 
histopathologists using IHC or examination for owl’s eye inclusions which are known 
to be insensitive (Mattes et al., 2000;  Smith et al.,  1975).  The sensitivity of the ISH 
technique is unlikely to detect latent infection, so the HCMV DNA in the biopsies most 
likely represents low level virus replication or abortive infection.
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Immunohistochemical staining with an anti-active caspase 3 mAb failed to identify any 
evidence of apoptosis  in HCMV DNA positive  biopsies.  Apoptosis  is  an  important 
innate antiviral defence that can result in aborted infection and the elimination of virus- 
infected cells.  However, despite the presence of extensive HCMV DNA in the graft, 
apoptosis is not occurring.  HCMV has been found to encode four anti-apoptotic gene 
products, IE-1, IE-2 pUL36 and pUL37.  The IE-1  and IE-2 proteins each inhibit the 
induction of apoptosis by TNF-a or by the ElB-19-kDa-protein-deficient adenovirus 
(Zhu et al., 1995).  UL36 encodes a protein designated vICA (viral inhibitor of caspase 
activation)  which  inhibit  caspase-8  activation  (Skaletskaya  et  al.,  2001)  and  UL37 
encodes a protein designated vMIA (viral mitochondria-localized inhibitor of apoptosis) 
which inhibits mitochondrial megapore activation in a manner similar to members of 
the anti-apoptotic Bel family (Goldmacher et al., 1999).
Studies have shown that the onset of HCMV infection, as indicated by the detection of 
HCMV  in the blood by PCR is  around 4 to  8  weeks  after SOT  (Kidd  et al.,  2000; 
Griffiths et al.,  1999a).  Although the exact time course of HCMV in renal allografts 
can only be determined in a prospective  study testing protocol biopsies,  detection of 
HCMV DNA by ISH was  found predominantly during the early post-transplantation 
course (63% biopsies taken during  1-19 d post-transplantation were HCMV positive) 
suggesting that in some cases it is most likely to be of donor origin.  The detection of 
HCMV DNA in a biopsy by ISH frequently preceded detection of virus in the blood. 
Twenty percent of patients had at least one HCMV DNA positive renal biopsy, without 
detection  of  HCMV  in  the  peripheral  blood  in  the  120  d  post-transplant  period. 
Although no detectable HCMV DNA in the blood does not rule out the presence of low 
levels of active infection below the detection level of our PCR, the findings may reflect 
the  role  of  local  immune  response  in  limiting  virus  dissemination  following 
reactivation.  Evidence  from  mouse  cytomegalovirus  (MCMV)  models  have  also 
demonstrated the importance of the immune response in limiting reactivation at local 
sites  where  it  occurs,  and  preventing  dissemination  of virus  to  cause  widespread 
infection (Reddehase et al., 2000).
Over the years evidence has been accumulating to indicate that acute rejection is not 
exclusively a T-cell mediated process but may also involve the generation of circulating 
Abs that react against the graft.  Until recently, the detection of Ab-mediated rejection
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has  been  difficult  to  diagnose  histologically  due  to  the  rapid  removal  of Igs  from 
endothelial cell surfaces.  It was work first pioneered by Feucht et al. (1991;  1993) and 
later demonstrated in subsequent studies (Collins et al.,  1999; Regele et al., 2001) that 
an end-product of complement C4d in PTC represented an attractive marker for acute 
humoral rejection.  In the present study, C4d staining was therefore used to analyse the 
incidence  of acute  humoral rejection  in the renal  transplant patients biopsied during 
120d  post-transplantation  for  suspected  renal  dysfunction.  Approximately  50%  of 
biopsies showed C4d staining, this finding is similar to that of other studies (Lederer et 
al., 2001; Feucht et al.t  1993).  In the present study both diffuse and focal staining of 
interstitial capillaries were included as “positive for humoral rejection” (similar to the 
approach used by Lederer et al., 2001).  Feucht et al. (1993) demonstrated in a previous 
study that the appearance of capillary C4d can follow a dynamic course.  Therefore, the 
staining of few capillaries indicates a transitional state, either representing an ongoing 
attack (resulting later in diffuse staining) or the ‘wash-out phase’  of a previous attack 
(Lederer et al., 2001; Regele et al., 2002).  Focal staining is therefore clinically relevant 
(Feucht et al.,  1993; Lederer et al., 2001).  Other studies have reported a much lower 
number of C4d-positive biopsies (30%) and this may in part be due to the inclusion of 
only widespread  and  bright  C4d  capillary  staining  (Mauiyyedi  et al.,  2002).  Other 
technical considerations may also contribute, such as sensitivity of the technique used 
(e.g. IHC or indirect immunofluorescence), Ab type and titre.
In some studies accumulation of C4d in renal allografts was found to be associated with 
acute  cellular  rejection  (Feucht  et  al.,  1993;  Nickeleit  et  al.,  2002),  whereas  other 
studies have  found  PTC  C4d  staining to  be  independent  of histologic  rejection type 
(Regele et al., 2001; Herzenberg et al., 2002).  In this study endothelial C4d staining 
was associated with intimal arteritis, a morphological sign of acute cellular rejection, 
this finding is similar to that of Nickeleit et al. (2002).  Endothelial C4d staining has 
also been found to be associated with vascular (Banff type II) rejection.  Another study 
by Feucht et al. (1993) also reported a close correlation between PTC C4d deposition 
and vascular rejection.  Endothelial C4d deposition was also demonstrated in a number 
of biopsies without morphological  signs of cellular rejection.  This  finding is  in  line 
with recent  studies  showing  that  Ab-mediated  rejection  can  occur  in  the  absence  of 
cellular rejection (Trpkov et al.,  1996; Regele et al., 2001).  It has been suggested that
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humoral mediated injury without signs of cellular rejection represents pure Ab-mediated 
rejection (Collins et al., 1999).
In some transplant recipients with HCMV infections, high levels of AECA have been 
found, and these Abs have been suggested to play an important role in the development 
of Ab-mediated rejection (Yard et al., 1993; Fredrich et al., 1999). However, in a recent 
study by Nickeleit et al. (2002), clinical evidence of infections  within 2 weeks before a 
renal allograft biopsy (HCMV, VZV, sepsis, bacterial infections) was not significantly 
associated with C4d deposition (Nickeleit et al., 2002).  In this study, the detection of 
HCMV DNA in the renal biopsies by ISH was not associated with C4d deposition.
As well as aiding understanding of pathogenesis of graft rejection, the findings of this 
study have important clinical implications.  A common clinical conundrum in patients 
who present with fever and graft dysfunction is the differential diagnosis of rejection or 
infection.  The  finding  that  HCMV  is  frequently  detected  in  biopsies  shows  that 
rejection and infection frequently co-exist.  The in situ hybridisation method for HCMV 
could be used to test biopsies  collected  during clinical trials  allowing patients  to  be 
randomised  to  receive  GCV  or  placebo;  the  results  would  then  determine  whether 
patients  with  graft  dysfunction  should  be  given  anti  HCMV  therapy  in  addition  to 
treatment for their graft rejection.
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Chapter 5 -  Role of the human ^-herpesviruses in allograft 
rejection following liver transplantation
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5.1  Introduction
HCMV is recognized as the single most important infectious agent post-transplantation, 
causing  severe end-organ diseases.  HCMV has  also been associated with acute  and 
chronic rejection of solid organs, or GVHD in the case of BMT, and secondary bacterial 
and fungal infections.  Following liver transplantation HCMV infection occurs in 30- 
65% of patients, of which  18-40% were symptomatic infection, and mostly developed 
one  to  three  months  after  transplantation  (Gao  et  al.,  2004).  The  evidence  for 
association of CMV with an increased risk of acute graft rejection comes from several 
cohort studies in liver (Fietze et al., 1994), renal (von Willebrand et al., 1986; Reinke et 
al.,  1994) and heart (Grattan et al.,  1989; Loebe et al.,  1990) transplant recipients.  In 
liver transplantation the  importance of concomitant CMV  infection during  late  acute 
rejections has been reported (Cakaloglu et al., 1995).  Persistent HCMV DNA has been 
demonstrated in hepatocytes of liver grafts with VBDS  (Arnold et al.,  1992),  in bile 
ducts  and  vascular  structures  of  liver  allografts  associated  with  chronic  rejection 
(Lautenschlager et al.,  1997a).  Various  animal models have  also been developed to 
study the effect of CMV infection on organ allografts.  In the rat, CMV has been shown 
to  increase  inflammation,  cause  vascular disease,  and  accelerate  chronic  rejection  in 
kidney and aortic allografts (Lautenschlager et al., 1997b; Lemstrom et al.,  1993;  1995; 
Streblow et al., 2003).  In a rat liver allograft model, CMV was found to significantly 
increase portal inflammation and cause more severe bile duct damage in liver allografts 
undergoing acute rejection, than in the uninfected grafts.  CMV was also linked to the 
induction  of VCAM-1  in  the  endothelial  cells.  The  results  support  an  association 
between CMV infection and the immunological mechanisms of rejection, as well as the 
role of CMV in the development of bile duct damage in liver allografts (Martelius et al.,
1998).  In studies involving antiviral therapy for CMV, treatment of CMV-infected graft 
recipients with  GCV  resulted  in  the  elimination  of virus-induced transplant vascular 
sclerosis (TVS) and prolonged graft survival (Lemstrom et al.,  1997; Lemstrom et al., 
1994).  In a prospective study of heart transplants, treatment with prophylactic GCV 
delayed the time to allograft rejection (Valantine et al., 1999), thereby implicating CMV 
as a causative agent of chronic rejection.
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Evidence against a causal role of CMV in graft rejection also exists.  Several clinical 
cohort studies have not reported a statistical association between HCMV and acute graft 
rejection  (Sherlock  et  al.,  1991;  Teixeira  et  al.,  2000;  Boyce  et  al.,  1988).  In  a 
prospective study by Paya et al. (1992) a correlation between the occurrence of HCMV 
infection  and  VBDS  in  liver  allograft  recipients  was  not  found.  Long  term 
complications  were  also  not  observed  in  a  large  study  on  CMV  hepatitis,  and  an 
association with chronic rejection was also not found (Seehofer et al., 2002), therefore 
the  causative  link  still  remains  questionable.  Immunosuppression  associated  with 
transplantation  may  also  enhance  the  replication  of  other  (3-herpesviruses,  namely 
HHV- 6, and/or HHV-7.  In liver transplant recipients, concurrent HHV-6 and HHV-7 
reactivation  is  frequently  found  together  with  HCMV  (Lautenschlager  et  al.,  2002; 
Razonable and Paya, 2002b).  Several studies have shown that coinfection of HHV-6 
and/or HHV-7  with HCMV is associated with an increase risk of HCMV disease  in 
transplant recipients (Dockrell et al., 1997; Mendez et al., 2001; Desjardin et al.,  1998; 
2001; Tong et al., 2000).  These viruses have also been associated with graft rejection 
after transplantation (Lautenschlager et al., 1998; Lautenschlager et al., 2000; Humar et 
al., 2002; Griffiths et al.,  1999a; Kidd et al., 2000).  Other studies however, have not 
been able to identify specific disease associations with HHV-6 infection in liver or renal 
transplant recipients (Schmidt et al., 1996; Herbein et al., 1996).
In prospective studies conducted in our department a relationship between HHV-6 and 
HHV-7 and graft rejection in different organ transplant recipients has been suggested 
(Griifiths  et al.,  1999a;  Kidd et al.,  2000).  In the  study by Griffiths  et al.  (1999a), 
qualitative PCR was used to detect active [3-herpesvirus infections in the 120 day period 
following liver transplantation.  Infections with HHV-6 and HHV-7 were found to be 
common  after  transplantation,  and  they  occurred  earlier  than  HCMV  infection  (the 
median time to first PCR-positive sample was 20 days for HHV-6, 26 days for HHV-7 
and 36 days for HCMV).  QC-PCR results showed that the median peak virus load for 
HCMV was significantly greater than that for HHV-6 and HHV-7.  Clinicopathological 
analyses also revealed that all three viruses were temporally associated with altered liver 
function, suggesting each virus was associated with episodes of hepatitis.  HCMV and 
HHV-6, but not HHV-7 were also independently associated with biopsy proven graft 
rejection.  It was therefore concluded that HHV-6 may be a previously unrecognized 
pathogen in this patient group (Griffiths et al., 1999a).
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The work in this chapter is an extension of this prospective study whereby ISH and IHC 
were  used  for  the  direct  detection  of these  viruses  in  liver biopsies  taken  from  the 
patients in the original cohort.  Protocolled liver biopsies were obtained at scheduled 
times after transplantation,  and whenever liver dysfunction occurred (Griffiths et al., 
1999a).  Since  it  was  not  feasible  to  test  all  biopsies,  biopsies  were  selected  from 
patients taken nearest to the time of PCR positivity in the blood for any of the human 13- 
herpesviruses.  The detection of HCMV, HHV-6 and/or HHV-7 in the biopsies would 
determine whether these viruses were involved in the graft rejection process.  ISH with 
DIG  labelled  riboprobes  specific  for  HCMV,  HHV-6,  and  HHV-7  were  used  for 
detection of virus DNA in the liver biopsies.  IHC with MAbs directed against human 13- 
herpesvirus late proteins; HCMV late protein, HHV-6 gB, and HHV-7 pp85, were used 
to detect active infections.
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5.2  Results
5.2.1  Detection of human ^-herpesviruses DNA in liver biopsies by ISH
Fifty four allograft biopsies from 30 patients obtained from a previous prospective study 
of 60 patients who underwent their first liver transplantation between  1st August  1993 
to 11th October 1995 (Griffiths et al.,  1999a) were available for in situ detection of the 
human (3-herpesviruses.  Inclusion criteria for this present study was the availability of 
at least one fine needle biopsy taken near the time of PCR positivity in blood for any of 
the  human  p-herpesviruses  (median -2.5,  range  -33  to  +8  days)  during  the  120-day 
post-transplant period.  Consecutive liver biopsies were also taken for 4 patients.  Using 
optimised ISH conditions for the liver biopsies (see section 2.4.3.4), each liver sample 
was  stained  for  HCMV  gB,  HHV-6  U67  and  HHV-7  DNA  using  DIG  labelled 
riboprobes constructed in section 2.2.  Two biopsies from 2 patients were insufficient 
for ISH.  HCMV gB DNA was detected in  17/29 (59%) liver transplant patients and 
28/52 (54%) biopsies by ISH.  No CMV inclusion bodies were demonstrated in any of 
these liver biopsies.  One patient had insufficient biopsy for ISH.  All  liver biopsies 
from  these  patients  were  reviewed  by  Dr  Richard  Standish,  Department  of 
Histopathology, Royal Free and University College Medical School.  Table 5.1  shows 
the detection of HCMV gB DNA by ISH together with the serological status of these 
patients.
Table 5.1 HCMV serostatus and tbe detection of HCMV gB DNA by ISH
HCMV serostatus CMVISH+ CMVISH- Total
D+R+ 7 3 10
D+R- 3 4 7
D-R+ 3 4 7
D-R- 2 0 2
D-R? 1 0 1
D+R? 1 1 2
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HCMV gB DNA was detected in various structures of the liver allograft (see table 5.2). 
HCMV  DNA  was  found  predominantly  in  the  nuclei  of  liver  hepatocytes,  and 
endothelial cells.  Sinusoidal endothelial cells and to a lesser extent Kupffer cells and 
inflammatory cells also stained positive for HCMV gB DNA.  The number of HCMV 
gB DNA-positive hepatocytes varied between liver biopsies.  In some, none or only a 
few occasional hepatocyte nuclei were positive for HCMV gB DNA, whereas in other 
liver biopsies infected hepatocytes were common (see fig 5.1).  The intensity of HCMV 
gB DNA staining also varied.  However, the distribution and intensity of staining of 
infected cells in the liver biopsy did not correlate with histological rejection.  Staining 
for HHV-6 and HHV-7 DNA by ISH did not produce convincing results.
Ten  liver biopsies positive for HCMV gB  DNA were also  stained for HCMV US28 
DNA by ISH to confirm hybridisation results.  All  10 HCMV gB DNA positive liver 
biopsies also stained positive for HCMV US28 DNA.  Five HCMV gB DNA negative 
liver biopsies also  stained negative for HCMV US28  DNA.  The pattern of staining 
detected  for HCMV US28  DNA was very similar to that of HCMV  gB  DNA,  with 
positive hybridisation signals predominantly detected in the nuclei of liver hepatocytes. 
Figure  5.2  shows  a comparison  of positive hybridisation  signals  for HCMV  gB  and 
US28 DNA.
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Table 5.2 HCMV gB DNA in various structures of the liver
liver 
biopay no hepatocytes
HCMV DNA in the liver
wMiniMwl  gqwawlal  Kupffer 
endothelial  cells
inflammatory
cells
1 ++ ++ +
2 ++ ++  +-h
3 ++
4 ++ -H-  ++
5 +
6 + +
7 +
8 +
9 ++
10 +
11 +
12 ++
13 + ++  +
14 +
15 +
16 ++ ++ +
17 +
18 ++ +  +
19 ++
20 + +
21 ++ + +
22 +
23 ++
24 +
25 +
26 ++
27 ++
28 ++
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Figure 5.1 Detection of HCMV gB DNA in liver biopsies by ISH.  Patient 1: A and 
B)  HCMV  gB  DNA  and  C)  negative  control  showing  same  section  stained  with  no 
probe.  Patient 2: D) and E) HCMV gB DNA and F) negative staining with HHV-6 U67 
probe.  Arrows indicate HCMV infected liver hepatocytes.
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Figure 5.2  Liver biopsy showing comparison  of hybridisation signals for HCMV 
gB  and  US28  DNA  by  ISH.  A)  HCMV  gB  DNA;  B)  HCMV  US28  DNA;  and  C) 
negative  staining  with  HHV-6  U67  probe.  Arrows  indicate  positive  hybridisation 
signals.
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5.2.2  Detection of human p-herpesviruses proteins in liver biopsies by IHC
HCMV-specific  late  protein  of 47-55  kDa  was  detected  in  only  2  of the  54  (4%) 
biopsies (one of which was independently shown to be positive for HCMV p52 protein 
by the Histopathology Diagnostic service at the Royal Free Hospital) from 2 of the 30 
(7%) liver transplant patients.  In these two liver biopsies, only a few occasional HCMV 
infected liver hepatocytes were detected  (see  figure  5.3).  These 2 biopsies were not 
tested  by  ISH  as  there  was  insufficient  material.  Immunohistochemical  staining  for 
HHV-6 and HHV-7 late proteins on liver biopsies did not produce convincing results.
Figure 5.3 Liver biopsy from a patient showing HCMV late proteins by IHC.  A)
HCMV late proteins in liver hepatocytes (see arrows) and B) Isotype control.
&
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5.23 HCMV serostatus and HCMV disease
Eighteen (60%) of the 30 recipients were HCMV seropositive pre-transplantation.  Of 
those,  1  patient had a biopsy that was positive for HCMV late Ag as detected by IHC, 
but  biopsy  was  insufficient  for  ISH.  Ten  (59%)  of those  17  HCMV  seropositive 
patients  had  HCMV  DNA  detected  in  their  biopsy  by  ISH.  Five  of  9  (56%) 
seronegative patients had HCMV DNA detected in their biopsy by ISH suggesting virus 
transmission from the donor.  However, two of these patients received a transplant from 
a seronegative donor.  HCMV DNA was also detected in the blood by PCR  17 days 
post-transplant in one of these two patients.
Of  the  30  recipients,  8  (27%)  had  biopsy-proven  HCMV  disease  (1  gastric,  3 
pneumonitis,  4 hepatitis).  This  was more  common  in the  CMV  D+R-  serogroup:  5 
(71%) of 7 developed HCMV disease versus  1   (14%) of 7 patients, and 1   (10%) of 10 
patients in the D-R+ and D+R+ serogroups, respectively.  Of those 8 recipients who 
developed HCMV disease, 5 (63%) had HCMV DNA detected in their biopsy by ISH 
(and in the blood by PCR).  One patient had HCMV late Ags detected in the biopsy by 
IHC, but biopsy was insufficient for ISH.  HCMV gB DNA was also detected in  12 
(55%) out of 22 patients who did not develop HCMV disease (p = 0.26).
5.2.4  Correlation of HCMV ISH results with HCMV DNAemia
Eighteen (62%) of the 29 recipients had HCMV DNA detected in the blood by PCR. 
Of those,  10 (55%) also had HCMV DNA detected in their biopsy.  HCMV DNA was 
also detected in at least one biopsy in 7 (64%) of 11 recipients who did not have HCMV 
DNA detected in the peripheral blood.  In this study, consecutive liver biopsies (n = 21) 
were taken for 4 recipients during  120 d post-transplant.  In all 4 recipients,  HCMV 
DNA was detected in the biopsy by ISH before virus was detected in the blood by PCR. 
In 3 of 4 of these patients, HCMV DNA was detected in the biopsy early during the 
post-transplantation course (median time for detection of HCMV DNA in biopsies was 
13 d (range 1  to 34) post-transplant, as compared to 51 d (range 3 to 83) post-transplant 
for HCMV DNA negative biopsies).  In one patient HCMV DNA was not detected in 
biopsies  taken  early  during  the  post-transplantation  course  (within  10  d  post­
transplantation), but in biopsies taken near the time of HCMV PCR positive blood (36 d 
post-transplantation).  This patient had HCMV serostatus D+R+.
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5.2.5 Correlation of HCMV ISH results with histological rejection
HCMV  DNA  was  detected  in  16/28  (57%)  biopsies  with  no  rejection,  8/16  (50%) 
biopsies with  mild  acute  rejection,  and  4/8  (50%)  biopsies  with  moderate  or  severe 
acute histological rejection (p= .6065).  Histological rejection was not more frequent in 
liver biopsies that were HCMV DNA positive by ISH.
5.2.6 Correlating HCMV ISH findings with the timing of post-transplant ALT 
peaks
The temporal relationships between detection of HCMV gB DNA in the biopsy by ISH, 
histological grading of the liver biopsies and timing post-transplant of “virus-associated 
ALT peaks” were examined.  A peak was defined as a transient elevation in which the 
mean of the maximum value and the subsequent value was both at least 1.5 times higher 
than the previous lowest level and greater than 40 units/L.  A “virus-associated ALT 
peak”  was  defined  as  one  occurring  within  7  days  of PCR  positivity  for  any  virus 
(Griffiths et al., 1999a).
Of the 52 liver biopsies (29 recipients), 24 (46%) biopsies (in  14 patients) were taken 
within 7 days of an ALT peak.  Of those, 21  biopsies (12 patients) were taken during a 
human  (3-herpesvirus  associated  peak.  Six  biopsies  (5  patients)  were  taken  during 
HCMV associated peaks (1  showing mild rejection, 1  moderate rejection), 6 biopsies (5 
patients)  were  taken  during  HHV-6  associated  peaks  (all  showing  mild-moderate 
rejection),  8  biopsies  (6  patients)  were  taken  during  HHV-7  associated  peaks  (2 
showing mild rejection,  1   severe rejection) and 1   biopsy (graded as moderate rejection) 
was taken during two peaks each associated with HHV-6 and HCMV.
Of the 24 biopsies taken within 7 days of an ALT peak, 14 (58%) biopsies were HCMV 
gB  DNA positive.  Of those,  12  biopsies were taken  during a virus associated  ALT 
peak.  Four biopsies were taken during  CMV  associated peaks  (1  showing moderate 
rejection),  5  biopsies  during  a  HHV-6  associated  peak  (all  showing  mild-moderate 
rejection), 3 biopsies during a HHV-7 associated peak (1  mild rejection).  Three out of 
the  28  (11%)  HCMV  gB  DNA  positive  biopsies  were  taken  with  no  ALT  peak 
observed.  Of those 5 HCMV gB DNA positive biopsies (5 patients) taken within 7 days
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of a virus ALT peak showing no histological evidence of rejection, 4 were diagnosed 
cases of HCMV disease (1 hepatitis, 1  gastric, 2 pneumonitis).
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5.3  Discussion and Conclusions
The results of this study show that HCMV DNA was frequently detected in biopsies 
from patients with liver allografts by ISH.  Similar to other studies, HCMV DNA was 
predominantly detected in liver hepatocytes (Evans et al.,  1999; Arnold et al.,  1992) 
although other cell types including endothelial  cells,  Kupffer cells  and  inflammatory 
cells  were  found to  contain HCMV  DNA.  CMV replication has been  shown to be 
permissive in endothelial and epithelial cells (Ho et al., 1984; Sinzger et al., 1995).
In this study the biopsies containing HCMV DNA were not more likely to show graft 
rejection, therefore HCMV was not found to be a frequent trigger of rejection.  Since 
the biopsies were taken during 120 d post-transplantation period, rejection in this case is 
likely to reflect that of an acute rather than of a chronic nature.  There are very few 
studies investigating the role of HCMV in acute liver allograft rejection.  One recent 
PCR-based  study has  shown  that neither  CMV  viraemia  or CMV  disease  adversely 
affects the incidence and grade of acute rejection episodes or the histological outcome 
of post-transplant  HCV  recurrence,  during  the  first  year  after  liver  transplantation 
(Teixeira  et  al.,  2000).  Most  studies  have  focussed  on  the  role  of HCMV  in  the 
development of chronic rejection in liver transplant recipients, where the virus has been 
demonstrated in liver grafts with VBDS and in bile ducts and vascular structures of liver 
allografts associated with chronic rejection (Arnold et al.,  1992; Lautenschlager et al., 
1997a).  These findings, however, have not been confirmed in other studies (Paya et al., 
1992; Wright, 1992).
HHV-6 infections complicating the post-transplantation period have also been reported 
in liver transplant patients  (Herbein  et al.,  1996;  Singh et al.,  1997;  Dockrell  et al.,
1999).  Several studies have suggested a role of HHV-6 in allograft rejection (Humar et 
al., 2002; Lautenschlager et al.,  1998; 2000).  In this study, HHV-6 or HHV-7 DNA 
was not detected in any of the liver biopsies using ISH of similar sensitivity, therefore 
these two viruses are unlikely to have a direct pathological role  in graft rejection  or 
dysfunction.  This finding is in contrast to the situation in the blood where HCMV and 
HHV-6 were independently associated with biopsy proven graft rejection (Griffiths et 
al., 1999a).
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In this study, IHC was used to look for late HCMV proteins in liver allografts which is 
indicative of a productive infection.  HCMV late proteins were only detected in two 
biopsies  from  two  patients.  The  failure  to  detect  HCMV  late  proteins  shows  that 
HCMV expression was at a low level, not detectable by EHC.  HHV-6 or HHV-7 late 
proteins were also not detected in any of the liver biopsies.  This finding is in contrast to 
studies  conducted  by  Lautenschlager  et  al  (1998;  2000)  where  HHV-6  Ags  were 
detected  by  immunohistochemical  staining  in  liver  biopsy  specimens  from  liver 
transplant patients with graft rejection.  In a study of 51  consecutive liver transplant 
patients, HHV-6 infection was diagnosed in  11  (22%) of patients during the first year 
after transplantation.  Significant graft dysfunction with organ rejection was associated 
with the detection of HHV-6 antigenemia in 8 of the 11 patients, and importantly, HHV- 
6 Ags could also be detected by immunohistochemical staining in the liver biopsies of 
these 3 patients (Lautenschlager et al., 2000).  In our study, lack of detection of HHV-6 
Ags in the liver biopsies could be due to technical differences in immunoshistochemical 
staining, and in the studies conducted by Lautenschlager’s group frozen sections of liver 
biopsies were used, whereas our studies used paraffin-embedded liver biopsies which 
may affect the sensitivity of staining of the MAbs.
Studies have shown that the onset of HCMV infection, as indicated by the detection of 
HCMV  in the blood by PCR  is around 4  to  8  weeks  after SOT (Kidd  et al.,  2000; 
Griffiths et al., 1999a).  The exact time course of HCMV in liver allografts can only be 
determined in a prospective study testing protocol biopsies.  In this  study it was not 
feasible to test all protocolled liver biopsies during 120 day post-transplantation for this 
cohort of patients (biopsies were taken nearest the time of PCR positivity for any of 
human ^-herpesviruses).  Consecutive liver biopsies were only taken for four patients. 
In  3  of the 4 patients detection of HCMV DNA by ISH was  early during the post­
transplantation  course  (86%  biopsies  taken  during  1-14  d  post-transplantation  were 
HCMV DNA positive), possibly suggesting virus transmission from the donor.  Similar 
to the findings in the renal transplant patients (see chapter 4), a small population of liver 
transplant patients (24%) had HCMV DNA detected in at least one of their biopsy with 
no virus detected  in the  peripheral blood by PCR during  120  d post-transplantation. 
Again, this may reflect the role of local immune response in limiting virus reactivation 
to local sites, and thereby preventing widespread virus infection.
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In this study, 56% seronegative patients had HCMV DNA detected in their biopsy by 
ISH  suggesting virus  transmission  from  the  donor.  However,  two  of these  patients 
received  a  transplant  from  a  seronegative  donor.  Our  findings  are  similar  to  other 
studies where CMV DNA has been detected in tissue organs by ISH from seronegative 
individuals (Hendrix et al.,  1997; Kraat et al.,  1992).  This may be explained by low 
levels of Ab that are not detectable by serological assays and hence resulting in a false 
negative CMV serostatus.
Because HCMV is a known cause of hepatitis confirmed by histological identification 
of CMV inclusion bodies, it was suggested that HHV-7 associated ALT peaks for which 
no rejection was observed may represent HHV-7 associated hepatitis (Griffiths et al., 
1999a).  However, in this study, HHV-7 (or HHV-6) DNA was not detected by ISH in 
the liver biopsies taken during 7 days of an HHV-7 associated ALT peak for which no 
rejection was observed, therefore these two viruses are unlikely candidates for the cause 
of hepatitis.  In this study, HCMV DNA was detected in 62% biopsies (from 5 patients) 
taken during 7 days of an ALT peak for which no rejection was observed.  These may 
represent  further  cases  of CMV  hepatitis.  The  ISH  method  has  been  shown  to  be 
sensitive  for  detection  of  HCMV  infected  cells  in  liver  biopsies.  As  mentioned 
previously  the  ISH  method  does  not  discriminate between  active  or  latent  infection. 
However, it is unlikely that the sensitivity of the assay is able to detect latent infection. 
Therefore,  HCMV DNA  in the  liver allograft most likely represents  low  level active 
virus replication or abortive infection.
The  findings  in  this  study  show  that  in  contrast  to  the  situation  in  the  blood,  the 
detection of HCMV and HHV-6  DNA  in  liver biopsies  is not statistically associated 
with rejection.  Although HHV-6 and HHV-7 are frequently detected in the blood by 
PCR of patients following transplantation, these two viruses were not detected in organs 
of liver (or renal) patients with graft dysfunction or rejection and are therefore unlikely 
to have direct pathogenic role in organ transplantation.
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Chapter 6 -  Development of Fluorescence I n   S i t u  
Hybridisation using HHV-6 specific probes for the analysis of 
HHV-6 integration into human chromosomes.
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6.1  Introduction
HHV-6 was  first isolated from the peripheral blood of six patients with a variety of 
lymphoproliferative disorders and AIDS (Salahuddin et al., 1986).  HHV-6 is classified 
into  two  variants,  HHV-6A  and  -6B,  based  on  genetic  and  biological  properties 
(Ablashi et al., 1993), although no serological test can distinguish between Abs to either 
variant.  HHV-6  is ubiquitous  in the population with >90%  seropositivity  in  adults. 
Infection with HHV-6 usually occurs within the first two years of life, and in this age 
group HHV-6 causes febrile illness including ES  (Yamanishi et al.,  1988).  As with 
other herpesviruses, HHV-6 persists in the host after primary infection by establishing a 
latent  state possibly in  monocytes  and  bone  marrow progenitor  cells  (Kondo  et al., 
1991; Luppi et al.,  1999), and chronic infection in salivary glands (Jarrett et al.,  1990). 
Reactivation of latent virus may occur under conditions of immunosuppression, such as 
in transplant recipients receiving immunotherapy, and thus resulting in various disease 
manifestations  including  encephalitis,  pneumonitis,  and  bone  marrow  suppression 
(Carrigan  et  al.,  1991;  Cone  et  al.,  1993;  Drobyski  et  al.,  1993;  1994;  Singh  and 
Carrigan,  1996).  In healthy immunocompetent individuals, HHV-6 can be detected in 
PBMCs by sensitive nested-PCR when sufficient quantities of DNA are tested (Clark et 
al.,  1996), suggestive of low levels of latent virus in the peripheral blood (Jarrett et al., 
1990; Clark et al., 1996; Kidd et al., 1996).
An  alternative  form  of HHV-6  persistence  characterised by very high  viral  loads  in 
PBMC and integration of viral sequences into host cell chromosomes is in a minority of 
the  population.  This  recognized  phenomenon  of chromosomal  integration  was  first 
reported in three patients with abnormally high viral loads in PBMC that were detected 
by  Southern  blotting;  1   non-Hodgkin’s  lymphoma,  1   Hodgkin’s  disease,  and  1   MS 
patient (Luppi et al., 1993).  Pulsed field gel electrophoresis (PFGE) analysis of PBMCs 
from these three patients  showed fragments of molecular weight higher than  170 kb 
segment, indicating that the viral sequences are linked to high molecular weight cellular 
DNA.  Further analysis of these three patients using FISH with HHV-6 specific probes 
showed in all three cases the presence of a specific hybridisation site, located on the 
short arm of chromosome  17 (Torelli et al.,  1995).  Morris et al. (1999) suggested that 
the sites of integration were close to or in the telomeres of chromosome  17,  in band 
pi3.3 (17pl3.3).  In addition, the integrated viral sequences were typed as variant B in 
all three cases.  Although the exact mechanism of HHV-6 integration is not yet know, it
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may be of relevance that HHV-6 variants A and B have telomere-like repeat sequences 
present in the direct regions that flank the viral genome (Gompels and Macaulay, 1995; 
Isegawa et al., 1999), a characteristic also found in Marek’s Disease virus (an avian a- 
herpesvirus) which is known to integrate in to cellular chromosomes including telomere 
regions (Delecluse et al., 1993).
Recently,  integration has  also been mapped to  chromosome  22ql3  and  chromosome 
lq44 in different individuals, and the possibility of chromosomal transmission of HHV- 
6 DNA has been reported (Daibata et al.,  1999; Tanaka-Taya et al., 2004).  A woman 
with Burkitts lymphoma, and her asymptomatic husband had HHV-6 DNA integrated at 
chromosome 22ql3 and lq44 respectively.  Their daughter was found to have integrated 
virus at both these chromosomal sites suggesting that her viral genomes were inherited 
chromosomally from both parents (Daibata et al.,  1999).  Recently, Tanaka-Taya et al. 
(2004) identified five unrelated individuals with persistent high HHV-6 DNA (4 variant 
A,  1   variant B), and an additional five members of their families with similar HHV-6 
DNA levels in PBMC.  In two of these families examined, a mother and son, and a 
father and daughter were all  shown to have chromosomally integrated HHV-6.  The 
concept  of an  ‘endogenous  herpesvirus’  and  its  inheritance  as  a  genetic  element  is 
completely novel.  Alternatively, in the absence of inheritance, high viral loads found in 
PBMC could represent integration of viral sequences in a bone marrow progenitor cell 
which gives rise to a large number of cells/cell types in peripheral blood carrying copies 
of the viral genome.
In our own studies at the Royal Free, QC-PCR has been used to measure viral loads in a 
number  of patient  groups.  In  one  study,  HHV-6  loads  in  the  PBMC  of healthy 
individuals were  investigated (Clark et al.,  1996).  Using  1   pg  of DNA  in  a nested 
qualitative PCR assay, the prevalence of HHV-6 was found to be 36% (9/25).  Eight 
persons had viral loads ranging from 5-32 genome copies/pg DNA.  The viral burden in 
the ninth individual (VI) was 1.2 x 106 HHV-6 genome copies/pg DNA which remained 
constant over a 10-month period (see table 6.1).
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Sample Time (Weeks) 0  1 4 6 10 14 36 45
HHV-6 viral load 
(loglO genomes/jig 
PBMC DNA
6.08  5.90 6.04 5.85 6.08 6.00 6.15 6.18
Table 6.1 Consistently high viral loads in the peripheral blood of case VI overtime 
by qualitative PCR (Clark et al., 1996)
Furthermore, prospective studies carried out using the QC-PCR assay, have identified a 
number  of  transplant  recipients  with  consistent  abnormally  high  viral  loads 
(approximately 107  viral genomes/ml blood) in all samples collected over time (Kidd et 
al., 2000; Griffiths et al., 1999a).  Three such patients in 60 liver transplant patients (see 
figure  6.1),  1   of 52  renal  patients  and  1   of 71  bone  marrow  recipients  have  been 
identified.  These are likely to be individuals with integrated virus as such viral loads 
are characteristic of this phenomenon.  This would place the prevalence of integration at 
approximately 3% (Duncan Clark, pers. comm.).  Tanaka-Taya et al. (2004) estimated 
the  prevalence  of  integrated  HHV-6  in  a  Japanese  population,  determined  by 
consistently high viral loads in PBMC, at 0.21%.
It was hypothesized that if persons with integrated virus became stem cell donors, then 
genetic transmission of integrated virus to the recipient could be misinterpreted as active 
HHV-6  infection post-transplantation.  By  initiating pre-transplant  screening  of stem 
cell  donors,  a  stem  cell  donor  with  a  viral  load  of  8xl06  genomes/ml  blood  was 
identified.  In this chapter, cell lines were established from VI  and from the stem cell 
donor by Dr Duncan Clark.  The PBMCs from these individuals were immortalized by 
infection  with  EBV  to  give  rise  to  B-lymphoblastoid  cell  lines  (LCL).  FISH  was 
developed using HHV-6 specific probes for mapping the integration site of HHV-6 in 
these individuals.
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Figure 6.1 Maximum viral load of CMV, HHV-6 and HHV-7 in patients after liver 
transplantation  (Griffiths  et al.,  1999a).  The  horizontal  bars  indicate  the  median 
value for each of the (3-herpesviruses.
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6.2  Results
In this chapter, HHV-6 FISH was developed to map the site of viral integration in three 
individuals; a healthy individual with 1.2 x  106 HHV-6 genome/copies/|ig DNA which 
remained constant over a 10-month period (VI), a stem cell donor with a pre-transplant 
viral load of 8xl06 HHV-6 genomes/ml blood, and the sibling recipient.  The recipient, 
a  47  year  old  man  with  acute  myeloid  leukaemia  subtype  Ml  in  second  complete 
remission was referred for an HLA identical allogeneic stem cell transplant from his 37 
year old sister.  Eleven whole blood samples were collected from the recipient post­
transplantation and HHV-6 PCR was negative on days -7 and 0 but became positive on 
day 7 with a viral load of 2.4 x  104 genomes/ml blood (see figure 6.2).  Neutrophil 
engraftment (neutrophil count greater than 0.5  X  109/L)  occurred on day  17  and the 
viral  load  rose  to  2.3x106  HHV-6  genomes/ml  blood.  Subsequent  weekly  testing 
showed a consistent viral load of between 2.5-10xl06 HHV-6 genomes/ml blood.  The 
rise  in viral  load paralleled engraftment and the rise  in white cell  count.  On day 7 
following transplant the recipient was treated with meropenem for a neutropenic fever 
with negative blood cultures.  Serial CMV PCR surveillance of peripheral blood from 
the recipient detected a single positive sample at day 38 and two consecutive positive 
blood samples on days  73  and 76.  The recipient was treated with intravenous GCV 
(lOmg/kg  per  day)  which  was  discontinued  after  5  days  when  CMV  PCR  became 
negative.  He  was  discharged  from  this  transplant  centre  five  months  following 
transplantation but relapsed 3 months later.
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Figure 6.2  HHV-6 viral  load  in  a  stem  cell transplant recipient who  received  a 
transplant from a sibling donor with viral load of 8x10< >  HHV-6 genomes/ml blood.
Metaphase  chromosomes  were  successfully  generated  from  the  LCLs  of the  healthy 
individual  (VI)  and the  stem cell  donor but not from the recipient.  Cultures  of the 
recipient cell  line  grew very slowly and a seeding density of lxl06/ml could not be 
achieved.  Therefore, FISH was performed only for VI  and the stem cell donor.  The 
development of FISH using direct labelling of HHV-6 plasmid pZVH14 (see  section 
2.8.1) did not produce convincing results.  No specific hybridisation signals could be 
visualized for both cell lines.  For signal amplification, the HHV-6 pZVH14 probe was 
also indirectly labelled with biotin-dUTP, and secondary detection was carried out using 
fluorescein conjugated avidin (see section 2.8.2).  Hybridisation was also carried out at 
24  and  48  hr,  and  a  blocking  step  was  incorporated  to  improve  non-specific 
hybridisation.  Again,  no  specific  hybridisation  signals  were  observed  for  both  cell 
lines.  FISH  was  further  developed  using  a  cocktail  of eight  plasmids  containing 
between 9 and 16 kb inserts of the HHV-6 genome (nonoverlapping) (see figure 2.4) as 
probes  (7  plasmids  were  kindly provided  by  Dr  Scott  Schmid,  Centres  for  Disease 
Control, Atlanta (Lindquester et al.,  1996), and plasmid pZHV14 (kindly provided by 
Professor  Ruth  Jarrett,  University  of Glasgow,  UK).  These  plasmids  were  directly
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labelled as described in section 2.8.3.  Using a cocktail of HHV-6 specific plasmids as 
probes for FISH, the viral genome was found to be integrated close to the end of the 
short arm of chromosome 17 for the stem cell donor.  For VI, HHV-6 viral genome was 
integrated on the short arm of chromosome  11.  Figure 6.3  show specific symmetrical 
doublet signals on both chromatids of a single homolog of chromosome 17 for the stem 
cell  donor  and  chromosome  11  for  VI.  This  part  of the  FISH  was  carried  out  in 
collaboration with Drs Nacheva, Brazma (Haematology) and Leong (Virology).
Figure  6.3  FISH  analysis  using  fluorescently  labelled  HHV-6  specific  probes 
showing integration of HHV-6 sequences on A) chromosome lip in Vl-LCL and 
B) chromosome 17p in LCL of the stem cell donor (pictures provided by D.Clark).
Separate analysis using PCR primers to each of the predicted ORFs in the unique region 
of the viral genome conducted by Edward Tsao and Hoe Nam Leong in our department 
has shown that the complete genome is present in both cell lines and is variant B in VI 
and variant A in the stem cell donor.
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6.3  Discussion and Conclusions
Our FISH results identified integration of HHV-6 sequences in chromosome  lip and 
17p  for Vl-LCL  and the  donor LCL,  respectively.  Subsequent FISH  using HHV-6 
probe combined with Spectrum Orange labelled telomere probe specific for either the 
long  arm  of chromosome  11  or  17  (done  in  collaboration  with  Dr  Nacheva)  have 
confirmed the  specific integration site of HHV-6  sequences on chromosome  lip 15.5 
and  17pl3.3  for Vl-LCL and the LCL of the stem cell donor, respectively.  Similar 
analysis  on  a  bone  marrow  preparation  from  the  recipient  108  days  pre-transplant 
showed no evidence of integrated HHV-6.  FISH analysis on PBMC and bone marrow 
samples on days 31  and 88 post-transplant based on XX and XY chromosome status 
showed  successful  engraftment.  In  a  bone  marrow  sample  taken  on  day  88  post­
transplantation  from  the  recipient,  HHV-6  sequences  have  been  identified  on 
chromosome 17pl3.3 (D.Clark, pers. comm.).
Results in this chapter, and subsequent FISH analysis of the donor LCL and recipient 
bone  marrow  post-transplantation  have  confirmed  integrated  sequences  present  on 
chromosome  17p, a site where integration has previously been identified (Luppi et al., 
1993;  Torelli  et  al.,  1995;  Morris  et  al.,  1999).  HHV-6  integration  has  also  been 
mapped to chromosome 22ql3 and lq44 (Daibata et al., 1999).  In this study, the HHV- 
6 integration site for Vl-LCL was located in the short arm of chromosome 11.  This has 
not been previously reported elsewhere, and represents another integration site for the 
vims.
At present the underlying molecular mechanisms which control integration of HHV-6 to 
chromosomal sites are unknown.  All reported integration sites are in the most telomeric 
regions.  The HHV-6 viral genome contains a region that is homologous to the human 
telomeric  sequence  (Gompels  and Macaulay,  1995).  Thus  viral  integration  into  the 
human telomeric region may occur by a targeted recombination event (Tanaka-Taya et 
al., 2004).  Further fine mapping of the site of integration for these individuals will be 
required to determine whether integration is close to or within telomeric regions of the 
viral genome.  HHV-6 is unique amongst the human herpesviruses by encoding an ORF 
(U94)  homologous  to  the  human  adeno-associated  vims  type-2  (AAV-2)  rep  gene 
products Rep68  and Rep78  (Thomson et al.,  1991).  The AAV-2  rep  gene plays  an 
essential role in viral DNA replication and has been shown to regulate gene expression.
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HHV-6 U94 has been  shown to  complement rep  in  function in replication defective 
AAV-2 (Thomson et al.,  1994).  The AAV-2 rep gene products Rep68 and Rep78 are 
also  thought  to  play  an  important  role  in  AAV-2  integration  and  can  target  DNA 
sequences to a specific locus in the human genome (Surosky et al., 1997).  Since HHV- 
6 U94 shows homology to both these AAV proteins it may be that it functions in a 
similar manner by binding to recognition sequences present in particular chromosomes.
We have demonstrated that a stem cell recipient can become positive for HHV-6 DNA 
by  PCR  when  engraftment  takes  place  from  a  donor  with  integrated  HHV-6.  The 
pattern  of  HHV-6  viral  loads  for  this  recipient  (see  figure  6.2)  could  easily  be 
misinterpreted as active infection prompting administration of potentially toxic antiviral 
drugs  such  as  GCV.  From  a  management  perspective,  pre-transplant  screening  of 
donors would therefore be useful in identifying those with integrated virus and therefore 
prevent misdiagnosis of active infection post-transplantation.  To date there have been 
no  controlled  trials  of antiviral  therapy  against  HHV-6  infection,  but  a  number  of 
studies have shown the ability of GCV and PFA to suppress HHV-6 replication in vitro 
(Takahashi et al., 1997b).
Although the clinical significance of chromosomally integrated HHV-6 is still unclear, 
integrated  virus  is  a  potential  confounder  in  studies  investigating  HHV-6  disease 
associations  and  also  in  the  medical  management  of infection.  Previous  unproven 
associations  between  HHV-6  and  disease,  may  have  reflected  the  unrecognized 
detection of integrated virus  and interpreted as  a high viral  load.  For example,  in  a 
study by Challoner et al. (1995) representational difference analysis (RDA) was used to 
look for novel DNA sequences in the brains of MS patients compared to control tissue 
(PBMCs from healthy persons).  An HHV-6 sequence was amplified from the brain of 
one MS  case (MS-1).  Limiting dilution analysis was also performed to estimate the 
viral load in MS  and control brain samples.  MS-1  produced a positive PCR up to a 
dilution of 1/262000, and a second MS brain was positive to a dilution of 1/65000.  In 
contrast  a  maximum  of  1/16  dilution  was  amplified  from  the  other  47  MS  and  51 
control brains.  The CSF of MS-1 was also HHV-6 DNA positive by PCR.  Therefore, it 
is  likely  that  this  individual  with  abnormally  high  HHV-6  load  in  the  brain  had 
integrated HHV-6, possibly inherited,  and the virus  is unlikely to be  associated with 
disease pathogenesis in this case.
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In summary, this chapter describes the development of HHV-6 FISH using a cocktail of 
HHV-6  probes  that  can  now  be  utilised  to  examine  sites  of virus  integration.  We 
propose that all stem cell donors should be screened for integrated HHV-6 and suggest 
that  integration  should  be  excluded  in  all  reports  associating  this  virus  with  novel 
disease associations.
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7.1  General Discussion and Conclusions
HCMV  is  the  most  important  post-transplant  infection.  It  causes  overt  end-organ 
disease  such as hepatitis,  pneumonitis,  and  gastrointestinal  ulceration,  (Griffiths  and 
Emery,  1997).  These are collectively termed the “direct effects” of CMV because the 
virus  can  be  seen  directly  in  biopsies  of  the  infected  organ  using  classical 
histopathological techniques to visualise “owl’s eye inclusions” (Smith, 1959; Macasaet 
et  al.,  1975).  In  addition,  HCMV  is  associated  with  a  variety  of  other  medical 
conditions  (graft  rejection,  accelerated  atherosclerosis  and  an  immunosuppressive 
syndrome (Rubin,  1989), collectively termed “indirect effects” because the virus is not 
seen histopathologically in affected organs.
The  involvement  of  CMV  infection  in  transplant  rejection  was  first  proposed  by 
Richard  Simmons  and  coworkers  in  1970.  Since  then,  several  studies  based  upon 
clinical  observations  in  individual  patients,  statistical  association  with  CMV  disease 
and/or CMV infection in cohorts of patients as well as the results of clinical trials of 
antiviral agents have provided further evidence for a causal role of CMV in allograft 
rejection (Grattan et al., 1989; Loebe et al., 1990; Bando et al., 1995; von Willebrand et 
al.,  1986; Fietze et al.,  1994; Reinke et al.,  1994; Valantine et al.,  1999; Rubin et al., 
2000).  Specifically,  the  trial  of  Lowance  et  al.  (1999)  randomised  208  HCMV 
seronegative patients to receive prophylaxis with VACV or placebo for ninety days after 
transplant of a seropositive kidney, reported that the incidence of biopsy-proven acute 
graft rejection was  decreased by 50% among those receiving  VACV.  This  finding, 
together  with  supporting  evidence  from  animal  models  of allotransplantation  in  the 
presence of animal CMVs with/without GCV therapy, strongly indicated that CMV was 
an  unrecognized  major  contributor to  acute  graft rejections  (Lemstrom  et al.,  1995;
1997).
However, evidence against a causal role for HCMV in triggering allograft rejection also 
exists.  Several clinical cohort studies have not reported a statistical association with 
HCMV (Dickenmann et al., 2001; Sherlock et al., 1991; Teixeira et al., 2000; Boyce et 
al.,  1988).  In the Lowance study, a parallel group of 408 renal transplant patients who 
were HCMV seropositive pre-transplant also did not demonstrate a beneficial effect of 
VACV  prophylaxis  on  the  incidence  of  biopsy-proven  graft  rejection. 
Immunosuppression associated with transplantation may also enhance the replication of
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other (J-herpesviruses, namely HHV- 6, and/or HHV-7.  These two viruses have also 
been associated with graft rejection and with HCMV end organ disease (Griffiths et al., 
1999a; Kidd et al., 2000; Osman et al., 1996; Desjardin et al., 1998; Ratnamohan et al.,
1998).  Since HHV-6 and to a lesser extent HHV-7, are susceptible in vitro to drugs 
which inhibit HCMV including GCV (De Clercq et al., 2001) it remains possible that 
the beneficial effects of antiviral prophylaxis on acute graft rejections may be operating 
through inhibition of these newer (3-herpesviruses and/or inhibition of HCMV.
To  address  this  complex  situation  prospective  studies  were  conducted  in  our  centre 
where QC-PCR assays were applied to quantitatively measure the viral load of each of 
these three (3-herpesviruses in renal (Kidd et al, 2000) and liver (Griffiths et al.,  1999a) 
transplant patients.  In the study by Kidd et al. (2000), HCMV was found to be the most 
commonly detected virus post-transplant (58% of patients) followed by HHV-7 (46%) 
and HHV-6 (23%).  The median maximum viral loads for HCMV was also significantly 
higher than those for HHV-6 (p=0.01) and HHV-7 (P>0.0001), and a trend for HHV-7 
viral load to be greater than HHV-6 (p=0.08).  It was revealed that in those patients with 
graft rejection, HHV-7 was associated with more episodes of rejection (p=0.02).  There 
was also a significant increase in HCMV disease occurring in patients with HCMV and 
HHV-7 coinfection compared to those with HCMV infection only (p=0.04).  Therefore, 
HHV-7  should be  further investigated as  a possible  co-factor in  the  development  of 
HCMV  disease  in  renal  transplant  patients  and  may  potentially  exacerbate  graft 
rejection.  Similarly, in the study by Griffiths et al. (1999a), infections with HHV-6 and 
HHV-7 were also found to be common after transplantation.  The median peak virus 
load  for  HCMV  was  again  significantly  greater  than  that  for  HHV-6  and  HHV-7. 
HCMV and HHV-6, but not HHV-7 were also found to be independently associated 
with biopsy proven graft rejection.  It was therefore concluded that HHV-6 may be a 
previously  unrecognized  pathogen  in  this  patient  group  (Griffiths  et  al.,  1999a). 
However,  to  fully  understand  the  pathogenic  role  of  these  viruses  in  organ 
transplantation,  detection  of  these  viruses  must  be  made  at  the  tissue  level. 
Traditionally, the diagnosis of HCMV direct end organ disease has relied on classical 
histopathological  detection  of “owl’s  eye  inclusions”  in  the  biopsies  of the  affected 
organ.  Although  this  method  was  specific  for  HCMV  (inclusion  bodies  were  not 
induced by HHV-6 or HHV-7  in vivo),  it was found to be insensitive (Mattes et al., 
2000).
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One of the main aims of this thesis was therefore to develop specific and more sensitive 
in  situ  techniques  including  ISH  and  IHC  for  the  detection  of  the  human  13- 
herpesviruses in organ biopsies to further investigate the incidence and pathogenesis of 
these viruses in transplant recipients.  Chapter 3 describes the development of ISH using 
DIG  labelled  riboprobes  specific  for  each  of  the  human  (3-herpesviruses  for  the 
detection  of virus  DNA  in  formalin-fixed  paraffin-embedded  culture  infected  cells. 
Furthermore, HCMV ISH was optimised for the detection of HCMV infected cells in 
biopsy  material.  A  DIG  labelled  riboprobe  directed  against  the  HCMV  IE-1  gene 
transcript  for  RNA  ISH  was  also  constructed  to  further  investigate  HCMV  gene 
expression in renal biopsies.  A riboprobe specific for a |3-globin sequence was used to 
determine the level of sensitivity of the ISH technique.  Detection of DNA was found 
not to approach single-copy levels.  However, HHV-6 DNA was detected by ISH with a 
HHV-7 U67 riboprobe in an EBV-transformed cell line with an estimated  12copies of 
integrated HHV-6 genome (Vl-LCL).  IHC was also developed using MAbs specific for 
each of the human (3-herpesvirus proteins in formalin-fixed paraffin-embedded culture 
infected cells.  These assays were shown to be sensitive and specific for the respective 
virus.  For  IHC,  a number of MAbs were  used with  optimal  staining  obtained  with 
MAbs to HCMV late protein, HHV-6 gB and HHV-7 pp85.
The in situ techniques were then used for the detection of these viruses directly in renal 
biopsies (Chapter 4) taken from the patients in the original cohort who required biopsy 
to  investigate  the  cause  of graft  dysfunction  (Kidd  et  al.,  2000),  and  also  in  liver 
biopsies (Chapter 5) taken from the patients in the original cohort where protocolled 
liver biopsies were obtained at scheduled times after transplantation, and whenever liver 
dysfunction occurred (Griffiths et al.,  1999a).  Since it was not feasible to test all liver 
biopsies, biopsies were selected from patients taken nearest the time of PCR positivity 
in the blood for any of the human [3-herpesviruses.
Using  ISH,  HCMV  DNA  was  detected  in  a  significant  proportion  of  biopsies 
(approximately 50%) from patients with renal and liver allografts, with detection being 
widespread  especially in  the  renal  allografts.  The renal  biopsies  containing  HCMV 
DNA  were  however,  not  more  likely  to  show  graft rejection  so  the  hypothesis  that 
HCMV is a frequent trigger of rejection was not supported.  Instead, it is proposed that 
HCMV  infection  of the  graft causes  post transplant graft dysfunction  which  mimics
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rejection clinically and which can be prevented by antiviral prophylaxis such as that 
used by Lowance et al.  (1999).  Similarly,  HCMV  DNA was not more  likely to be 
detected in liver biopsies showing graft rejection, therefore HCMV was also found not 
to be statistically associated with rejection in this patient group.
In the renal allografts,  HCMV IE-1  gene transcripts were also not detected by RNA 
ISH, and this may be due to the quality of the biopsies as (J-actin transcripts were only 
detected (and in low abundance) in some renal allografts suggesting RNA degradation. 
Therefore, although HCMV DNA was detected in the renal and liver allografts, the type 
of HCMV infection could not be established by ISH.  The failure to detect HCMV Ags 
shows that HCMV expression was at a low level and explains why this phenomenon has 
not been described previously by histopathologists using IHC or examination for owl’s 
eye  inclusions which are known to be  insensitive  (Mattes et al.,  2000;  Smith  et al., 
1975).  However,  the  sensitivity  of the  ISH  technique  is  unlikely  to  detect  latent 
infection,  so the HCMV DNA in the biopsies most likely represents  low  level virus 
replication or abortive infection.
In renal (and cardiac) transplantation, high levels of AECA have been demonstrated in 
transplant recipients who had HCMV infections (Toyoda et al.,  1997;  1999).  These 
Abs have been proposed to play an important role in the development of Ab-mediated 
rejection (Yard et al., 1993; Fredrich et al., 1999).  The deposition of C4d in the PTC of 
the renal graft was used to investigate the incidence of Ab mediated injury in the renal 
transplant patients.  Approximately 50% of biopsies showed C4d staining, this finding 
is  similar  to  that  of other  studies  (Lederer et  al.,  2001;  Feucht  et  al.,  1993).  The 
detection of HCMV DNA  in the renal  biopsies by ISH  was not associated with Ab 
mediated rejection as determined by C4d deposition.  This  finding  is  in  line with  a 
recent study by Nickeleit et al. (2002), where clinical evidence of infections  within 2 
weeks before a renal allograft biopsy (HCMV, VZV, sepsis, bacterial infections) were 
not significantly associated with C4d deposition (Nickeleit et al., 2002).  However, a 
recent study by Aiello et al. (2004), showed the presence of PTC C4d deposition in the 
graft  of  some  renal  transplant  patients  undergoing  early  acute  rejection  and  who 
experienced  viral  infections  (CMV  or  EBV)  within  the  first  year  following 
transplantation.
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HHV-6 or HHV-7 were not detected in organs of liver or renal transplant patients by 
ISH or IHC.  This finding is in contrast to the situation in the blood where HHV-6 and 
HHV-7 DNA were commonly detected in the blood by PCR (Griffiths et al.,  1999a; 
Kidd et al., 2000).  HHV-7 was also associated with increased episodes of rejection in 
the  renal  patients  (Kidd  et  al.,  2000),  and  HCMV  and  HHV-6  were  independently 
associated  with  biopsy  proven  graft  rejection  in  the  liver  patients  (Griffiths  et  al., 
1999a).  The role of these (J-herpesviruses in graft dysfunction or rejection is therefore 
also not supported.  Although the findings in this thesis do not support a role of the 
newer  (J-herpesviruses  as major pathogens  in  solid  organ  transplant recipients,  these 
viruses were however, only examined in the liver and kidney which may not necessarily 
be  the  site  of HHV-6/7  disease.  Several  studies  have  shown  that  HHV-6  may  be 
associated  with  other  disease  associations  such  as  encephalitis  and  bone  marrow 
suppression (Drobyski et al.,  1994;  Carrigan and Knox,  1994;  Imbert-Marcille et al., 
2000), therefore HHV-6 may still be an important pathogen post-transplant.
In the renal transplant population there was  a trend towards the presence  of HCMV 
DNA  in  the  graft  as  detected  by  ISH  and  the  long-term  outcome  among  the  renal 
transplant recipients although this did not achieve statistical  significance.  This  study 
was however, limited to low patient numbers and future work could involve extending 
this  study  to  incorporate  a  larger number  of renal  transplant  patients.  In  the  liver 
transplant patients it was not feasible to test all protocolled liver biopsies during  120 
day post-transplantation for this cohort of patients (biopsies were taken nearest the time 
of PCR positivity for any of human p-herpesviruses).  Consecutive liver biopsies were 
only tested for four patients, therefore future work could involve  extending this to  a 
larger number of patients which would help determine the exact time course of HCMV 
in liver allografts.  In our centre, formalin-fixation followed by tissue processing for 
paraffin-embedding  is  the  routine  method  for  preservation  of  tissue  biopsy  for 
microscopic analysis.  Future work could  also involve testing  frozen  liver and renal 
biopsies from transplant patients to compare our in situ results, and also those of the 
findings by Lautenschlager’s group, where HHV-6 Ags were detected by IHC in frozen 
liver sections.
242Chapter 7  General  Discussion and Conclusions
In conclusion, the finding that HCMV DNA is frequently detected in biopsies by ISH 
shows that rejection and infection frequently co-exist.  A common clinical conundrum 
in patients who present with fever and graft dysfunction is the differential diagnosis of 
rejection  or  infection.  The  in  situ  hybridisation  method  for  HCMV  has  been 
demonstrated to be a sensitive method for the detection of HCMV infected cells in liver 
and renal biopsies.  It could be used to further test biopsies collected during clinical 
trials allowing patients to be randomised to receive GCV or placebo; the results would 
then determine  whether patients with  graft dysfunction  should be  given  anti  HCMV 
therapy in addition to treatment for their graft rejection.
Although the role of HHV-6 in graft dysfunction or rejection was not shown, a number 
of transplant  recipients  were  identified  with  consistent  abnormally  high  viral  loads 
(approximately 10  viral genomes/ml blood) in all samples collected over time (Kidd et 
al., 2000; Griffiths et al.,  1999a).  In another study, where 1   pg of DNA was used in a 
nested  qualitative  PCR  assay  to  measure  HHV-6  loads  in  the  PBMC  of  healthy 
individuals, the prevalence of HHV-6 was found to be 36% (9/25) (Clark et al.,  1996). 
Eight persons were found to have viral loads ranging from 5-32 genome copies/pg DNA. 
The viral burden in the ninth individual (VI) was  1.2 x  106 HHV-6 genome copies/pg 
DNA  which  remained  constant  over  a  10-month  period.  These  are  likely  to  be 
individuals  with  integrated  virus  as  such  viral  loads  are  characteristic  of  this 
phenomenon.  This  would  place  the  prevalence  of integration  at  approximately  3% 
(Duncan Clark, pers. comm.).  Tanaka-Taya et al. (2004) estimated the prevalence of 
integrated HHV-6, determined by consistently high viral loads in PBMC, at 0.21% in 
the Japanese population.
It was hypothesized that if persons with integrated virus became stem cell donors, then 
genetic transmission of integrated virus to the recipient could be misinterpreted as active 
HHV-6  infection post-transplantation.  By initiating pre-transplant  screening  of stem 
cell  donors,  a  stem  cell  donor  with  a  viral  load  of  8xl06  genomes/ml  blood  was 
identified.  Chapter 6 describes the development of FISH using a cocktail of HHV-6 
specific probes for mapping the integration site of Vl-LCL and the  stem cell  donor. 
Attempts to generate an LCL from the stem cell recipient were unsuccessful as B cell 
counts were very low in peripheral blood.  Our FISH results identified integration of 
HHV-6  sequences  in  chromosome  lip  and  17p  for  Vl-LCL  and  the  donor  LCL,
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respectively.  Subsequent FISH analyses (conducted by Dr Elisabeth Nacheva, Dr Diana 
Brazma and Dr Hoe Nam  Leong)  confirmed  the  specific  integration  site  of HHV-6 
sequences on chromosome  llpl5.5 and 17pl3.3 for Vl-LCL and the LCL of the stem 
cell  donor,  respectively.  Similar  analysis  on  a  bone  marrow  preparation  from  the 
recipient  108  days  pre-transplant  showed  no  evidence  of integrated  HHV-6.  FISH 
analysis on PBMC and bone marrow samples on days 31  and 88 post-transplant based 
on XX and XY chromosome status showed successful engraftment.  In a bone marrow 
sample taken on day 88 post-transplantation from the recipient, HHV-6 sequences have 
been  identified  on  chromosome  17pl3.3  (Duncan  Clark,  pers.  comm.).  We  have 
demonstrated that a stem cell recipient can become positive for HHV-6 DNA by PCR 
when engraftment takes place from a donor with integrated HHV-6.  We propose that 
pre-transplant screening of donors  can be useful  in  identifying those  with  integrated 
virus and therefore prevent misdiagnosis of active infection post-transplantation
Whilst the clinical  significance  of chromosomally integrated  HHV-6  is  still  unclear, 
integrated  virus  is  a  potential  confounder  in  studies  investigating  HHV-6  disease 
associations  and  also  in  the  medical  management  of infection.  Previous  unproven 
associations  between  HHV-6  and  disease,  may  have  reflected  the  unrecognized 
detection  of integrated  virus  and  interpreted  as  a  high  viral  load.  Therefore,  it  is 
recommended that integration should be excluded in all reports associating this virus 
with novel disease associations.
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